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 Zusammenfassung 
Einleitung 
Beschreibung der Technologie 
Vollständig bioresorbierbare Stents oder Scaffolds (BRS/ bioresorbable scaf-
fold oder BVS/ bioabsorbable vascular scaffold) stellen die neueste Genera-
tion von Stents zur myokardialen Revaskularisation dar. Sie bestehen aus ei-
nem abbaubaren Material, meist einem Polymer wie Polymilchsäure oder 
einer Magnesiumlegierung und sind entweder medikamentenbeschichtet 
oder unbeschichtet. Sie werden hauptsächlich verwendet, um das Risiko von 
Spätkomplikationen wie Gerüstthrombose (ScT) oder Restenose vorzubeu-
gen, die auftreten können, wenn das starre geflochtene Gerüst eines her-
kömmlichen Metallstents dauerhaft im kranken Gefäß verankert bleibt. Bis-
lang haben fünf Produkte (Absorb®, DESolve®, ART Pure, Fantom® und 
Magmaris) das CE-Zertifikat zur Implantation in erwachsenen PatientInnen 
mit koronarer Herzkrankheit (KHK) erhalten. Absorb® (bioresorbable vas-
cular scaffolds, BVS) wurde 2016 auch von der US-amerikanischen Zulas-
sungsbehörde FDA zugelassen. Absorb® ist nun aber nicht mehr auf dem 
Markt erhältlich, da der Hersteller den Verkauf im Mai 2017 eingestellt hat.  
Myokardiale Revaskularisation bei PatientInnen mit CAD kann verschiedene 
Arten erfolgen: mittels einer perkutanen koronaren Intervention (PCI) oder 
einer koronaren Bypass-Operation (CABG). Die erste PCI-Technik war die 
Ballonangioplastie (PTA). Die Koronarstenose konnte zwar mit PTA erfolg-
reich behandelt werden, führte aber auch zu einer hohen Rate an akuten Ge-
fäßverschlüssen und Restenosen. Die Entwicklung von unbeschichteten Me-
tallstents (Bare metal stents, BMS) leitete daraufhin eine Revolution ein. Die 
Implantation des BMS reduzierte den Gefäßrückstoß und führte deswegen 
zu besseren akuten Ergebnissen. Der Nachteil ist, dass das Metallgerüst dau-
erhaft im Gefäß verbleibt und einen dauerhaften Reiz durch Gefäßschädi-
gung mit Risiko für Thrombose und Restenose darstellt. Um die neointimale 
Hyperplasie und dadurch die Rate der Restenose zu reduzieren, wurden Me-
dikamente freisetzende Stents (Drug Eluting Stents, DES) entwickelt. Bei 
DES wird das Metallgerüst mit einem immunsuppressiven oder zytotoxi-
schen Wirkstoff beschichtet, der freigesetzt wird. Thrombozytenaggregati-
onshemmer (TAH) sind aufgrund des Stent-Thrombose Risikos erforderlich, 
allerdings können sie zu Blutungskomplikationen führen. Stents mit biore-
sorbierbarer Polymer-Beschichtung wurden entwickelt, um das Risiko für 
Polymer-induzierte Entzündungsreaktionen zu reduzieren und auf diese 
Weise arterielle Heilungsprozesse zu beschleunigen.  
Die koronaren Bypass-Operation (CABG) ist eine Operation am offenen Her-
zen, die den Blutfluss zum Herzen verbessert. Bei der CABG wird eine ge-
sunde Arterie oder Vene mit der blockierten Koronararterie verbunden, so-
dass die transplantierte Arterie oder Vene den blockierten Teil der Koronar-
arterie umgeht. Obwohl die perkutane Koronarintervention (PCI, auch: per-
kutane transluminale koronare Angioplastie, PTCA) derzeit die am häufigs-
ten eingesetzte Revaskularisationstechnik ist, spielt CABG nach wie vor eine 
wichtige Rolle bei der Behandlung von PatientInnen mit fortgeschrittener 
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 obstruktiver Koronarerkrankung. Im Vergleich zur Implantation eines 
Stents, ist CABG invasiver und damit mit höheren periprozeduralen Risiken 
verbunden.  
Indikation und therapeutisches Ziel 
Die koronare Herzkrankheit (KHK) ist eine Manifestation der Arteriosklero-
se in den Koronararterien und gehört zu den häufigsten Krankheiten. KHK 
ist die häufigste Todesursache in Europa. Zu den Risikofaktoren gehören 
Rauchen, hoher Alkoholkonsum, Bewegungsmangel, hoher Cholesterinspie-
gel im Blut, Übergewicht oder Fettleibigkeit, Diabetes mellitus, Bluthoch-
druck und psychosoziale Belastungen wie Stress oder Depressionen. Men-
schen mit KHK haben ein erhöhtes Risiko für Myokardinfarkt (MI), Herz-
rhythmusstörungen wie Vorhofflimmern, Herzinsuffizienz und vorzeitige 
Mortalität. Symptome für KHK sind typischerweise Kurzatmigkeit und 
Brustschmerzen (Angina pectoris). Bei PatientInnen mit stabiler Angina pec-
toris ändern sich die Symptome über einen längeren Zeitraum nicht, wäh-
rend bei PatientInnen mit instabiler Angina pectoris die Symptome ohne 
körperliche Anstrengung plötzlich zunehmen oder sich die Belastungs-
schwelle ändert. 
Im Jahr 2015 lebten in Europa fast 17 Millionen Männer und mehr als 13 
Millionen Frauen mit KHK: die Gesamtkosten (einschließlich direkter Ge-
sundheitskosten, Produktivitätsverluste und informeller Pflegekosten) wur-
den auf über 59 Milliarden Euro geschätzt. 
Die Diagnose und Bewertung von stabiler KHK beinhaltet die klinische Ab-
klärung, einschließlich der Identifizierung von signifikanter Dyslipidämie, 
Hyperglykämie oder anderen biochemischen Risikofaktoren und spezifi-
scher kardialer Untersuchungen wie Stresstests oder koronare Bildgebung. 
Bei vermutetem akutem koronarem Syndrom (ACS) werden zur Differenti-
aldiagnostik aus dem klinischen Erscheinungsbild (d.h. Symptome, Vitalpa-
rameter) verschiedene Merkmale mittels 12-Kanal-Elektrokardiogramm 
(EKG) und Biomarkern (insbesondere Troponin) erhoben. Eine nicht-
invasive Bildgebung, wie die transthorakale Echokardiographie, kann zur 
Diagnose beitragen.  
Methoden 
Der Bericht wurde im EUnetHTA HTA Core Model® REA Version 4.2 erstellt 
und basiert auf der systematischen Übersichtsarbeit zum gleichen Thema 
vom LBI-HTA 2015 (DSD 81: http://eprints.hta.lbg.ac.at/1060). Die systemati-
sche Suche wurde in mehreren Datenbanken durchgeführt (Medline, Pub-
Med, Embase, Cochrane Central Register of Controlled Trials, und Cochrane 
Database for Systematic Reviews). Weitere Informationen wurden durch 
Handsuche nach potentiell relevanten Primärstudien, Informationen des 
Herstellers, systematische Suche nach klinischen Leitlinien in der G-I-N Da-
tenbank sowie der Suche nach laufenden Studien (Clinical Trials Registry 
Platform [ICTRP] und Clinicaltrials.gov) gewonnen.  
Für die Beurteilung der klinischen Wirksamkeit wurden nur randomisierte 
kontrollierte Studien (RCTs) und nicht randomisierte kontrollierte Studien 
(nicht-RCTs) eingeschlossen. Für die Beurteilung der Sicherheit wurden ne-
ben RCTs und nicht-RCTs prospektive unkontrollierte Studien mit mindes-
tens 50 PatientInnen berücksichtigt.  
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Zur Beurteilung der internen Validität der eingeschlossenen RCTs wurde das 
Cochrane Risk of Bias (RoB) Tool verwendet. Die IHE-20-Checkliste wurde 
zur Bewertung der internen Validität der eingeschlossenen Studien ohne 
Kontrollgruppe verwendet. Die Qualität der Evidenz wurde mit der GRADE-
Methode (Grading of Recommendations, Assessment, Development and Eva-
luation) bewertet. 
Ergebnisse 
Verfügbare Evidenz 
Es wurden acht RCTs mit insgesamt 5.863 PatientInnen für die Bewertung 
der Wirksamkeit eingeschlossen. Alle RCTs bewerteten den Absorb® BVS. In 
sieben RCTs war ein Stent mit permanenter Everolimusbeschichtung 
(Xience® oder Synergy®) der Komparator. Eine Studie verwendete zwei 
verschiedene Komparatoren: ein Stent mit permanenter Everolimusbe-
schichtung (Promus Element, DES) und ein Stent mit permanenter Bi-
olimusbeschichtung (Biomatrix Flex, DES). Für die Beurteilung der Sicher-
heit wurden noch zusätzlich 45 prospektive unkontrollierte Studien einge-
schlossen. Von denen untersuchten drei Studien (345 PatientInnen) DESol-
ve®, zwei Studien (184 PatientInnen) Magmaris, eine Studie (mit einem 
Follow-Up von 6 Monaten bei 117 von 240 PatientInnen) Fantom®, und 39 
Studien (insgesamt mehr als 15.000 PatientInnen) Absorb®. Keine Studie 
konnte identifiziert werden, die den ART Pure Stent untersuchte. 
Klinische Wirksamkeit 
Die wichtigsten Endpunkte zur Wirksamkeit waren schwerwiegende uner-
wünschte koronare Komplikationen (MACE, major adverse cardiac events), 
Gesamtmortalität, Koronarmortalität, Angina pectoris, MI, Lebensqualität, 
Aktivitäten des täglichen Lebens. Darüber hinaus wurden die Surrogatend-
punkte Zielgefäß-Revaskularisation (TVR) und Zielläsion-Revaskularisation 
(TLR) bewertet.  
Die Meta-Analyse zeigte…  
b keinen signifikanten Unterschied zwischen Absorb® und dem DES 
mit permanenter Beschichtung für die Gesamtmortalität und Herz-
mortalität (RR 0.84 [95% CI 0.63 - 1.11] und RR 0.91 [95% CI 0.60 - 
1.39]), 
 
b ein signifikant erhöhtes Risiko für MACE (RR 1.36 [95% CI 1.06 – 
1.73]), MI (RR 1.49 [95% CI 1.21 – 1.84]) und TLR (RR 1.36 [95% CI 
1.08 – 1.71]) für PatientInnen, die mit dem Absorb® BVS behandelt 
wurden, und  
 
b keinen Unterschied zwischen Absorb® und dem DES mit permanen-
ter Beschichtung für die Lebensqualität und die Aktivitäten des tägli-
chen Lebens.  
Es wurde keine Evidenz für die Beantwortung der Forschungsfragen zur 
Wirksamkeit der weiteren (CE-zertifizierten) vollständig bioresorbierbaren 
Stents DESolve®, Magmaris, ART Pure und Fantom® gefunden. 
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 Sicherheit 
Um die Sicherheit  der vollständigen BRS zu beurteilen, wurden schwerwie-
gende unerwünschte Ereignisse (SAEs), wie periprozeduraler MI oder Mor-
talität, Gerüstthrombose (ScT), die nach mindestens einem Jahr Follow-up 
auftraten, Mortalität als Folge von Blutungen oder Schlaganfällen oder un-
erwünschte Ereignisse, wie Blutungen als Folge einer Antiplättchentherapie, 
Komplikationen beim Gefäßzugang oder verfahrensbedingte kontrastmittel-
induzierte Nephropathie, berücksichtigt.  
b Absorb®  
Die RCTs zeigten keinen statistischen Unterschied für periprozeduralen MI 
im Vergleich zu DES mit permanenter Beschichtung [RR 1.22 (95% CI 0.82-
1.82)]. In acht unkontrollierten Studien trat während oder kurz nach der 
Implantation des Absorb® BVS kein MI auf, in weiteren 20 unkontrollierten 
Studien betrug die Medianrate der periprozeduralen MI 2.8%. Periproze-
duraler Tod wurde nur in zwei RCTs und 22 unkontrollierten Studien be-
richtet, wobei in 21 Studien, einschließlich der beiden RCTs, keine Patien-
tInnen während des Verfahrens starben. In den übrigen drei unkontrollier-
ten Studien betrugen die Raten der periprozeduralen Mortalität 0.04%, 0.5% 
bzw. 1.3%. Die Gesamtrate von ScT, die nach mindestens 1-Jahres Follow-up 
auftrat, war in den eingeschlossenen Studien gering. Dennoch führte die Me-
ta-Analyse aus RCTs im Vergleich zu DES mit permanenter Beschichtung zu 
einem statistisch signifikant höheren Risiko für sehr später ScT bei Patien-
tInnen, die mit dem Absorb® BVS behandelt wurden [RR 5.09 (95% CI 1.9-
13.17)]. In sieben unkontrollierten Studien kam es zu keiner sehr späten 
ScT. In 13 unkontrollierten Studien lag die Rate der sehr späten ScT zwi-
schen 0.2% und 1.7%. Blutungen als Folge der Thrombozytenaggregations-
hemmung wurden nur in fünf unkontrollierten Studien (Ereignisrate: 1%-
4.4%) und Mortalität als Folge von Blutungen oder Schlaganfällen in elf Stu-
dien berichtet, wobei in neun Studien keine und in den verbleibenden beiden 
Studien jeweils ein Todesfall auftraten. Komplikationen beim vaskulären Zu-
gang wurden nur aus zwei unkontrollierten Studien abgeleitet (Ereignisrate: 
0.09% und 0.7%). Es wurden keine Hinweise auf verfahrensbedingte kon-
trastmittelinduzierte Nephropathie gefunden. Es wurde kein Unterschied in 
Bezug auf die Rate der Sicherheitsereignisse aus RCTs oder prospektiven 
unkontrollierten Studien mit überwiegend PatientInnen mit stabiler Angina 
im Vergleich zu Studien mit überwiegend PatientInnen mit ACS festgestellt. 
b DESolve® 
Es lagen keine Sicherheitsergebnisse aus RCTs vor. In drei unkontrollierten 
Studien wurden periprozedurale Todesfälle oder periprozedurale MIs be-
richtet, wobei kein/e PatientIn während oder kurz nach dem Eingriff starb 
und nur bei einem/r PatientIn ein periprozeduraler MI auftrat. Darüber hin-
aus starb kein/e PatientIn an Blutungen oder Schlaganfällen. Sehr späte ScTs 
konnten nur aus einer Studie abgeleitet werden, ohne dass Ereignisse ge-
meldet wurden. Es wurden keine Hinweise auf Blutungen als Folge von An-
tiplättchentherapie, Komplikationen des Gefäßzugangs oder verfahrensbe-
dingte kontrastmittelinduzierte Nephropathie gefunden. 
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b Magmaris (Dreams 2G) 
Es lagen keine Sicherheitsergebnisse von RCTs vor. In zwei unkontrollierten 
Studien wurden periprozedurale Todesfälle oder periprozedurale MIs be-
richtet. In beiden Studien starb kein/e PatientIn und es erlitt kein/e Patien-
tIn während oder kurz nach dem Eingriff einen MI. Darüber hinaus starb 
kein/e PatientIn an Blutungen oder Schlaganfällen. Eine Studie berichtete, 
dass keine sehr späten ScTs auftraten. Es wurden keine Hinweise auf Blu-
tungen als Folge von Antiplättchentherapie, Komplikationen des Gefäßzu-
gangs oder verfahrensbedingte kontrastmittelinduzierte Nephropathie ge-
funden. 
b Fantom®  
Es konnte nur eine unkontrollierte Studie mit 6 Monaten Follow-up identifi-
ziert werden. In dieser Studie starb kein/e PatientIn während oder kurz 
nach dem Eingriff und es trat ein Fall von periprozeduralem MI auf. Darüber 
hinaus starb kein/e PatientIn während der 6-monatigen Nachbeobachtung 
an Blutungen oder Schlaganfällen. Da die Publikation nur über 6 Monate 
Follow-up-Ergebnisse berichtete, waren sehr späte ScT-Raten für Fantom® 
nicht verfügbar. Es wurden keine Hinweise auf Blutungen als Folge von An-
tiplättchentherapie, Komplikationen des Gefäßzugangs oder verfahrensbe-
dingte kontrastmittelinduzierte Nephropathie gefunden. 
Laufende Studien 
Es konnten zehn laufende RCTs und 21 Beobachtungsstudien identifiziert 
werden. Neun der RCTs und 12 der Beobachtungsstudien untersuchen Ab-
sorb® BVS, ein RCT und vier Beobachtungsstudien untersuchen Magmaris 
(Dreams 2G) BRS, zwei Beobachtungsstudien untersuchen DESolve® BRS 
und weitere zwei Beobachtungsstudien untersuchen Fantom® BRS. In einer 
Beobachtungsstudie war unklar, welches BRS Modell untersucht wurde. Die 
geplanten Studienabschlusstermine für die RCTs lagen zwischen Dezember 
2018 und April 2024. Darüber hinaus gab es sieben beendete oder derzeit 
eingestellte RCTs und zwei beendete oder eingestellte Beobachtungsstudien 
des Absorb® BVS sowie eine eingestellte Beobachtungsstudie des DESolve® 
BRS und eine weitere der Magmaris BRS. Gründe für die Aussetzung oder 
Beendigung der Studie waren eine langsame PatientInnenrekrutierung, Si-
cherheitsprobleme oder die Nichtverfügbarkeit des BRS. 
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 Diskussion 
Die Qualität der Evidenz für das Absorb® BVS wurde als hoch bis mittelgra-
dig für die Wirksamkeitsergebnisse und mittelgradig bis sehr niedrig für die 
Sicherheitsergebnisse beurteilt. Hauptgründe für die niedrige Qualität der 
Evidenz waren sehr niedrige Ereignisraten in den Studien und/oder ein ho-
hes Verzerrungsrisiko. Sieben Jahre nach der CE-Zulassung des Absorb® 
BVS zeigten die Ergebnisse von acht RCTs, darunter fast 6.000 PatientInnen, 
eine geringere Wirksamkeit in Bezug auf patientenrelevante Endpunkte im 
Vergleich zur 2. Generation von DES mit permanenter Beschichtung. Dies 
zeigte sich an den höheren Raten der Revaskularisation, MI und MACE, des 
kombinierten patienten-relevanten Endpunkts, der alle Todesfälle, alle MI 
und alle Revaskularisation umfasst. Bezüglich Sicherheitsendpunkte zeigten 
die Ergebnisse aus diesen RCTs ein signifikant höheres Risiko für sehr späte 
ScT nach 1-Jahres Follow-up oder länger bei PatientInnen, die mit Absorb® 
BVS behandelt wurden, als bei PatientInnenen, die mit DES mit permanenter 
Beschichtung behandelt wurden. Alle diese Ergebnisse basieren ausschließ-
lich auf Daten von Absorb BVS® Studien und können daher nicht direkt auf 
andere BRS übertragen werden.  
Für alle anderen CE- zertifizierten BRS (DESolve®, Magmaris, ART Pure und 
Fantom®) liegen derzeit keine Ergebnisse aus RCTs oder zumindest aus 
nicht randomisierten kontrollierten Studien vor. Sicherheitsergebnisse für 
diese andere CE- zertifizierten BRS sowie für Absorb® lagen nur aus weni-
gen unkontrollierten Kurzzeitstudien vor. Daher wird die derzeit verfügbare 
Evidenz für diese Produkte als sehr niedrig erachtet und man kann keine zu-
verlässigen Schlussfolgerungen auf ihre klinische Wirksamkeit und Sicher-
heit ziehen.  
Im Prinzip wurden vollständige BRS entwickelt, um unerwünschte Ereignis-
se wie Thrombose oder Restenose vorzubeugen, die durch das permanente 
Vorhandensein von Metallstents in den Gefäßen entstehen können. Nun, 
zehn Jahre nach ihrer Implementierung, zeigt die Evidenz aus Langzeit-RCTs 
genau das Gegenteil, nämlich mehr späte Thrombosen und höhere TLR-
Raten für PatientInnen, die mit BRS behandelt werden. Aufgrund dieser Er-
kenntnisse hat der Hersteller des Absorb® BVS dessen Produkt im Mai 2017 
vom Markt genommen. Alle anderen BRS sind deutlich weniger gut unter-
sucht. Da es jedoch erhebliche Unterschiede zwischen den einzelnen CE- zer-
tifizierten Stents sowohl in Bezug auf das Grundgerüstmaterial, das freige-
setzte Medikament, die Strebendicke und die Zeitdauer bis zum vollständi-
gen Abbau des Materials gibt, ist die Übertragbarkeit der Ergebnisse aus den 
Studien zur Untersuchung des Absorb® BVS auf die klinische Wirksamkeit 
und Sicherheit anderer Produkte begrenzt.  
Darüber hinaus ist die Anwendbarkeit der Ergebnisse aus den vorliegenden-
klinischen Studien eingeschränkt. Die meisten PatientInnen innerhalb der 
Studien waren Männer (60% oder mehr) im Alter zwischen 60 und 70 Jah-
ren, mit - in den meisten Fällen - einer oder maximal zwei einfachen Läsio-
nen. Die Ergebnisse dürfen auf weibliche Patientinnen, ältere PatientInnen 
oder PatientInnen mit komplexeren Läsionen nur mit großer Vorsicht über-
tragen werden. Darüber hinaus hatten in den ersten RCTs die meisten der 
eingeschlossenen PatientInnen eine stabile Angina, hingegen umfassten ei-
nige neuere RCTs überwiegend PatientInnen mit ACS. Jedoch sind die Ergeb-
nisse sowohl für PatientInnen mit stabiler Angina Pectoris als auch für Pati-
entInnen mit ACS anwendbar, da die Subgruppenanalysen, die RCTs mit 
mehr PatientInnen mit stabiler KHK mit jenen, mit mehr PatientInnen mit 
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instabiler KHK verglichen, keinen Unterschied in wichtigen Endpunkten 
zeigten.  
Aktuelle Guideline zur myokardialen Revaskularisation legen dar, dass die 
Evidenz für andere BRS als Absorb® BVS begrenzt ist und dass BRS nicht 
außerhalb gut kontrollierter klinischer Studien verwendet werden sollte. Die 
Ergebnisse aus RCTs für andere BRS als Absorb® BVS werden dringend be-
nötigt. Eine große Anzahl laufender Studien ist derzeit in ClinicalTrials.gov 
und der WHO-ICTR-Datenbank registriert, aber es wurde nur ein RCT identi-
fiziert, der nicht Absorb® BVS (sondern Magmaris) untersucht.  
Schlussfolgerung  
Basierend auf der verfügbaren Evidenz aus acht RCTs gilt der vollständig bi-
oresorbierbare Everolimus-eluierende Stent Absorb® BVS als weniger wirk-
sam und hat ein schlechteres Sicherheitsprofil als Stents mit permanenter 
Everolimus- oder Biolimusbeschichtung. Diese Schlussfolgerung basiert auf 
einem statistisch höherem Risiko für MI, TLR und sehr späte Thrombosen 
(nach einem Jahr oder länger) bei PatientInnen, die mit Absorb® BVS inner-
halb von bis zu vier Jahren behandelt wurden, und es konnte kein Nutzen für 
alle anderen Wirksamkeits- oder Sicherheitsendpunkte gezeigt werden.  
Es gibt keine ausreichende Evidenz, um festzustellen, ob Absorb® BVS als 
weniger wirksam oder weniger sicher als andere Revaskularisationsstrate-
gien angesehen wird.  
Es gibt keine ausreichende Evidenz, um festzustellen, ob die anderen vier 
derzeit CE-zertifizierten BRS (DESolve®, Magmaris, Art Pure oder Fan-
tom®) effektiver als (oder mindestens so effektiv wie) und/oder mit besse-
ren (oder mindestens ähnlichen) Sicherheitsprofilen als DES mit permanen-
ter Beschichtung oder andere Revaskularisationsstrategien sind. 
Es besteht ein dringender Bedarf an RCTs oder zumindest nicht-
randomisierten kontrollierten Studien mit einer höheren PatientInnenzahl 
und Langzeit-Follow-up, um feststellen zu können, ob die CE-zertifizierten 
BRS (DESolve®, Magmaris, Art Pure oder Fantom®) geeignete Alternativen 
zu DES mit permanenter Beschichtung oder anderen Revaskularissations-
strategien sind. 
aktuelle Guidelines 
empfehlen BRS nicht 
außerhalb kontrollierter 
klinischer Studien 
 
RCT-Ergebnisse für 
andere BRS als Absorb® 
dringend benötigt 
Absorb® ist weniger 
wirksam und sicher als 
Stents mit permanenter 
Beschichtung 
keine Aussage möglich zu… 
…Absorb® im Vergleich zu 
anderen 
Revaskularisationsstrategien  
 
…DESolve®, Magmaris, Art 
Pure oder Fantom® im 
Vergleich zu DES mit 
permanenter Beschichtung 
oder anderen 
Revaskularisationsstrategien 
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SUMMARY OF THE RELATIVE EFFECTIVENESS OF BIORESORBABLE 
STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS 
(CORONARY ARTERY DISEASE) 
Scope 
The scope can be found here: Scope. 
 
Introduction 
Description of technology and comparators 
The technology  
Fully bioresorbable stents or scaffolds (BRS) represent the latest generation of devices for myo-
cardial revascularisation strategies [1]. They comprise a degradable material, most commonly a 
polymer, such as poly(L-lactic acid) (PLLA) or a magnesium alloy, and are either drug coated or 
drug free. They are mainly built to overcome the risk of late complications, such as scaffold throm-
bosis or restenosis, which can occur when the rigid metal backbone of a conventional metal stent 
remains permanently embedded in the diseased vessel [2, 3]. To date, five devices (Absorb®, 
DESolve®, ART Pure, Fantom® and Magmaris) have received Conformité Européenne (CE) mark-
ing for their use in adult patients with coronary artery disease (CAD). Absorb® was also approved 
by the US market authorisation agency (Food and Drug Administration; FDA) in 2016. However, it 
has not been available on the market since the manufacturer stopped sales in May 2017 [4].  
The comparators 
The two main options currently available for revascularisation in patients with CAD are percutane-
ous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG) [5]. The first PCI 
technique developed was balloon angioplasty (percutaneous transluminal angioplasty; PTA). Alt-
hough coronary stenosis could be treated successfully with PTA, it also led to a high rate of acute 
vessel closures and restenosis. The next step was the introduction of bare metal stents (BMS). 
The implantation of such stents reduced vessel recoil, leading to better acute results, but resteno-
sis, resulting from neointimal hyperplasia, remained an issue [2]. To reduce this neointimal hyper-
plasia, so-called ‘drug-eluting stents’ (DES) were developed. With these stents, the metal scaffold 
is coated with an immunosuppressant or cytotoxic drug. A polymer coating is usually used for drug 
loading and control of elution kinetics. Sustained release of the drug reduces neointimal hyperplas-
ia, leading to a reduction in the rate of restenosis. However, because stent implantation can also 
lead to stent thrombosis with potentially deleterious consequences, it necessitates potent antiplate-
let therapy with a combination of aspirin and P2Y12 inhibitors, thus leading to potential bleeding 
complications. A consequence of the implantation of metal stents is that the metal cage remains in 
the vessel, providing a permanent stimulus for thrombosis and restenosis [2]. Nevertheless, per-
manent metallic stents with metallic cages remain the standard treatment technique for PCI [5]. 
CABG is a type of open-heart surgery that improves blood flow to the heart. During CABG, a 
healthy artery or vein is connected to the blocked coronary artery, so that the grafted artery or 
vein bypasses the blocked portion of the coronary artery. Although PCI is currently the most 
commonly used revascularisation intervention, CABG still has an important role in the manage-
ment of patients with advanced obstructive coronary disease. Compared with the implantation of a 
stent, CABG is more invasive and, thus, associated with higher periprocedural risk [2]. 
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Health problem 
The target population for this assessment was patients with stable or unstable CAD. CAD is a 
prevalent disease defined as the manifestation of arteriosclerosis in the coronary arteries and is 
the leading cause of death in Europe [6]. Risk factors for CAD that can be controlled are smoking, 
high alcohol consumption, lack of physical activity, high blood cholesterol levels, overweight or obe-
sity, diabetes mellitus, hypertension and psychosocial burden, such as stress or depression [7-9]. 
Patients with CAD have an elevated risk for myocardial infarction (MI), cardiac arrhythmias, such 
as atrial fibrillation, heart failure and premature mortality [7]. Symptoms for CAD typically include 
shortness of breath and chest pain (angina pectoris). In patients with stable angina pectoris, the 
symptoms do not change over a long time period, whereas, in patients with unstable angina pec-
toris, either the symptoms suddenly increase without physical exertion or the exertion threshold 
changes [10]. 
In 2015, almost 17 million men and more than 13 million women were living with CAD in Europe. 
The overall costs for CAD (including direct healthcare costs, productivity losses and informal care 
costs) have been estimated at over €59 billion [11]. 
The diagnosis and assessment of stable CAD involves clinical evaluation, including identifying 
significant dyslipidaemia, hyperglycaemia, or other biochemical risk factors, and specific cardiac 
investigations, such as stress testing or coronary imaging. For suspected acute coronary syndromes 
(ACSs), initial assessment is based on the integration of low-likelihood and/or high-likelihood fea-
tures derived from clinical presentation (i.e., symptoms and vital signs), 12-lead electrocardiog-
raphy (ECG) and biomarkers (especially cardiac troponin). Non-invasive imaging, such as trans-
thoracic echocardiography, can aid diagnosis [9].  
 
Methods 
The HTA Core Model Application for Rapid Relative Effectiveness Assessment (REA; 4.2) was 
the primary source for selecting assessment elements. This assessment was based on a system-
atic review of the same topic authored by Ludwig Boltzmann Institute for Health Technology As-
sessment (LBI-HTA) in 2015 [12]. To identify primary studies for Effectiveness (EFF) and Safety 
(SAF) domains fulfilling the predefined inclusion criteria outlined in the Scope of this assessment, 
we conducted systematic literature searches on the 10th September 2018 of the bibliographic data-
bases Medline, PubMed, Embase and the Cochrane Central Register of Controlled Trials. In addi-
tion, we searched the Cochrane Database for Systematic Reviews for topic-related review arti-
cles. References from relevant original articles and reviews were hand-searched to identify addi-
tional primary studies. Furthermore, a search for relevant ongoing studies was carried out of the 
clinical trial registries ClinicalTrials.gov and World Health Organisation (WHO)-International Clini-
cal Trials Registry Platform (ICTRP). Information for the ‘Description and technical characteristics 
of technology’ (TEC) and ‘Health problem and current use of technology’ (CUR) domains was de-
rived from current clinical guidelines on the topics ‘management of stable/unstable CAD’ or ‘re-
vascularisation strategies’ identified through a systematic search of the Guidelines International 
Network (GIN) database, and from consultations with the manufacturers of relevant devices and 
with clinical experts. 
For TEC and CUR domains, no quality assessment tool was used, but multiple sources were 
used to validate individual, possibly biased, sources. Descriptive analyses of different information 
sources were performed. For the EFF and SAF domains, we applied EUnetHTA guidelines to the 
selection of quality-rating tools. Risk of bias at the study level and endpoint level for randomised 
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controlled trials (RCTs) was assessed using the Cochrane risk of bias tool [13]. Risk of bias at the 
study level for the single-arm studies was assessed using the Institute of Health Economics (IHE) 
20-Criteria checklist [14, 15]. Two reviewers performed the risk of bias assessment independently. 
Disagreements were resolved by consensus. The quality of the body of evidence was assessed 
using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 
methodology [16]. 
 
Results 
Available evidence 
The inclusion criteria for assessing the clinical effectiveness of fully BRS were exclusively restrict-
ed to studies with a comparison group, including RCTs and non-RCTs. The inclusion criteria for 
assessing safety considered in addition to RCTs and non-RCT studies were prospective studies 
without a control group (single-arm studies, case series and registry studies) with at least 50 pa-
tients. In our systematic literature search, eight relevant RCTs, reported in 18 publications, were 
identified [17-34]. All studies assessed the everolimus-eluting Absorb® bioresorbable vascular scaf-
fold (BVS) as intervention. In seven RCTs, an everolimus-eluting permanent metal stent (Xience® 
or Synergy®) was the comparator device. One study used two different comparators: an everoli-
mus-eluting permanent metallic stent (Promus Element) and a biolimus-eluting permanent metal 
stent (Biomatrix Flex) [22, 33]. The total number of patients included in the eight RCTs was 5863. 
All but one study [28] included patients with stable or unstable CAD. In these studies, the per-
centage of patients with stable angina ranged from 20% to 65%. One RCT included only patients 
with acute ST-segment elevation MI (STEMI) [28]. Most study participants were male (70–80%), 
with a mean age range of 57–67 years.  
For safety outcomes, we additionally identified 45 prospective single-arm studies (observational 
studies and registries) [35-105], that met our inclusion criteria. Three of the 45 prospective studies, 
with 345 patients, investigated the DESolve® device [37, 61, 76] and two studies, totalling 184 pa-
tients, investigated the Magmaris (Dreams 2G) device [35, 56, 58, 82], one with published results 
at 12 months and the other at 24 months of follow-up. One publication reported results at 6 months 
follow-up for 117 of 240 patients treated with the Fantom® device [52]. No relevant study was 
identified for the ART Pure bioresorbable stent. In the remaining 39 prospective uncontrolled stud-
ies with a total of more than 15,000 patients, the Absorb® BVS was the investigated device [36, 
38-51, 53-55, 57, 59, 60, 62-75, 77-81, 83-105]. Most of these studies had a mean duration of 
follow-up of 12 to 24 months [38, 39, 41, 43, 45, 47, 50, 53-55, 57, 59, 64, 65, 67-69, 71-75, 77, 
79-81, 83, 84, 87-89, 94, 100-104]. Six studies reported results for a longer follow-up [36, 40, 44, 
46, 60, 66, 70, 78, 85, 86, 92, 93, 95-99, 105].  
In all 45 uncontrolled studies included, the study population was predominately male (60–90%) 
with a mean age range of 54–66 years. In 22 studies (two for DESolve®, one for Magmaris and 19 
for Absorb®), most patients had stable angina at study inclusion [36, 41, 44, 46-48, 53-55, 58-61, 
65-67, 69-71, 74, 76, 77, 79-82, 86, 87, 91, 92, 100, 102, 103, 105], whereas, in another 19 stud-
ies, all investigating the Absorb® BVS, the patients predominantly had an ACS [38-40, 42, 43, 45, 
49-51, 57, 62-64, 68, 72, 73, 77, 83-85, 88-90, 94, 95, 99, 101, 104]. In the remaining four studies 
details on the indication for stent implantation were not reported [35, 37, 52, 56, 78, 93, 96-98]. 
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Clinical effectiveness 
To describe the clinical effectiveness of fully BRS, the following patient-relevant outcomes were 
considered: major adverse cardiac events (MACE), all-cause mortality, cardiac mortality, angina, 
MI, quality of life, and daily functioning. In addition, the surrogate endpoints target vessel revascu-
larisation (TVR) and target lesion revascularisation (TLR) were assessed. Whereas meta-anal-
yses for all-cause mortality and cardiac mortality showed no significant difference between Ab-
sorb® BVS and permanent metal DES {risk ratio (RR) 0.84 [95% confidence interval (CI) 0.63–
1.11] and RR 0.91 (95% CI 0.60–1.39)}, there was a significant increased risk for MACE [RR 1.36 
(95% CI 1.06–1.73)], MI [RR 1.49 (95% CI 1.21–1.84)], and TLR [RR 1.36 (95% CI 1.08–1.71)] for 
patients treated with the Absorb® BVS. For quality of life and daily functioning, no differences be-
tween Absorb® BVS and permanent metal DES were reported.  
No evidence was identified to answer the research questions regarding the effectiveness for the 
other four CE-marked fully BRS (DESolve®, Magmaris, ART Pure and Fantom®). 
 
Safety 
To assess the safety of fully BRS, serious adverse events (SAEs), such as periprocedural MI or 
mortality, scaffold thrombosis (ScT) that occurred after at least 1 year of follow-up, mortality as a 
result of bleeding or stroke, or adverse events, such as bleeding as a result of antiplatelet therapy, 
vascular access-site complications, or procedure-related contrast-induced nephropathy, were con-
sidered.   
For the Absorb® BVS, results from RCTs showed no statistically difference for periprocedural MI 
compared with permanent metal DES [RR 1.22 (95% CI 0.82–1.82)]. No MIs occurred during or 
shortly after the implantation of the Absorb® BVS in eight single-arm studies, whereas, in a further 
20 single-arm studies, the median rate of periprocedural MI was 2.8% (range 0.2%–12%). Results 
of periprocedural death were published only in two RCTs and 22 single-arm studies, with no pa-
tients dying during index procedure in 21 studies, including the two RCTs. In the remaining three 
single-arm studies, the rates of periprocedural mortality were 0.04%, 0.5%, and 1.3%, respective-
ly. The overall rate of ScT that occurred after at least 1 year of follow-up was low in the included 
studies. Nevertheless, compared with permanent metal DES, the meta-analysis from RCTs re-
sulted in a statistically significant higher risk for very late ScT in patients treated with the Absorb® 
BVS [RR 5.09 (95% CI 1.9–13.17)]. In seven single-arm studies investigating the Absorb® BVS, 
no very late ScT occurred. In 13 single-arm studies, the rate of very late ScT ranged from 0.2% to 
1.7%. Bleeding resulting from antiplatelet therapy was reported only in five single-arm studies 
(event rate: 1%–4.4%) and mortality as a result of bleeding or stroke in 11 single-arm studies, with 
no events in nine studies and one death each in the remaining two studies. Results of vascular 
access site complications were derived from only two single-arm studies (event rate: 0.09% and 
0.7%). No evidence was found for the endpoint of procedure-related contrast-induced nephropa-
thy. Comparing the results from RCTs or prospective uncontrolled studies including predominantly 
patients with stable angina to those studies including predominantly patients with ACS, no differ-
ence was found regarding the rates of safety events. 
For the DESolve® device, no safety results were available from RCTs. Periprocedural death or 
periprocedural MIs were reported in three uncontrolled studies, with no patient dying during or short-
ly after the procedure and only one case of periprocedural MI occurred. In addition, no patient 
died from bleeding or stroke. Very late ScTs could be derived only from one study, with no events 
reported. No evidence was found for the endpoints bleeding as a result of antiplatelet therapy, 
vascular access site complication, or procedure-related contrast-induced nephropathy. 
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For the Magmaris (Dreams 2G) device, no safety results were available from RCTs. Periproce-
dural death or periprocedural MIs were reported in the two uncontrolled studies. In both studies, 
no patient died or had a MI during or shortly after the procedure. In addition, no patient died from 
bleeding or stroke. Very late ScTs could be derived only from one study, with no events reported. 
No evidence was found for the endpoints bleeding as a result of antiplatelet therapy, vascular 
access site complication, or procedure-related contrast-induced nephropathy. 
For the Fantom® device, no RCTs and only one publication reporting data at 6 months follow-up 
from an uncontrolled study could be identified. In this study, no patient died during or shortly after 
the procedure and one case of periprocedural MI occurred. In addition, no patient died from bleed-
ing or stroke during the 6 months follow-up. Given that the publication reported only 6 months 
follow-up results, very late ScT rates were not available for the Fantom® device. No evidence was 
found for the endpoints bleeding as a result of antiplatelet therapy, vascular access site complica-
tion, or procedure-related contrast-induced nephropathy. 
 
Upcoming evidence 
Searches of ClinicalTrial.gov and WHO-ICTRP for fully BRS identified ten ongoing RCTs and 21 
ongoing observational studies. Nine of the RCTs and 12 of the observational studies are investi-
gating the Absorb® BVS, one RCT and four observational studies were investigating the Magmaris 
(Dreams 2G) device, two observational studies were investigating the DESolve® and another two 
observational studies were investigating the Fantom® device. In one observational study, the type 
of the investigated BRS was unclear. Planned study completion dates for the RCTs ranged from 
December 2018 to April 2024. In addition, there were seven terminated or currently suspended 
RCTs and two terminated or suspended observational studies of the Absorb® BVS, and a sus-
pended observational study of the DESolve® device and another of the Magmaris device listed. 
Reasons for study suspension or termination were slow enrolment, BRS safety issues, or unavail-
ability of the BRS device. 
 
Discussion 
The overall quality of evidence for the Absorb® BVS is high to moderate for effectiveness outcomes 
and moderate to very low for safety outcomes (Table 1: ). Main reasons for the low quality of evi-
dence were very low event rates in the studies and/or a high risk of bias. Seven years after the CE 
approval of the Absorb® BVS, the results of eight RCTs, together including nearly 6000 patients, 
indicated a lower effectiveness in terms of patient-relevant outcomes compared with the second 
generation of permanent metal DES. This was apparent from the higher rates of target-lesion 
revascularisation, all MI, and MACE, and of the combined patient-oriented composite endpoint 
(POCE), which includes all death, all MI, and all revascularisation. Regarding safety outcomes, the 
evidence from these RCTs showed a significantly higher risk of very late ScT after 1 year of follow-
up or longer for patients treated with Absorb® BVS compared with patients treated with drug-eluting 
permanent metal stents. All these results are exclusively based on Absorb BVS® data and, there-
fore, cannot directly be transferred to other BRS devices.  
For all other CE-marked BRS devices (DESolve®, Magmaris, ART Pure and Fantom®), no results 
from randomised or at least nonrandomised controlled trials are currently available. Safety results 
for these other CE-market devices in addition to Absorb® were available only from some individual 
single-arm short-term studies. Therefore, the evidence currently available for these products is very 
low and does not allow reliable conclusions to be drawn with regard to their clinical effectiveness 
and safety (Table 2, Table 3 and Table 4).  
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In principle, fully BRS have been developed to overcome adverse events, such as device throm-
bosis or restenosis that can arise from the permanent presence of metallic stents in the vessels. 
Now, ten years after their implementation, the evidence from long-term RCTs shows exactly the 
opposite, namely more late ScT and higher rates of TLRs for patients treated with BRS devices. 
Based on this evidence, the manufacturer of the Absorb® BVS withdrew the device from the mar-
ket in May 2017. All other BRS are less well studied. However, given that there are considerable 
differences between the individual CE-marked devices with regard to both the backbone material, 
the drug released, the strut thickness and the time to full mass loss, the transferability of the re-
sults from the studies investigating the Absorb® BVS to the clinical effectiveness and safety of 
other products is limited.  
Beyond that, applicability of the results from both current clinical trials and current single-arm stud-
ies to routine patients is limited. Most of the patients within the studies were males (60% or more) 
aged between 60 and 70 years, with, in most cases, one or a maximum of two simple lesions. 
Therefore, caution is required when transferring the results to female patients, patients with a wid-
er age range, or patients with more complex lesions. Whereas, in initial RCTs, most of the includ-
ed patients had stable angina, some recent RCTs predominantly included patients with ACS. 
Subgroup analyses comparing RCTs including more patients with stable CAD with those including 
more patients with unstable CAD showed no difference in key endpoints. Therefore, the results 
are applicable for both patients with stable angina pectoris and patients with ACS.  
Current guidelines on myocardial revascularisation state that evidence for BRS other than Absorb® 
BVS is limited and any BRS should not be used outside well-controlled clinical studies. Results 
from RCTs for BRS other than the Absorb® BVS are urgently needed to investigate the technolo-
gy of fully BRS. A large number of ongoing studies are currently registered on ClinicalTrials.gov 
and the WHO-ICTR database, but there is only one RCT among them that examines a device 
(Magmaris) other than the Absorb® BVS.  
 
Conclusion 
Based on evidence from eight RCTs, the fully bioresorbable everolimus-eluting stent Absorb® BVS 
is considered to be less effective and to have a worse safety profile compared with everolimus- or 
biolimus-eluting permanent metal stents. This conclusion is based on a statistically higher risk for 
MI, TLR and very late ScT (after 1 year of follow-up or longer) for patients treated with Absorb® BVS 
within a follow-up of up to 4 years, with no benefit in all other effectiveness or safety endpoints.  
There is insufficient evidence to determine whether Absorb® BVS is considered less effective or 
less safe than other revascularisation strategies.  
There is insufficient evidence to determine whether the other four currently CE-certificated fully 
bioresorbable sent systems [DESolve®, Magmaris (Dreams 2G), Art Pure or Fantom®] are more 
effective than (or at least as effective as) and/or have better (or at least similar) safety profiles 
compared with drug-eluting permanent metal stents or other revascularisation strategies. 
There is an urgent need for RCTs, or at least nonrandomised controlled trials, with a higher num-
ber of patients and long-term follow-up to be able to determine whether the CE-certificated fully 
BRS systems (DESolve®, Magmaris, Art Pure or Fantom®) are suitable alternatives to drug-eluting 
permanent metal stents or other revascularisation strategies. 
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Table 1: Summary of findings table of Absorb® BVS 
Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with DES Risk with Absorb® BVS 
Effectiveness 
All-cause mortality  
(2–4 years follow-up) 
38 per 1000 32 per 1000  
(24–43) 
RR 0.84  
(0.63–1.11) 
5645 ⨁⨁⨁⨀ 
moderate1 
— 
All-cause mortality  
(≥3 years follow-up) 
41 per 1000 34 per 1000  
(26–46) 
RR 0.82  
(0.62–1.10) 
5001 ⨁⨁⨁⨀ 
moderatea 
— 
Cardiac mortality  
(6 months–4 years follow-up) 
16 per 1000 15 per 1000  
(10–23) 
RR 0.91  
(0.60–1.39) 
5830 ⨁⨁⨁⨀ 
moderatea 
— 
Cardiac mortality  
(≥3 years follow-up) 
18 per 1000 16 per 1000  
(11–25) 
RR 0.89  
(0.58–1.38) 
5185 ⨁⨁⨁⨀ 
moderatea 
— 
MI (1–4 years of follow-up) 49 per 1000 73 per 1000  
(60–91) 
RR 1.49  
(1.21–1.84) 
5845 ⨁⨁⨁⨁  
high 
— 
MI (≥3 years follow-up) 53 per 1000 77 per 1000  
(62–96) 
RR 1.44  
(1.16–1.80) 
5001 ⨁⨁⨁⨁  
high 
— 
Safety 
Periprocedural mortality — — — 419 ⨁⨁⨀⨀  
low2 
No events of periprocedural mortality occurred 
in either the BRS or DES groups in two RCTs 
Periprocedural MI 60 per 1000 73 per 1000  
(49–109) 
RR 1.22  
(0.82–1.82) 
5503 ⨁⨁⨁⨀  
moderatea 
— 
Mortality as a result of 
bleeding or stroke (6–60 
months follow-up) 
— — — 1402 ⨁⨀⨀⨀  
very low3 
Two deaths from bleeding or stroke occurred  
in 11 single-arm observational studies with 
Absorb® BVS in 6–60 months follow-up 
Very late ScT (after at least  
1 year of follow-up) 
1 per 1000 7 per 1000  
(3–17) 
RR 5.09 
(1.97–13.17) 
5549 ⨁⨁⨁⨀  
moderate4 
— 
Abbreviations: BRS=bioresorbable scaffold; BVS=bioresorbable vascular scaffold; CI=confidence interval; DES=drug-eluting stent; MI=myocardial infarction; RR=risk ratio; ScT=scaffold thrombosis. 
                                                     
1 Downgraded by by 1 point because of imprecision. 
2 Downgraded by by 2 points because of imprecision. 
3 Downgraded by by 3 points because of risk of bias and imprecision. 
4 Downgraded by by 1 point because of imprecision. 
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Table 2: Summary of findings table for the DESolve® Scaffold System 
Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with DES or other 
revascularisation strategies 
Risk with DESolve® 
Scaffold System 
Effectiveness 
All-cause mortality  — — — — — Outcome not reported 
Cardiac mortality  — — — — — Outcome not reported 
MI  — — — — — Outcome not reported 
Safety 
Periprocedural mortality — — — 345 ⨁⨀⨀⨀  
very low5 
No events of periprocedural mortality 
occurred in three single-arm observational 
studies of the DESolve® Scaffold System 
Periprocedural MI — — — 345 ⨁⨀⨀⨀  
very lowe 
One periprocedural MI occurred in three 
single-arm observational studies of the 
DESolve® Scaffold System 
Mortality as a result  
of bleeding or stroke  
(12 months follow-up) 
— — — 219 ⨁⨀⨀⨀  
very lowe 
No death from bleeding or stroke occurred 
in two single-arm observational studies of 
the DESolve® Scaffold System in 12 months 
follow-up 
Very late ScT  
(after at least 1 year  
of follow-up) 
— — — 126 ⨁⨀⨀⨀  
very lowe 
No very late ScT after at least 1 year  
of follow-up occurred in one single-arm 
observational study of the DESolve® 
Scaffold System 
Abbreviations: CI=confidence interval; DES=drug-eluting stent; MI=myocardial infarction; ScT=scaffold thrombosis. 
 
 
                                                     
5 Downgraded by by 3 points because of risk of bias and imprecision. 
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Table 3: Summary of findings table for RMS Magmaris  
Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with DES or other 
revascularisation strategies 
Risk with  
RMS Magmaris  
Effectiveness 
All-cause mortality  — — — — — Outcome not reported 
Cardiac mortality  — — — — — Outcome not reported 
MI  — — — — — Outcome not reported 
Safety 
Periprocedural mortality — — — 184 ⨁⨀⨀⨀ 
very low6 
No events of periprocedural mortality 
occurred in two single-arm observational 
studies of RMS Magmaris 
Periprocedural MI — — — 184 ⨁⨀⨀⨀ 
very lowf 
No periprocedural MI occurred in two 
single-arm observational studies of RMS 
Magmaris 
Mortality as a result  
of bleeding or stroke  
(24 months follow-up) 
— — — 184 ⨁⨀⨀⨀ 
very lowf 
No death from bleeding or stroke occurred 
in two single-arm observational studies of 
RMS Magmaris in 24 months follow-up 
Very late ScT (after at 
least 1 year of follow-up) 
— — — 123 ⨁⨀⨀⨀ 
very lowf 
No very late ScT occurred after at least  
1 year of follow-up in one single-arm 
observational study of RMS Magmaris 
Abbreviations: CI=confidence interval; DES=drug-eluting stent; MI=myocardial infarction; RMS=resorbable magnesium scaffold; ScT=scaffold thrombosis. 
  
                                                     
6 Downgraded by by 3 points because of risk of bias and imprecision. 
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Table 4: Summary of findings table for Fantom® BRS  
Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with DES or other 
revascularisation strategies 
Risk with  
Fantom® BRS 
Effectiveness 
All-cause mortality  — — — — — Outcome not reported 
Cardiac mortality  — — — — — Outcome not reported 
MI  — — — — — Outcome not reported 
Safety 
Periprocedural mortality — — — 117 ⨁⨀⨀⨀ 
very low7 
No events of periprocedural mortality 
occurred in two single-arm observational 
studies of Fantom® BRS 
Periprocedural MI — — — 117 ⨁⨀⨀⨀ 
very lowg 
One periprocedural myocardial infarction 
occurred in one single-arm observational 
study of Fantom® BRS 
Mortality as a result  
of bleeding or stroke  
(24 months follow-up) 
— — — 117 ⨁⨀⨀⨀ 
very lowg 
No death from bleeding or stroke occurred 
in two single-arm observational studies of 
Fantom® BRS in 6 months follow-up 
Very late ScT (after at 
least 1 year of follow-up) 
— — — — — Outcome not reported 
Abbreviations: BRS=bioresorbable scaffold; CI=confidence interval; DES=drug-eluting stent; MI=myocardial infarction; ScT=scaffold thrombosis. 
                                                     
7 Downgraded by by 3 points because of risk of bias and imprecision. 
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1 SCOPE 
Description Project Scope 
Population  Adult patients with CAD, including stable angina, unstable angina, and/or MI 
[International Classification of Diseases (ICD)-10 code I20-I25] who require, 
and are eligible for, myocardial revascularisation  
Major Subject Heading (MeSH) terms: Heart Disease [C14.280], Myocardial 
Ischemia [C14.280.647], Acute Coronary Syndrome [C14.280.674.124] Angina 
Pectoris [C14.280.647.124], Coronary Disease [C14.280.647.250], Coronary 
Artery Disease [C14.280.64], Myocardial Infarction [C14.280.674.7.250.260]  
Intervention  PCI with implantation of a fully bioabsorbable, biodegradable or bioresorbable 
vascular scaffold or stent (BRS) 
Product names: Absorb, DESolve®, MAGMARIS (DREAMS),  
ART Pure (ART18Z), Fantom® 
Trials: ABSORB, BIOSOLVE, DESolve Nx-Trial, ARTDIVA, RESTORE 
MeSH terms: Percutaneous Coronary Intervention [E04.100.814.529.968], 
Stents [E07.695.750], Drug-Eluting Stents [E07.695.750.500] 
Comparison PCI with implantation of other stent types or other revascularisation strategies 
MeSH-terms: Percutaneous Coronary Intervention [E04.100.814.529.968], 
Stents [E07.695.750], Drug-Eluting Stents [E07.695.750.500], Coronary Artery 
Bypass [E04.100.376.719.332] 
Rationale: PCI by implanting a permanent DES or BMS or with a bioresorbable 
polymer DES is currently the main strategy to treat CAD [7, 9, 106]; another 
alternative for revascularisation is CABG, which can result in more complete 
revascularisation, but with a higher procedural risk [7, 9, 106]. 
Outcomes Effectiveness: 
Clinical endpoints 
• Mortality (cardiac, all-cause)  
• Morbidity: angina, MI 
• Quality of life 
• Daily functioning 
Composite endpoints:  
• MACE 
Surrogate endpoints: 
• Revascularisation: TVR, TLR 
Other endpoints:  
• Duration of procedure 
Long-term results  
• ≥3 years of follow-up 
Rationale: CAD is associated with an increased risk of mortality and with 
impaired quality of life, reduced physical endurance, mental depression and 
recurrent hospitalisation or outpatient visits [7]. Therefore, revascularisation 
should ideally prolong life expectancy, reduce symptoms and future 
revascularisations, and increase health-related quality of life. 
Safety: 
Adverse events (AEs) 
• vascular access site complication 
• procedure-related contrast-induced nephropathy 
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SAEs 
• late/very late (after ≥1 year) ScT and/or stent thrombosis and  
its consequences  
• bleeding as a result of antiplatelet therapy  
• periprocedural MI or mortality 
• mortality as a result of bleeding and/or stroke 
• other SAEs  
Long-term results 
• ≥1 year of follow up 
Rationale: compared with CABG, PCI + stenting has lower periprocedural risks 
but bears the risk of late stent thrombosis with potentially severe consequences. 
Furthermore, the treatment requires long-term antiplatelet therapy, which bears 
the risk of potentially life-threatening bleeding. Finally, PCI + stenting can be 
associated with complications at the vascular access site or with nephropathy 
because of the contrast media used in the coronary angiography [107, 108]. 
Study 
design 
Effectiveness: RCTs 
Safety: RCTs; prospective nonrandomised controlled trials; prospective 
(single-arm) observational studies (e.g., case series), registries with at least  
50 patients 
Abbreviations: AE=adverse event; BMS=bare metal scaffold; BRS=bioresorbable scaffold; CABG=coronary artery 
bypass graft surgery; CAD=coronary artery disease; DES=drug-eluting stent; MACE=major adverse cardiac events; 
MI=myocardial infarction; PCI=percutaneous coronary intervention; RCT=randomised controlled trial; SAE=serious 
adverse event; ScT=scaffold thrombosis; TLR=target lesion revascularisation; TVR=target vessel revascularisation. 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment Team 
Description of the distribution of responsibilities and the workload between authors and co-authors: 
IAMEV (author): 
• Develop first draft of the project plan; amend the project plan following comments  
of co-authors, dedicated reviewers and external experts. 
• Perform the literature search, study selection, data extraction and risk of bias assessment; 
meta-analyses and the quality of the body of evidence assessment; check the discrepancies 
from study selection with the co-author and resolve via third reviewer 
• Answer assessment elements for TEC and CUR domains  
• Develop first draft of assessment 
• Send draft versions to co-authors, dedicated reviewers and external experts,  
and perform amendments according to comments 
• Prepare final assessment, including an executive summary. 
SNSPMPDSB (co-author): 
• Review and comment on the draft project plan 
• Check and approve literature search 
• Perform study selection 
• Check all data extractions and risk of bias assessments for included studies 
• Review the draft assessment, propose amendments if necessary and provide  
written feedback 
 
2.2 Source of assessment elements 
The HTA Core Model Application for rapid REA (4.2) is the primary source for selecting assessment 
elements. The selected assessment elements (generic questions) were translated into specific 
research questions.  
 
2.3 Search 
To identify primary studies fulfilling the inclusion criteria for EFF and SAF domains, systematic 
literature searches were conducted on the 10th September 2018 of the following databases:  
• Medline via Ovid 
• PubMed 
• Embase  
• Cochrane Central Register of Controlled Trials 
• Cochrane Database for Systematic Reviews 
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In addition to the electronic search, references from relevant original articles and reviews (identified 
by a search of the Cochrane Database for Systematic Reviews) were assessed. 
Furthermore, a search for relevant ongoing studies was carried out of the following clinical trials 
registries: 
• ClinicalTrials.gov 
• WHO-ICTRP  
Current clinical guidelines on the topics ‘management of stable/unstable CAD’ or ‘revascularisa-
tion strategies’ were searched in the GIN database, to retrieve information for the TEC and CUR 
domains. 
We contacted manufacturers, particularly for information regarding CE marks, marketing, availability 
and current use of the technology. Manufacturers were also asked about unpublished trial results. 
Detailed tables on search strategies are included in Appendix 1. 
 
2.4 Study selection 
The systematic literature searches of bibliographic databases yielded 4408 citations. After removal 
of duplicates, 2376 references remained. One additional reference was identified through the search 
of study registries. Two researchers independently screened the 2377 citations for eligibility. In 
case of disagreements, a third researcher was involved to resolve the differences. In a first step, 
2192 citations were excluded based on their titles and abstracts and, in a second step, 96 of the 
remaining 185 articles were excluded after reviewing the full texts. This left 89 articles meeting the 
inclusion criteria, of which 18 reported on eight RCTs [17-34] and 71 on 45 prospective cohort stud-
ies [35-105] (Figure 1). Hand searches of the reference lists of the included studies or topic-related 
systematic reviews and enquiries to the device manufacturers resulted in no additional relevant 
studies. 
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Figure 1: Flow chart of literature review process. 
Searches of the study registries ClinicalTrial.gov and WHO-ICTRP identified 267 potentially rele-
vant entries after the removal of duplicates. Two researchers independently screened the registry 
entries for eligibility. In case of disagreements, a third researcher was involved to resolve the dif-
ferences. At the end of the study selection process, 57 relevant studies investigating fully BRS 
remained. These include five completed trials, three of which were already included from the 
search of bibliographic databases, with the other two without published results, and ten ongoing 
RCTs. In addition, there were seven terminated or currently suspended RCTs listed. In all but one 
RCT, the Absorb® BVS was the investigated device. Details of the characteristics of ongoing RCTs 
are presented in the Appendix 1. 
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(n = 2192) 
Full-text articles assessed 
for eligibility  
(n = 185) 
Full-text articles excluded,  
with reasons  
(n = 96) 
Exclusion criteria are: 
• No primary study (n = 17) 
• No full-text publication (n = 15) 
• No relevant outcome (n = 39) 
• Not English/German/ 
French/Spanish (n = 1) 
• Control intervention (n = 1) 
• Cohort study not 
prospectively planned (n = 18) 
• Cohort study <50 persons 
(n = 5) 
Studies included in qualitative synthesis  
(n = 89) 
• RCTs [8 studies (18 articles)] 
• Uncontrolled cohort trials  
[45 studies (71 articles)] 
Studies included in quantitative synthesis 
(meta-analyses) 
RCTs [8 studies (18 articles)] 
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2.5 Data extraction and analyses 
The following characteristics and all reported results regarding the predefined outcomes from all 
included studies were extracted in evidence tables by one reviewer and checked independently 
by another reviewer: 
• Study characteristics (authors, year of publication, setting/country, objective, inclusion crite-
ria, study design, study duration, primary study endpoint, clinical trial identification number/ 
registry identifier and funding source)  
• Participant/patient characteristics (number of participants in the trial, age, sex, and condition)  
• Intervention and control characteristics (name/type of the device, comparator, description of 
procedure, antiplatelet co-therapy, length of follow-up and loss to follow-up)  
Dichotomous data were expressed as a RR or odds ratio (OR) with 95% CIs or as the number of 
events and percentages. Continuous outcomes were given using the mean with standard deviation 
(SD). For endpoints reported in at least two included RCTs, meta-analyses were performed using 
the Cochrane Review Manager software, Review Manager 5.3 [109]. Subgroup analyses were 
planned for the type of eluted drug, the indication for stent implantation (stable/unstable condition) 
or type of antiplatelet therapy after stent implantation. Given that the included RCTs only investi-
gated the everolimus-eluting Absorb® BVS with nearly the same postprocedural antiplatelet therapy, 
including patients with stable and unstable disease, these subgroup analyses were not possible. 
 
2.6 Quality rating  
For the TEC and CUR domains, no quality assessment tools were used, but multiple sources were 
used to validate individual, possibly biased, sources. Descriptive analyses of different information 
sources were performed. 
For the EFF and SAF domains, we applied EUnetHTA guidelines to the selection of quality-rating 
tools. Risk of bias at the study level and endpoint level for RCTs was assessed using the Cochrane 
risk of bias tool [13]. Risk of bias at the study level for the single-arm studies was assessed using 
the IHE 20-Criteria checklist [14, 15]. Two reviewers performed the risk of bias assessment inde-
pendently. Disagreements were resolved by consensus. 
The quality of the body of evidence was assessed using the GRADE methodology [16]. The 
authors performed the GRADE assessment and the co-authors checked it. 
 
2.7 Description of the evidence used 
For the EFF domain, data from eight RCTs were analysed, and for the SAF domain, in addition to 
the already mentioned RCTs, data from 45 prospective single-arm cohort studies were included 
(Table 5). 
 
2.8 Deviations from project plan 
The Xlimus® bioresorbable stent (Cardionovum Corporate, Bonn, Germany), which was considered 
relevant in the project plan, was not included in the assessment because it is not a fully BRS but a 
bioresorbable polymer-coated metal stent [2, 110]. 
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Table 5: Main characteristics of studies included 
Author and year 
or study name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Length of 
follow-up 8 
Included in clinical 
effectiveness and/or 
safety domain 
Absorb II [19, 20, 
23, 27, 32, 34] 
RCT, superiority 501  
(335 vs. 
166) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent metallic 
stent/Xience®  
Vasomotion; MLD post nitrate minus 
MLD postprocedure post nitrate by 
QCA 
4 years Effectiveness and 
safety 
Absorb III  
[24, 30] 
RCT, non-inferiority 2008  
(1322 
vs. 686) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent metallic 
stent/Xience®  
Number of patients with TLF (cardiac 
death, TV-MI or ID-TLR) at 1 year 
3 years Effectiveness and 
safety 
Absorb Japan 
[26, 31] 
RCT, non-inferiority 400  
(266 vs. 
134) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent metallic 
stent/Xience Prime or Xience Xpedition®  
Number of patients with TLF (cardiac 
death, TV-MI or ID-TLR) at 1 year 
3 years Effectiveness and 
safety 
Absorb China 
[17, 29] 
RCT, non-inferiority 480  
(242 vs. 
239) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent metallic 
stent/Xience® 
Angiographic in-segment LL after  
1 year 
3 years Effectiveness and 
safety 
AIDA [18, 25] RCT, non-inferiority 1845  
(924 vs. 
921) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent metallic 
stent/Xience Prime or Xience Xpedition®  
TVF (cardiac death, TV-MI or TVR) 
at 2 years 
3 years Effectiveness and 
safety 
Trofi II [28] RCT, non-inferiority 191  
(95 vs. 
96) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent metallic 
stent/Xience Prime® 
Optical frequency domain imaging-
derived healing score at 6 months 
3 years Effectiveness and 
safety 
Everbio II  
[22, 33] 
RCT, non-inferiority 238  
(78 vs. 80 
vs. 80) 
Everolimus-eluting BRS/Absorb® vs. 
Everolimus-eluting permanent metallic 
stent/Promus Element vs. Biolimus-
eluting metallic stent/Biomatrix Flex 
LLL at 9 months 24 months Effectiveness and 
safety 
Hernandez 2017 
[21] 
RCT 200  
(100 vs. 
100) 
Everolimus-eluting BRS/Absorb® vs. 
everolimus-eluting permanent platinum 
chromium stent/Synergy® 
Fluoroscopy time, median dose-area 
product, contrast agent volume, 
periprocedural troponin release 
12 months Effectiveness and 
safety 
Gunes 2017 [61] Single-centre,  
cross-sectional study 
117 Novolimus-eluting BRS/DESolve® nr 12 months Safety 
                                                     
8 Maximum length of follow-up of published results  
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Author and year 
or study name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Length of 
follow-up 8 
Included in clinical 
effectiveness and/or 
safety domain 
DESolve Nx 
2016 [76] 
Prospective, 
multicentre,  
single-arm study 
126 Novolimus-eluting BRS/DESolve® MACE (cardiac death, TV-MI or 
clinically indicated TLR) at 6 months, 
LLL at 6 months 
24 months Safety 
DESolve PMCF 
[37] 
Prospective, 
multicentre,  
single-arm registry 
102 Novolimus-eluting BRS/DESolve® MACE (cardiac death, TV-MI or 
clinically indicated TLR) at 1, 6,  
12 months, 2, 3, 4, and 5 yr 
12 months Safety 
Fantom II [52] Prospective 
multicentre,  
single-arm study 
240 Sirolimus-eluting coronary 
BRS/Fantom® 
MACE (cardiac death, MI or TLR)  
at 6 months, LLL at 6 months 
6 months Safety 
Biosolve II  
[35, 56, 58, 82] 
Prospective 
multicentre,  
single-arm study 
123 Sirolimus-eluting absorbable magnesium 
scaffold system/DREAMS 2G 
In-segment LLL at 6 months 24 months Safety 
Biosolve III  
[35, 56] 
Prospective 
multicentre,  
single-arm study 
61 Sirolimus-eluting absorbable magnesium 
scaffold system/DREAMS 2G 
Procedure success  12 months Safety 
Fam 2016 [72] Single-centre,  
cohort study 
151 Everolimus-eluting BRS/Absorb® BVS nr 18 months Safety 
Maes 2018 [38] Single-centre,  
cohort study 
118 Everolimus-eluting BRS/Absorb® BVS Procedural success 12 months Safety 
Costopoulos 
2014 [91] 
Single-centre  
cohort study 
92 Everolimus-eluting BRS/Absorb® BVS Clinical efficacy 6 months Safety 
Panolas 2016 
[69] 
Single-centre  
cohort study 
70 Everolimus-eluting BRS/Absorb® BVS MACE 12 months Safety 
Jamshidi 2016 
[74] 
Observational  
single-centre  
single-arm study 
65 Everolimus-eluting BRS/Absorb® BVS Composite endpoint of TLR, ScT, MI, 
or death at 6 or 12 months 
12 months Safety 
Grimfjard 2017 
[50] (SCAAR)  
Prospective 
multicentre registry 
460 Everolimus-eluting BRS/Absorb® BVS Incidence of definite ScT 24 months Safety 
Teeuwen 2015 
[104] 
Prospective  
single-centre registry 
108 Everolimus-eluting BRS/Absorb® BVS nr 24 months Safety 
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Author and year 
or study name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Length of 
follow-up 8 
Included in clinical 
effectiveness and/or 
safety domain 
Felix 2016 [68] 
(BVS Expand) 
Investigator-initiated, 
prospective,  
single-centre,  
single-arm study  
249 Everolimus-eluting BRS/Absorb® BVS MACE (cardiac death, MI or TLR) 18 months Safety 
Kraak 2015 [90] Prospective  
single-centre registry 
135 Everolimus-eluting BRS/Absorb® BVS nr 6 months Safety 
Remkes 2017 
[47] 
Prospective  
single-centre registry 
105 Everolimus-eluting BRS/Absorb® BVS TLF (cardiac death, nonfatal TV-MI, 
clinically indicated TLR) 
19.8 
months 
Safety 
Alfonso 2017 
[53] (RIBS VI) 
Investigator-initiated, 
prospective, 
multicentre,  
single-arm study  
141 Everolimus-eluting BRS/Absorb® BVS In-segment MLD at 6 and 9 months 12 months Safety 
PRAGUE 19  
[73, 83]  
Prospective 
multicentre open-label 
single-arm study 
114 Everolimus-eluting BRS/Absorb® BVS Combination of death, MI and TVR 24 months Safety 
Iwanczyk 2017 
[18, 25] 
Prospective, 
multicentre registry 
165 Everolimus-eluting BRS/Absorb® BVS nr 12 months Safety 
Gil 2016 [79] Prospective 
multicentre open-label 
single-arm study 
139 Everolimus-eluting BRS/Absorb® BVS MACE (cardiac death, MI and 
clinically driven TLR) 
12 months Safety 
Dudek 2014 [94] Prospective 
multicentre single-arm 
registry 
100 Everolimus-eluting BRS/Absorb® BVS MACE (cardiac death, MI, and 
clinically driven TLR) at 12 months 
12 months Safety 
Rzeszutko 2016 
[48] (ORPKI 
Registry) 
Prospective 
multicentre single-arm 
registry 
2258 Everolimus-eluting BRS/Absorb® BVS nr Peri-
procedural 
Safety 
Briede 2018 [41] Prospective  
single-centre  
single-arm registry 
187 Everolimus-eluting BRS/Absorb® BVS MACE (death, MI, cerebral infarction, 
CABG major bleeding, ScT, in-scaffold 
restenosis, TLR, and TVR)  
24 months Safety 
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Author and year 
or study name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Length of 
follow-up 8 
Included in clinical 
effectiveness and/or 
safety domain 
GABI-R registry 
[42, 72] 
Prospective, 
observational, 
multicentre study 
3231 Everolimus-eluting BRS/Absorb® BVS MACE (death, MI, clinically motivated 
TVR), MACCE (MACE + stroke), 
stent thrombosis 
6 months Safety 
Cortese 2017a 
[55] 
Prospective  
single-centre registry 
122 Everolimus-eluting BRS/Absorb® BVS LLL at 1 year, ID-TLR at 2 years 24 months Safety 
Cortese 2017b 
[63] 
Prospective 
multicentre  
single-arm study 
67 Everolimus-eluting BRS/Absorb® BVS DOCE (cardiac death, MI or TLR) 7 months Safety 
MICAT Absorb 
Substudy) [40, 
85, 99] 
Prospective  
single-centre registry 
657 Everolimus-eluting BRS/Absorb® BVS MACE (death, cardiac death, MI  
or TLR) 
3 years Safety 
ISAR-Absorb 
[59, 71, 80] 
Prospective 
multicentre  
single-arm study 
419 Everolimus-eluting BRS/Absorb® BVS MACE (death, MI or TLR) 24 months Safety 
Absorb Extend 
[44, 46, 66, 86, 
92] 
Prospective,  
single-arm, open-
label clinical study 
812 Everolimus-eluting BRS/Absorb® BVS MACE (cardiac death, MI or ID-TLR) 
at 7, 30, 180 and 360 days  
3 years Safety 
Wöhrle 2015 [88] 
(ASSURE) 
Prospective 
multicentre, 
observational registry 
183 Everolimus-eluting BRS /Absorb® BVS MACE (cardiac death, MI or ID-TLR) 
at 24 months 
12 months Safety 
Khamis 2016 
[102] 
Uncontrolled cohort 
study 
264 Everolimus-eluting BRS/Absorb® BVS MACE (cardiac death, MI or ID-TLR) 24 months Safety 
Tanaka 2017 [65] 
Kawamoto 2015 
[103] 
Uncontrolled cohort 
study 
264 Everolimus-eluting BRS/Absorb® BVS TLF, MACE 12 months Safety 
Moscarella 2015 
[100] 
Moscarella 2016 
[75] 
Uncontrolled cohort 
study 
116 Everolimus-eluting BRS/Absorb® BVS Procedural success defined as 
successful delivery and use of BVS at 
target lesion with <30% final residual 
stenosis and without in-hospital MACE 
and/or cerebrovascular events; DOCE 
(cardiac death + target vessel MI + TLR) 
15 months Safety 
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Author and year 
or study name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Length of 
follow-up 8 
Included in clinical 
effectiveness and/or 
safety domain 
Maggio 2016 
[77] 
Prospective, single-
centre registry 
112 Everolimus-eluting BRS/Absorb® BVS MACE 12 months Safety 
Regazzoli 2018 
[36] 
Prospective 
multicentre registry 
573 Everolimus-eluting BRS/Absorb® BVS TLF, definite and probable ScT 4 years Safety 
Naganuma 2017 
[54] 
Cohort study 147 Everolimus-eluting BRS/Absorb® BVS TLF 24 months Safety 
Azzalini 2016 
[67] 
Multicentre registry  153 Everolimus-eluting BRS/Absorb® BVS TVF 24 months Safety 
Testa 2017 [57] Multicentre, 
prospective registry 
1002 Everolimus-eluting BRS/Absorb® BVS Cumulative hierarchical incidence of 
MACE defined as: cardiac death, 
nonfatal TV-MI, or clinically driven 
target lesion revascularisation 
12 months Safety 
Ielasi 2017 [51] Multicentre, 
prospective registry 
505 Everolimus-eluting BRS/Absorb® BVS Device-oriented composite endpoint 
of cardiac death, any MI (STEMI or 
NSTEMI) clearly attributable to 
intervention culprit vessel (TV-MI) 
and ID-TLR within 30 days after 
index procedure 
1 month Safety 
RAI registry  
[43, 45, 64, 84, 
89, 101]  
Multicentre, 
prospective registry 
1505 Everolimus-eluting BRS/Absorb® BVS TLR, definite/probable device 
thrombosis 
21.6 
months 
Safety 
Robaei 2016 [81, 
87] 
Multicentre, 
prospective registry 
100 Everolimus-eluting BRS/Absorb® BVS nr 24 months Safety 
CSI-Ulm-BVS 
[60, 70] 
Prospective single-
centre study, registry  
319 Everolimus-eluting BRS/Absorb® BVS Cardiac death, MI not clearly related 
to a nontarget vessel and ID-TLR 
36 months Safety 
Hellenkamp 
2017 [62] 
Nonrandomised 
observational registry 
study, single centre 
204 Everolimus-eluting BRS/Absorb® BVS MACE (all-cause death and/or MI) 834 days Safety 
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Author and year 
or study name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Length of 
follow-up 8 
Included in clinical 
effectiveness and/or 
safety domain 
Gori 2014 [95] Nonrandomised 
design, registry, 
single centre  
150 Everolimus-eluting BRS/Absorb® BVS MACE, including death, non-fatal 
MIR (with or without STE), or need 
for revascularisation (target or 
nontarget lesion/vessel, including 
planned staged revascularisations) 
6 months Safety 
Absorb Cohort B 
[78, 93, 96-98] 
Multicentre, 
uncontrolled cohort 
study 
101 Everolimus-eluting BRS/Absorb® BVS Ischaemic-driven MACE (ID-TLR, MI 
or cardiac death) 
5 years Safety 
Abbreviations: BES=biolimus-eluting stent; BRS=bioresorbable scaffold; BVS=bioresorbable vascular scaffold; CABG=coronary artery bypass graft surgery; DOCE=device-oriented composite endpoint; 
EES=everolimus-eluting stent; ID-TLR=ischaemic-driven target lesion revascularisation; LL=lumen loss; LLL=late lumen loss; MACE=major adverse cardiac events; MI=myocardial infarction; 
MLD=minimum lumen diameter; NSTEMI=non-ST-segment elevation myocardial infarction; nr=not reported; QCA=quantitative coronary angiography; RCT=randomised controlled trial; ScT=scaffold 
thrombosis; STEMI=ST-segment elevation myocardial infarction; TLF=target lesion failure; TLR=target lesion revascularisation; TVF=target vessel failure; TV-MI=target vessel myocardial infarction; 
TVR=target vessel revascularisation. 
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS  
OF TECHNOLOGY (TEC) 
3.1 Research questions  
Element ID Research question 
B0001 What are fully BRS and the comparators  
(other stent types or other revascularisation strategies)? 
A0020 For which indications have fully BRS received marketing authorisation  
or CE marking? 
B0002 What is the claimed benefit of fully BRS in relation to the comparators  
(other stent types or other revascularisation strategies)? 
B0003 What is the phase of development and implementation of fully BRS and the 
comparators (other stent types or other revascularisation strategies)? 
B0004 Who administers fully BRS and the comparators (other stent types or other re-
vascularisation strategies) and in what context and level of care are they provided? 
B0008 What kind of special premises are needed to use fully BRS and the comparators 
(other stent types or other revascularisation strategies)? 
B0009 What equipment and supplies are needed to use fully BRS and the comparators 
(other stent types or other revascularisation strategies)? 
A0021 What is the reimbursement status of fully BRS? 
 
3.2 Results 
Features of the technology and comparators 
[B0001] – What are fully BRS? 
Fully BRS, also called BVS, represent the latest generation of devices for myocardial revasculari-
sation strategies [1]. Instead of using a permanent metal backbone, as in other stent types, they 
comprise a degradable material, most commonly a polymer, such as PLLA or a magnesium alloy 
[2]. Therefore, fully BRS are designed to be absorbed by the body over time (1–3 years) [3]. Con-
ventional metal stents, where the rigid metal backbone remains permanently embedded in the 
diseased vessel, are associated with an increased risk of ScT or restenosis [2]. The aims of fully 
BRS are to overcome the risk of these late complications and to reduce the need for long-term 
antiplatelet drugs, with their risk of bleeding complications [2, 3]. As permanent metal stents, BRS 
can be either drug coated or drug free.  
To date, five products (Absorb®, DESolve®, ART Pure, Fantom® and Magmaris) have received CE 
marking for implanting in adult patients with CAD Table 6), although Absorb® has not been availa-
ble on the market since the manufacturer stopped sales in May 2017. Absorb® was also approved 
by the FDA in 2016 [4]. 
The Absorb® scaffold (Abbott Vascular) comprises a resorbable polymer PLLA scaffold that is 
coated with an everolimus-eluting resorbable poly(D,L-lactic acid) (PDLLA) polymer. It dissolves 
completely within ~3 years [4]. 
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The DESolve® scaffold (Elixir Medical) received CE marking in May 2014. It also comprises a 
PLLA scaffold with a strut thickness of 150 µm and coat thickness of <3 µm/side. Coating com-
prises a PLLA-based polymer, which elutes novolimus. It dissolves completely within ~1 year [4]. 
The ART Pure (Arterial Remodelling Technologies and Terumo) scaffold received CE marking in 
May 2015. This stent is drug free and comprises a PDLLA scaffold with a strut thickness of 150 
µm and coat thickness of 8 µm/side. It dissolves completely within ~1 year. 
Fantom® (Reva Medical) is a sirolimus-eluting scaffold comprising tyrosine polycarbonate. CE 
marking was granted in April 2017. According to the manufacturer, the key differentiating features 
of Fantom® compared with other polymeric BRS technologies include its 125-µm thickness after 
coating, DES-like radiographic visibility, single-step inflation, good expansion range and no spe-
cial storage or handling requirements. It dissolves completely within ~4 years [4]. 
The sirolimus-eluting magnesium drug-eluting absorbable metal scaffold was CE approved in June 
2016 and is currently marketed as Magmaris (Biotronik). It has a strut thickness of 150 µm and a 
coat thickness of 8 µm/side. It is the only metal-based BRS. According to the manufacturer, its key 
features are single-step inflation, good expansion range, no special storage or handling require-
ments, and electropolished struts for better laminar blood flow. In addition, the use of a metal back-
bone should result in reduced thrombogenicity, and accelerated endothelialisation compared with 
polymeric scaffolds. The Magmaris scaffold dissolves completely within ~1 year [4, 111, 112]. 
Table 6: Features of the technology 
Feature Fully BRS system 
Name Absorb® 
BVS 
DESolve® 
Scaffold System 
RMS 
Magmaris  
ART Pure BRS Fantom® BRS 
Manufacturer Abbott 
Vascular 
Elixir Medical Biotronik  Arterial Remodelling 
Technologies/Terumo 
Reva Medical 
Eluted drug  Everolimus Novolimus Sirolimus Drug free Sirolimus 
Stent 
material 
PLLA PLLA Magnesium PDLLA Tyrosine 
polycarbonate 
Strut/coat 
thickness 
150 µm/3 µm 
per side 
150 µm/<3 µm 
per side 
150 µm/8 
µm per side 
170 µm/uncoated 125 µm after 
coating 
CE certificate Yes (2011)9 Yes (2014) Yes (2016) Yes (2015) Yes (2017) 
FDA 
approval 
Yes (2016) No No No No 
Abbreviations: BRS=bioresorbable stent; BVS=bioresorbable vascular scaffold; CE=Conformité Européenne; FDA=Food 
and Drug Administration; RMS=resorbable magnesium scaffold. 
Source: [4]. 
 
Current European Society of Cardiology (ESC) guidelines do not recommend the use of BRS 
outside of scientific studies [5]. 
What are other stent types (permanent BMS or DES, bioresorbable polymer DES) or other re-
vascularisation strategies? 
The current two principal options for revascularisation in patients with CAD are PCI and CABG.  
                                                     
9 Manufacturer stopped selling the first-generation Absorb® BVS on 14th September 2017. 
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The indication, timing and modality of myocardial revascularisation is dependent on several factors, 
including risk stratification and risk factors, clinical presentation, comorbidities and life expectancy [5]. 
The most commonly used revascularisation intervention is PCI [5].  
Historically, the first PCI technique was balloon PTA. With PTA, coronary stenosis is treated by 
insufflation of a balloon, thus compressing and dissecting atherosclerotic plaques. Although coro-
nary stenosis can be treated successfully with PTA, it also leads to a high rate of acute vessel 
closures (caused by vessel dissection and recoil) and restenosis [2].  
The next step was the introduction of BMS. The implantation of such stents reduces vessel recoil, 
leading to better acute results. Additionally, they also reduce restenosis by abolishing late con-
strictive remodelling. Nevertheless, restenosis, resulting from neointimal hyperplasia, is a problem 
with BMS [2].  
To reduce this neointimal hyperplasia, so-called DES were developed. With these stents, the metal 
scaffold is coated with an immunosuppressant or cytotoxic drug. Usually, a polymer coating is used 
for drug loading and control of the elution kinetics. Initially, permanent polymer coatings were used, 
which can provoke inflammatory responses and delayed arterial healing. Therefore, biodegradable 
polymer and polymer-free coating technologies were developed to reduce these adverse events 
[2]. Sustained release of the drugs reduces neointimal hyperplasia, leading to a reduction in the 
rate of restenosis [2]. However, because stent implantation can also lead to stent thrombosis with 
potentially deleterious consequences, it necessitates potent antiplatelet therapy with a combination 
of aspirin and P2Y12 inhibitors, thus leading to potential bleeding complications. A consequence 
of the implantation of metal stents is that the metal cage remains permanently in the vessel, provid-
ing a permanent stimulus for thrombosis and restenosis [2]. Currently, permanent metallic stents 
with metallic cages are the standard treatment technique with PCI [5]. 
CABG is a type of open-heart surgery that improves blood flow to the heart. During CABG, a 
healthy artery or vein is connected to the blocked coronary artery, such that the grafted artery or 
vein bypasses the blocked portion of the coronary artery [113]. Although PCI is currently the most 
commonly used revascularisation intervention, CABG still has an important role in the manage-
ment of patients with advanced obstructive coronary disease [2]. 
This report evaluates the efficacy and safety of PCI in patients with CAD using implantation of a 
fully BRS compared with other revascularisation techniques: implanting other (permanent) stent 
types (permanent BMS or DES, or bioresorbable polymer-covered DES) and CABG. 
 
[A0020] – For which indications have fully BRS received marketing authorisation  
or CE marking? 
Fully BRSs have received CE marking for the treatment of coronary artery lesions in patients with 
CAD. The regulatory status of all five BRS systems, including the verbatim wording of the indica-
tions, is presented in Table A17 in Appendix 2. Contraindications are described only for the Ab-
sorb® BVS and include patients with contraindications for procedural anticoagulation or postpro-
cedural antiplatelet therapy and patients with contraindications to the eluted drug. 
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[B0002] – What is the claimed benefit of fully BRS in relation to the comparators  
(other stent types or other revascularisation strategies)? 
Compared with CABG, the implantation of a stent is less invasive and, thus, associated with lower 
periprocedural risks [5]. However, in contrast to acute MI (AMI), where stents improve the progno-
sis of patients significantly, in patients with stable CAD, stents primarily reduce the symptoms of 
angina and do not necessarily prolong life expectancy or reduce the rate of MIs [5]. Furthermore, 
the residual metal cage of metallic stents is associated with a substantial risk for late failure in the 
form of in-stent thrombosis and restenosis. This is believed to be a consequence of accelerated 
atherosclerosis developing inside the stent and of a loss of vasomotor function in the stented ves-
sel segment. In addition, stents might break [2]. One study found very late adverse events to oc-
cur up to 20 years after implantation [114]. Thus, stents comprising fully biodegradable material 
(e.g., polymers of PLLA and magnesium alloys) were thought to reduce the risk for very late fail-
ure because no permanent residue would remain in the coronary vessel [2]. 
 
[B0003] – What is the phase of development and implementation of fully BRS  
and the comparators (other stent types or other revascularisation strategies)? 
First attempts to develop fully bioresorbable devices for treating CAD began during the 1990s 
[115]. The first commercially available device was the Abbott Absorb® BVS, which uses PLLA as 
stent material and everolimus as the eluded drug. In 2010, Absorb® BVS was approved in Europe 
and has been used increasingly since then [12]. Other companies have also developed and test-
ed BRS using different stent materials. Currently, five BRS have received CE-market approval 
(Table 6) and more than ten further devices are in development [4, 115]. In 2017, the commercial 
use of Absorb® BVS was stopped. This stop was initiated by the manufacturer as a result of low 
commercial sales [116]. 
BMS and DES with permanent metal scaffolds are considered standard revascularisation treat-
ments for most patients with CAD. In addition, CABG surgery is a routine procedure with an im-
portant role, especially in patients with advanced CAD [2, 5]. 
 
[B0004] – Who administers fully BRS and the comparators (other stent types or other 
revascularisation strategies) and in what context and level of care are they provided? 
PCI is provided in hospitals. Specialised cardiologists implant stents supported by radiology assis-
tants and nurses. Implanting a BRS requires the same infrastructure, personnel and equipment as 
implanting other types of stent. However, stenting with BRS (except the metal-based Magmaris 
device) requires more extensive preparation of the lesion and invasive imaging. The latter is be-
cause the dimension of the affected vessel must be exactly known because of the expansion limits 
of BRS.  
CABG is open-heart surgery requiring the use of a heart-lung machine. The team comprises sur-
geons, anaesthesiologists, cardiotechnicians and nurses. CABG is performed in hospitals [117]. 
 
[B0008] – What kind of special premises are needed to use fully BRS  
and the other stent types or other revascularisation strategies? 
Institutions providing PCI need a cardiac catheterisation lab and a team comprising an interven-
tional cardiologist, assistant nurses and radiology assistants. 
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CABG is open surgery and requires an operating theatre, usually a cardiopulmonary bypass ma-
chine (heart-lung machine) and an intensive care unit. In terms of personnel, surgeons, nurses, 
cardiotechnicians and anaesthesiologists are required [5, 12]. 
 
[B0009] – What equipment and supplies are needed to use fully BRS  
and the comparators (other stent types or other revascularisation strategies)? 
To perform PCI with the implantation of stent, whether BRS or permanent metallic, balloon cathe-
ters, coronary guidewires, sheath introducers, introducer needles and guiding catheters are essen-
tial equipment. Some BRS require special storage facilities. 
Equipment for general anaesthesia, sternotomy and sewing material, along with chest tubes, are 
necessary for CABG [12]. 
 
[A0021] – What is the reimbursement status of fully BRS? 
The implantation of a fully BRS into the coronary vessels is currently not recommended for reim-
bursement in some European countries (Appendix 2). Nevertheless, the implantation of fully BRS 
is listed with a separate reimbursement code in the Austrian Diagnosis Related Group (DRG) 
System [118]. The status of reimbursement is not known for other countries. 
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
4.1 Research questions 
Element ID Research question 
A0002 What is CAD? 
A0003 What are the known risk factors for CAD? 
A0004 What is the natural course of CAD? 
A0005 What are the symptoms and the burden of CAD for the patient? 
A0006 What are the consequences of CAD for society?  
A0024 How is CAD currently diagnosed according to published guidelines and in practice? 
A0025 How is CAD currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
A0011 How much is fully BRS utilised? 
 
4.2 Results 
Overview of the disease or health condition 
[A0002] – What is CAD? 
CAD is defined as the manifestation of arteriosclerosis in the coronary arteries. Atherosclerotic 
plaque causes a narrowing of the coronary vessel, reducing blood flow to the heart muscle and 
resulting in an imbalance between oxygen demand and supply. CAD is usually progressive [3, 7]. 
CAD is one of the most prevalent diseases, and is the leading cause of death in Europe [6]. 
 
[A0003] – What are the known risk factors for CAD? 
Known risk factors for CAD that can be controlled are: smoking, high alcohol consumption, lack of 
physical activity, high blood cholesterol level, overweight or obesity, diabetes mellitus, hypertension 
and psychosocial burden, such as stress or depression. Risk factors that cannot be controlled are 
age, sex (men are generally at greater risk), family history and race [7-9] 
 
[A0004] – What is the natural course of CAD? 
Patients with CAD have an elevated risk for MI, cardiac arrhythmias, such as atrial fibrillation, heart 
failure and premature mortality [7]. Additionally, angina is associated with recurring discomfort, 
impaired quality of life, reduced physical endurance, mental depression and recurrent hospitalisa-
tion [5]. CAD is usually progressive [3]. 
CAD is a chronic disease that can appear for the first time as angina pectoris, but it can also lead 
to a heart attack without any previous symptoms [10]. 
 
Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 36 
Effects of the disease or health condition 
[A0005] – What are the symptoms and the burden of CAD for the patient? 
The symptoms of CAD typically include shortness of breath and chest pain (angina pectoris) usu-
ally exacerbated by exertion. These symptoms are typically associated with a feeling of anxiety or 
fear and can radiate into the arms, neck, back, upper abdomen or jaw. 
In patients with stable angina pectoris, symptoms do not change over an extended period of time. 
In patients with unstable angina pectoris, the symptoms suddenly increase without physical exer-
tion or the exertion threshold changes. This can mean that the pain occurs earlier, lasts longer 
and/or becomes more frequent or stronger. Any angina pectoris that occurs for the first time is 
unstable angina pectoris. In contrast to the stable form, unstable angina pectoris should be treat-
ed as an emergency [10]. 
 
[A0006] – What are the consequences of CAD for society? 
CAD has major human as well as economic costs. According to the European Cardiovascular Dis-
ease Statistics [11], ischaemic heart disease (IHD) accounted for 1% (€ 509,647,000) of the total 
healthcare expenditure or for € 59 per capita in 2015 in Austria. The biggest share (72%) was 
attributed to inpatient care (€ 368,901,000). In Europe, the overall costs for IHD (including direct 
healthcare costs, productivity losses and informal care costs) have been estimated at over € 59 
billion. 
 
Current clinical management of the disease or health condition 
[A0024] – How is CAD currently diagnosed according  
to published guidelines and in practice? 
The diagnosis and assessment of stable CAD involves clinical evaluation, including identifying 
significant dyslipidaemia, hyperglycaemia or other biochemical risk factors, and specific cardiac 
investigations, such as stress testing or coronary imaging. These investigations can be used to 
confirm the diagnosis of ischaemia in patients with suspected stable CAD, to identify or exclude 
associated conditions or precipitating factors, assist in stratifying risk associated with the disease 
and to evaluate the efficacy of treatment. In practice, diagnosis and prognostic assessments are 
conducted simultaneously, rather than separately, and many of the investigations used for diag-
nosis offer prognostic information [9]. 
In patients with suspected ACS, the initial assessment is based on the integration of low-likelihood 
and/or high-likelihood features derived from clinical presentation (i.e., symptoms and vital signs), 
12-lead ECG and biomarkers (especially cardiac troponin). Non-invasive imaging, such as trans-
thoracic echocardiography, can add to the diagnosis [119]. 
 
[A0025] – How is CAD currently managed according  
to published guidelines and in practice? 
As in the diagnosis of CAD, the management of CAD depends on its clinical presentation (stable 
or acute), on patient characteristics (age, comorbidities, etc.) and related risk prognoses, and on 
patient preferences [5]. 
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In patients with stable CAD, management decisions after the diagnosis depend on the severity of 
symptoms, on the patient’s risk factors for adverse cardiac events and on patient preferences. The 
choice is between preventive medication and symptomatic medical management only or, addition-
ally, revascularisation, in which case the type of revascularisation has to be determined [9]. Any 
strategy needs to be accompanied by recommendations for life-style modification [7]. 
Indications for revascularisation are the persistence of symptoms despite medical treatment and/ 
or improvement of prognosis [5]. Patient preferences also need to be taken into account [7]. In 
terms of revascularisation, whether PCI or CABG is preferred should depend on the risk:benefit 
ratios of these treatment strategies, weighing the risks of procedural death, MI and stroke against 
improvements in health-related quality of life, as well as long-term freedom from death, MI or re-
peat revascularisation. Decisions on the most appropriate revascularisation procedure should be 
guided by clinical judgement, multidisciplinary dialogue and patient preferences. Risk stratification 
models can support decisions [5]. In general, the choice of suitable revacularisation strategy (PCI 
or CABG) depends on the number of affected vessels (single-vessel or multivessel disease) and 
on the anatomical complexity of coronary lesions, whereby CABG appears to be advantageous in 
terms of mortality, MI and the need for reintervention in patients with multivessel CAD and inter-
mediate-to-high anatomical complexity [5, 7]. 
In patients with ACS, management depends on whether patients have non-STEMI (NSTEMI) or 
STEMI [5]. 
In patients with NSTEMI (the most frequent manifestation of ACS), treatment includes anti-is-
chaemic therapy (nitrate, beta-receptor blockers, etc.), antiplatelet therapy and, potentially, inva-
sive revascularisation. The latter depends on the potential risks associated with invasive and phar-
macological treatments [5]. In the case of a risk stratification that favours revascularisation, early 
routine angiography followed by revascularisation is favoured against a selective invasive strategy 
[5]. In patients who are stable, the choice of the revascularisation modality can be made in analogy 
to patients with stable CAD [5]. 
In the management of patients with STEMI, the timely implementation of reperfusion therapy (fi-
brinolysis or mechanical reperfusion by primary PCI) is key [5]. PCI (without prior fibrinolysis) has 
replaced fibrinolysis as the preferred reperfusion strategy, provided it can be performed in a timely 
manner in high-volume PCI centres with experienced operators [5]. Stenting should be preferred 
over plain balloon angioplasty, and new-generation DES have been found to be more effective 
and safer than BMS [5]. In settings where a timely PCI cannot be performed, fibrinolysis should be 
considered, particularly if it can be administered prehospital. After fibrinolysis, early invasive eval-
uation is recommended [5]. 
In general, patients need to undergo antithrombotic treatment after revascularisation. The choice, 
initiation, combination and duration of antithrombotic treatment depend on various factors (e.g., 
mode of revascularisation) [5]. 
Furthermore, myocardial revascularisation must always be accompanied by medical therapy and 
other secondary prevention strategies for risk factor modification and permanent lifestyle changes 
[5, 12]. 
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Target population 
[A0007] – What is the target population of this assessment? 
The target population in this assessment includes patients with CAD including stable angina, un-
stable angina and/or MI (ICD-10 code I20-I25) who require, and are eligible for, myocardial revas-
cularisation. 
This topic was chosen based on a request from the Austrian Federal Ministry of Labour, Social 
Affairs, Health and Consumer Protection who commissioned our agency to do an HTA on PCI 
with implantation of a fully BRS. The relevance of the topic lies in the fact that CAD, which is a 
manifestation of atherosclerosis of the coronary arteries, is one of most prevalent diseases and the 
leading cause of death in Europe [6]. 
 
[A0023] – How many people belong to the target population? 
According to the 2017 edition of European Cardiovascular Disease Statistics, in 2015 almost 17 
million men (41% of all CVD) and more than 13 million women (30% of all CVD) were living with 
CAD in Europe [11]. The total number of new cases for CAD was 5.75 million in Europe in 2015, 
with slightly more cases among males. Age-standardised prevalence CAD rates were lower in the 
European Union (EU; 20 per 1000 males, 11 per 1000 females) than in Europe as a whole (30 per 
1000 males, 17 per 1000 females). Changes in age-standardised prevalence rates were reported 
only for CVD in total. On average, in Europe, these rates had decreased from 137 per 1000 in-
habitants in 1990 to 128 per 1000 inhabitants in 2015 [11]. 
Inpatient admission rates for all CVD or for AMI were available for several European countries. On 
average, admission rates for CVD were 30% higher for males, and admission rates for AMI were 
more than twice as high for males than for females. Within Europe, admission rates for all CVD 
were lowest in Cyprus (6.1 per 1000 males, 2.9 per 1000 females) and highest in Lithuania (45.4 
per 1000 males, 50.1 per 1000 females) [11]. For AMI, high inpatient admission rates were ob-
served in Norway (5.7 per 1000 males, 2.9 per 1000 females), Sweden (4.1 per 1000 males, 2.5 
per 1000 females) and Lithuania (4.1 per 1000 males, 2.3 per 1000 females), whereas lowest rates 
were found in Cyprus (0.7 per 1000 males, 0.2 per 1000 females), Turkey (0.9 per 1000 males, 
0.4 per 1000 females) and Romania (1.1 per 1000 males, 0.6 per 1000 females) [11]. 
CAD is the leading single cause of death in Europe. Data from 2009 to 2014 suggest that, in Eu-
rope, approximately 1.8 million people per year die from CAD, with nearly the same rates for men 
and women (~20% of all deaths) [11]. Across the various European countries, age-standardised 
mortality rates from CAD ranged from 77 per 100,000 males and 32 per 100,000 females in France 
to 700 per 100,000 males and 429 per 100,000 females in Lithuania [11]. 
 
[A0011] – How much is fully BRS utilised? 
Data about the number of implantations of fully BRS in Europe are not available. For all coronary 
stenting procedures, the latest data for the whole of Europe come from a paper published in 2007. 
The authors reported that 769,766 stenting procedures were carried out in Europe in 2004, which 
was an increase of 22% compared with 2003 [120]. Data that are more recent were available from 
the Austrian Cardiovascular Disease Report. According to this report, a total of 6950 coronary stent 
implantations were registered in 2010 in Austria (0.8 implantations per 1000 inhabitants) [121]. 
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5 CLINICAL EFFECTIVENESS (EFF) 
5.1 Research questions 
Element ID Research question 
D0001 What is the expected beneficial effect of fully BRS on mortality? 
D0005 How does fully BRS affect symptoms and findings (severity and frequency) of CAD? 
D0006 How does fully BRS affect progression (or recurrence) of CAD? 
D0011 What is the effect of fully BRS on patients’ body functions? 
D0016 How does the use of fully BRS affect activities of daily living? 
D0012 What is the effect of fully BRS on generic health-related quality of life? 
D0013 What is the effect of fully BRS on disease-specific quality of life? 
 
5.2 Results 
Included studies 
The inclusion criteria to assess the clinical effectiveness of fully BRS were restricted to RCTs. In 
the systematic literature search, eight relevant RCTs, reported in 18 publications, were identified 
[17-34] (Table 5). All studies assessed the everolimus-eluting BRS Absorb® as intervention. In sev-
en RCTs, an everolimus-eluting permanent metal stent (Xience® or Synergy®) was the comparator 
device. One study used two different comparators: an everolimus-eluting metallic stent (Promus 
Element) and a biolimus-eluting permanent metal stent (Biomatrix Flex) [22, 33].  
Four of the included RCTs were multicentre trials and were sponsored by the device manufacturer 
[17, 19, 20, 23, 24, 26, 27, 29-32, 34], two were international trials and the other two were located 
in China and Japan, respectively. The other four RCTs [18, 21, 22, 25, 28, 33] were investigator 
initiated. Two of them were multicentre and two were single-centre trials, all located in Europe. 
Half of the included RCTs have been completed [19-23, 27, 28, 32-34], whereas the other four 
trials are ongoing and the publications included in this assessment report only interim results. The 
maximum time of follow-up reported in the study publications were 4 years [19, 20, 23, 27, 32, 34], 
3 years [17, 18, 24, 25, 29, 30] 2 years [22, 26, 31, 33], 1 year [21] and 6 months [28]. In addition, 
results from 3-year follow up for the Absorb Japan and Trofi II trial were reported in two recently 
published systematic reviews [122, 123]. 
The total number of patients included in the eight RCTs was 5863. All but one study [28] included 
patients with stable or unstable CAD. In these studies, the percentage of patients with stable an-
gina ranged from 20% to 65%. One RCTs included only patients with acute STEMI [28]. Patients 
with previous MI were included in all RCTs and the percentage ranged from 2% to 30%. Most 
study participants were male (70%–80%), with a mean age range of 57–67 years. After stent im-
plantation, dual antiplatelet therapy was given for at least 12 months in five RCTs [17, 18, 24-26, 
28-31] and for at least 6 months in two studies [19, 20, 22, 23, 27, 32-34]. Afterwards aspirin was 
maintained for at least 5 years [17, 29] or indeﬁnitely [22, 24, 26, 30, 31, 33]. One trial did not 
report any details about antiplatelet therapy [21]. Details of the characteristics of the included 
studies and the results are presented in the evidence tables included in Appendix 1. 
In our literature search, we could not identify any RCTs investigating one of the other CE-certifi-
cated fully BRS (DESolve®, Magmaris, ART Pure or Fantom®). 
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Mortality 
[D0001] – What is the expected beneficial effect of fully BRS on mortality? 
Two outcomes were considered relevant to assess the effect of fully BRS on mortality: all-cause 
mortality and cardiac mortality. All-cause mortality was reported in seven RCTs [17-20, 22-34]. A 
meta-analysis including results from the maximum length of follow-up in seven RCTs showed no 
significant difference between Absorb® BVS and permanent metal DES [RR 0.84 (95% CI 0.63–
1.11); p=0.22; 0% heterogeneity] (Figure 2). Including only studies with at least 3 years of follow-
up did not change the results [RR 0.82 [(95% CI 0.62–1.10); p=0.19; 0% heterogeneity].  
In terms of cardiac mortality, results from all eight RCTs were available [17-34]. Again, the meta-
analysis including all trials [RR 0.91 (95% CI 0.60–1.39); p=0.68; 0% heterogeneity] (Figure 3) or 
only trials with at least 3 years of follow-up [RR 0.89 (95% CI 0.58–1.38); p=0.61; 0% heterogene-
ity] resulted in no significant difference between Absorb® BVS and permanent metal DES.  
 
Figure 2: Meta-analysis for all-cause mortality (maximum length of follow-up). 
 
Figure 3: Meta-analysis for cardiac mortality (maximum length of follow-up). 
No evidence was identified to answer these research questions for the fully BRS DESolve®, Mag-
maris ART Pure and Fantom®. 
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Morbidity 
[D0005] – How does fully BRS affect  
symptoms and findings (severity and frequency) of CAD? 
Two outcomes were considered relevant to assess this research question: occurrence of MI and 
of angina. MI during follow-up was reported in all eight trials [17-34]. The meta-analysis for maxi-
mum length of follow-up showed statistically significant higher rates of MIs for patients treated with 
Absorb® BVS compared with patients treated with permanent metal DES [RR 1.49 (95% CI 1.21–
1.84); p=0.0002; 0% heterogeneity] (Figure 4). Including only studies with at least 3 years of fol-
low-up (five RCTs), the result remained significant against the Absorb® BVS [RR 1.44 (95% CI 
1.16–1.80); p=0.001; 0% heterogeneity]. 
 
Figure 4: Meta-analysis for all MI (maximum length of follow-up). 
Angina as an endpoint was reported in three studies [19, 20, 23, 24, 27, 28, 30, 32, 34]. In one 
study, the percentage of patients reporting angina after 1 year of follow-up was 18.3% in the Ab-
sorb® BVS group and 18.4% in the permanent metal DES group [24, 30]. In the other two RCTs, 
the percentage of patients free of angina was assessed using the Seattle Angina Questionnaire, 
with no difference between the study groups (74% vs. 73% after 3 years [19, 20, 23, 27, 32, 34] 
and 91.4% vs. 91.7% after 6 months [28], respectively).  
Beside individual outcomes, most of the trials also reported results for combined endpoints. In four 
RCTs [17, 19, 20, 22-24, 27, 29, 30, 32-34], MACE was reported, which comprises cardiac death, 
all MI, and ischaemic-driven TLR (ID-TLR). The meta-analysis for maximum length of follow-up 
showed statistically significant higher rates for patients treated with Absorb® BVS compared with 
patients treated with permanent metal DES [RR 1.36 (95% CI 1.06–1.73); p=0.01; 0% heteroge-
neity] (Figure 5). 
 
Figure 5: Meta-analysis for MACE (maximum length of follow-up). 
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In addition, a POCE, comprising all death, all MI, and all revascularisations, was reported in the 
RCTs. The meta-analysis for maximum length of follow-up including results from five RCTs showed 
statistically significant higher rates for patients treated with Absorb® BVS compared with patients 
treated with permanent metal DES [RR 1.13 (95% CI 1.01–1.26); p=0.04; 3% heterogeneity] 
(Figure 6). 
 
Figure 6: Meta-analysis for POCE (maximum length of follow-up). 
No evidence was identified to answer this research question for the fully BRS DESolve®, Magmaris, 
ART Pure and Fantom®. 
 
[D0006] – How does fully BRS affect progression (or recurrence) of CAD? 
The surrogate endpoints TLR and TVR were considered eligible to answer this research question. 
In a meta-analysis for all-TLR after a maximum length of follow-up (eight RCTs [17-34]), the TLR 
rate was significant higher in the Absorb® BVS group than in the DES group [RR 1.36 (95% CI 
1.08–1.71); p=0.009; 0% heterogeneity] (Figure 7). By contrast, the meta-analysis for TVR (eight 
RCTs) did not show any significant difference between Absorb® BVS and DES [RR 1.18 (95% CI 
0.98–1.41); p=0.08; 0% heterogeneity] (Figure 8). 
 
Figure 7: Meta-analysis for all TLR (maximum length of follow-up). 
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Figure 8: Meta-analysis for all TVR (maximum length of follow-up). 
No evidence was identified to answer this research question for the fully BRS DESolve®, Magmaris, 
ART Pure and Fantom®. 
 
[D0011] – What is the effect of fully BRS on patients’ body functions? 
No evidence was identified to answer the research question ‘patients’ body functions’ for the fully 
BRS. 
 
[D0016] – How does the use of fully BRS affect activities of daily living? 
The endpoint ‘daily functioning’ was considered eligible to answer the second research question. 
Only one RCTs reported results for this outcome [19, 20, 23, 27, 32, 34]. In the Absorb II trial, the 
domain score for ‘physical limitation’ in the Seattle Angina Questionnaire increased in both study 
groups from baseline (75 pts vs. 72 pts; p=0.77) to 1-year follow-up (87 pts vs. 86 pts; p=0.48), 
and remained constant for the following 2 years (at 3-year follow-up: 87 pts vs. 86 pts; p=0.54). 
There was no significant difference between patients in the Absorb® BVS group and patients in 
the DES group.  
No evidence was identified to answer this second research question for the fully BRS DESolve®, 
Magmaris, ART Pure and Fantom®. 
 
Health-related quality of life 
[D0012] – What is the effect of fully BRS on generic health-related quality of life? 
[D0013] – What is the effect of fully BRS on disease-specific quality of life? 
Disease-specific quality of life was defined as an outcome in three RCTs [18, 20, 23-25, 27, 30, 
32, 34], but published results were only available from two trials [20, 23, 24, 27, 30, 32, 34]. Both 
trials used the Seattle Angina Questionnaire, with no difference between the Absorb® BVS and DES 
groups after 1, 2 or 3 years (76 pts vs 74 pts; p=0.47) [19, 20, 23, 27, 32, 34] and 1 year [24, 30] 
(87 pts vs. 86 pts; p=nr), respectively. No evidence was identified in any of the trials to answer the 
research question on generic health-related quality of life. 
No evidence was identified to answer either of these research questions for the fully BRS DESolve®, 
Magmaris, ART Pure and Fantom®.   
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6 SAFETY (SAF) 
6.1 Research questions 
Element ID Research question 
C0008 How safe is fully BRS in relation to the comparators  
(other stent types or other revascularisation strategies)? 
C0004 How does the frequency or severity of harm change over time  
or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed 
through the use of fully BRS? 
B0010 What kind of data/records and/or registry is needed to monitor the use of BRS 
and the comparators (other stent types or other revascularisation strategies)? 
 
6.2 Results 
Included studies 
The inclusion criteria to assess the safety of fully BRS differed from those used for assessing clini-
cal effectiveness. In addition to RCTs, we also included prospective studies with or without control 
groups with at least 50 patients. In the systematic literature search, the same eight relevant RCTs 
were identified [17-34]. In addition, we identified 45 prospective single-arm studies (observational 
studies and registries) [35-105] that met our inclusion criteria (Table 5). For details of the RCTs, 
see Section 5 (Clinical Effectiveness) and the evidence tables included in Appendix 1. 
Three of the 45 prospective studies, with a total of 345 patients, investigated the DESolve® device 
[37, 61, 76] and two studies, with a total of 184 patients, investigated the Magmaris (Dreams 2G) 
device [35, 56, 58, 82], one with published results at 12 months of follow-up and the other at 24 
months of follow-up. One publication reported results at 6 months of follow-up for 117 of 240 pa-
tients treated with the Fantom® device [52]. No relevant study was identified for the ART Pure biore-
sorbable stent. In the six studies investigating DESolve® BVS, Magmaris (Dreams 2G) or Fantom®, 
the study participants were predominately male (70%–85%, 63%, and 70%, respectively). The 
mean age ranged from 60 to 65 years and most patients had stable angina. 
The Absorb® BVS was the investigated device in the remaining 39 prospective uncontrolled stud-
ies, with a total of more than 15,000 patients [36, 38-51, 53-55, 57, 59, 60, 62-75, 77-81, 83-105]. 
The mean duration of follow-up was 12 months in 12 studies and 24 months in ten studies. Six 
studies reported results for a longer follow-up (four studies with 3-year follow-up, one study with 4-
year follow-up and one study with 5-year follow-up). As in all other included studies, the study popu-
lation was predominately male (60%–90%) with a mean age range of 54–66 years. In 19 studies, 
most patients had stable angina at study inclusion [36, 41, 44, 46-48, 53-55, 59, 60, 65-67, 69-71, 
74, 77, 79-81, 86, 87, 91, 92, 100, 102, 103], whereas, in another 19 studies, the patients predomi-
nately had ACS (unstable angina, STEMI or NSTEMI) [38-40, 42, 43, 45, 49-51, 57, 62-64, 68, 72, 
73, 77, 83-85, 88-90, 94, 95, 99, 101, 104]. In the remaining study, details of the indication for 
treatment were not reported [78, 93, 96-98]. Details of the characteristics of the included prospec-
tive studies and the results are presented in the evidence tables included in Appendix 1. 
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Patient safety 
[C0008] – How safe is fully BRS in relation to the comparators  
(other stent types or other revascularisation strategies)? 
Absorb® BVS 
RCTs 
Results from RCTs were available for four (ScT ≥1 year, periprocedural MI, periprocedural mortality 
and all SAEs) of the eight predefined safety endpoints.  
Results of periprocedural death were published in two trials [17, 28, 29]. Both RCTs reported that 
no patients died during the index procedure either in the Absorb® BVS group or in the DES group.  
The occurrence of periprocedural MI was reported in seven of the eight trials [17-21, 23-32, 34]. 
The meta-analysis showed no statistically difference between Absorb® BVS and permanent metal 
DES [RR 1.22 (95% CI 0.82–1.82); p=0.32; 0% heterogeneity] (Figure 9). 
 
Figure 9: Meta-analysis for periprocedural MI. 
ScT that occurred after at least 1 year of follow-up (very late ScT) was reported in all six RCTs 
with a follow-up longer than 1 year [17-20, 22-27, 29-34]. Overall, the rate was very low, with ScT in 
35 of 3152 patients in the Absorb® BVS groups of the studies. Nevertheless, compared with per-
manent metal DES, the meta-analysis resulted in a statistically significant higher risk for very late 
ScT in patients treated with the Absorb® BVS [RR 5.09 (95% CI 1.97–13.17); p=0.0008; 0% het-
erogeneity] (Figure 10). 
 
Figure 10: Meta-analysis for very late ScT (≥1 year). 
 
Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 46 
Results for all SAEs were derived from the results section of the ClinicalTrials.gov study registry 
entry of two RCTs [17, 24, 29, 30]. In the Absorb III trial, the rates of SAEs were 30.1% versus 
28.9% after 1 year of follow-up. For the Absorb China trial, SAE rates of 18.7% versus 19.6% after 
3 years of follow-up were reported.  
No evidence from RCTs was found for the following endpoints: 
• Vascular access site complications 
• Procedure-related nephropathy 
• Bleeding as a result of antiplatelet therapy 
• Mortality as a result of bleeding and/or stroke 
Other studies 
Periprocedural mortality was reported in 22 of 39 studies assessing the Absorb® BVS device, with 
19 studies reporting that none of the 3733 patients included died during or shortly after the index 
procedure. In the three remaining studies, with 2258, 187, and 1505 patients, respectively, the rate 
of periprocedural mortality was 0.04%, 0.5%, and 1.3%, respectively. 
Periprocedural MIs were reported in 28 of 39 studies assessing the Absorb® BVS device. Where-
as eight studies (3206 participants) reported that no MI occurred during or shortly after the index 
procedure, the median rate of periprocedural MI was 2.8% (range 0.2%–12%) in the other 20 stud-
ies, which included a total of 9069 patients.  
From the 20 studies with follow-up duration of more than 1 year, all reported rates of very late ScT 
(≥1 year). As in the RCTs, the rates were very low. In seven studies, with a total of 1026 patients, 
no very late ScT occurred. In the other studies, with a total of 5515 patients, the rate ranged from 
0.2% to 1.7%.  
Bleeding as a result of antiplatelet therapy was reported in five studies, with a total of 1989 partic-
ipants (event rate: 1%–4.4%) and mortality as a result of bleeding or stroke in 11 studies, with no 
events in nine studies (1105 patients) and one death each in the remaining two studies, with 114 
and 183 patients, respectively [83, 89]. 
Results on vascular access site complications were derived from only two of the 39 studies [two in 
2258 participants (0.09%) and one in 153 participants (0.7%), respectively] [48, 67]. 
No published results were found for procedure-related nephropathy. 
All AEs reported in RCTs are presented in Table 7 categorised by study and severity. 
For other SAEs reported in uncontrolled studies, see results in the evidence tables included in 
Appendix 1. 
DESolve®  
RCTs 
No evidence from RCTs was found for any of the safety endpoints. 
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Other studies 
Periprocedural death or periprocedural MIs were reported in all three uncontrolled studies (a total 
of 345 patients) investigating the DESolve® device [37, 61, 76]. In all studies, no patient died dur-
ing or shortly after the procedure and only one case of periprocedural MI occurred. In addition, no 
patient died from bleeding or stroke in two studies with a total of 219 participants and 12 months 
follow-up [37, 61]. The remaining study did not report this endpoint. The very late ScT rate could 
be derived only from one study (126 patients) at 24 months of follow-up [76], with no events re-
ported. For other SAEs reported in uncontrolled studies, see results in the evidence tables includ-
ed in Appendix 1. 
For all other safety outcomes, no evidence was available. 
Magmaris (Dreams 2G)  
RCTs 
No evidence from RCTs was found for any of the safety endpoints. 
Other studies 
Periprocedural death or periprocedural MIs were reported in two uncontrolled studies, with a total 
of 187 patients, investigating the Magmaris (Dreams 2G) device [35, 56, 58, 82]. In both studies, 
no patient died or had a MI during or shortly after the procedure. In addition, no patient died from 
bleeding or stroke in two studies with 12 and 24 months of follow-up. The very late ScT rate could 
be derived only from one study, with 123 patients and 24 months of follow-up [35, 56, 58, 82], with 
no events reported. For other SAEs reported in uncontrolled studies, see results in the evidence 
tables included in Appendix 1. 
For all other safety outcomes, no evidence was available. 
Fantom® 
RCTs 
No evidence from RCTs was found for any of the safety endpoints. 
Other studies 
In the only study reporting 6-month follow-up results on the Fantom® device [52] for 117 patients, 
no patient died during or shortly after the procedure and only one case of periprocedural MI oc-
curred. In addition, no patient died from bleeding or stroke during the 6 months follow-up. Given 
that the publication reported only 6-month follow-up results, very late ScT rates were not available 
for the Fantom® device. For other SAEs reported in uncontrolled studies, see results in the evi-
dence tables included in Appendix 1. 
For all other safety outcomes, no evidence was available. 
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[C0004] How does the frequency or severity of harm change  
over time or in different settings? 
No evidence from RCTs was found to answer this research question.  
From results reported in prospective uncontrolled studies, no association could be found between 
the rate of bleeding as a result of antiplatelet therapy or the rate of death as a result of bleeding or 
stoke and the length of follow-up.  
 
[C0005] – What are the susceptible patient groups that are more likely  
to be harmed through the use of fully BRS? 
Comparing the results from RCTs or prospective uncontrolled studies including predominantly 
patients with stable angina to those studies including predominantly patients with ACS, no differ-
ence was found regarding the rates of safety events. A subgroup analysis on very late ScT com-
paring those RCTs where most of the included patients (60% or more) had stable angina and 
those in which most patients had ACS (60% or more) showed no statistically significant subgroup 
differences (Figure 11).  
 
Figure 11: Subgroup analysis of different patient groups (stable angina vs. ACS) for very 
late ScT (≥1 year). 
 
[B0010] – What kind of data/records and/or registry is needed to monitor the use  
of BVS and the comparators (other stent types or other revascularisation strategies)? 
No evidence was found to answer this research question. 
 
[name of technology] for [indication] 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 49 
Table 7: Frequency and severity of adverse events in comparative studies  
RCT Absorb II [19, 20, 23, 27, 32, 34] Absorb III [24, 30] Absorb Japan [26, 31] Absorb China [17, 29] 
Adverse events Absorb® BVS 
(N = 335) 
EES  
(N = 166) 
Absorb® BVS 
(N = 1322) 
EES  
(N = 686) 
Absorb® BVS 
(N = 266) 
EES  
(N = 134) 
Absorb® BVS 
(N = 241) 
EES  
(N = 239) 
All grades 
Vascular access site 
complication, n (%) 
— — — — — — — — 
Procedure-related contrast-
induced nephropathy, n (%) 
— — — — — — — — 
Grades ≥3 
Very late (after ≥1 year) ScT 
and/or stent thrombosis and its 
consequences, n (%)  
6 (1.8) 0 10 (0.8) 0 4 (1.6) 0 1 (0.4) 0 
Bleeding as a result of 
antiplatelet therapy, n (%) 
— — — — — — — — 
Periprocedural MI, n (%) 13 (4) 2 (1) 41 (3.1) 22 (3.2) 3 (1.1) 2 (1.5) 3 (1.3) 1 (0.4) 
Periprocedural mortality, n (%) — — — — — — 0 0 
Mortality as a result of 
bleeding and/or stroke, n (%) 
— — — — — — — — 
Total SAEs, n (%) — — 398 (30.1) 198 (28.9) — — 45 (18.7) 46 (19.3) 
Total deaths, n (%) 11 (3.2) 8 (4.7) 40 (3.1) 23 (3.4) 4 (1.5) 0 2 (0.8) 6 (2.6) 
Abbreviations: BVS=bioresorbable vascular scaffold; EES=everolimus-eluting stent; MI=myocardial infarction; SAE=serious adverse events; ScT=scaffold thrombosis. 
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Table 7: Frequency and severity of adverse events in comparative studies (continued) 
RCT AIDA [18, 25] TROFI II [28] Everbio II [22, 33] Hernandez [21] 
Adverse events Absorb® BVS 
(N = 924) 
EES 
(N = 921) 
Absorb® BVS 
(N = 95) 
EES 
(N = 96) 
Absorb® BVS 
(N = 78) 
EES  
(N = 80) 
BES  
(N = 80) 
Absorb® BVS 
(N = 100) 
EES 
(N = 100) 
All grades 
Vascular access site complication, n (%) — — — — — — — — — 
Procedure-related contrast-induced 
nephropathy, n (%) 
— — — — — — — — — 
Grades ≥3 
Very late (after ≥1 year) ScT and/or stent 
thrombosis and its consequences, n (%)  
14 (1.5) 3 (0.3) — — 0 0 0 — — 
Bleeding as a result of antiplatelet 
therapy, n (%) 
— — — — — — — — — 
Periprocedural MI, n (%) 9 (1.0) 6 (0.7) 0 0 — — — — — 
Periprocedural mortality, n (%) — — 0 0 — — — — — 
Mortality as a result of bleeding and/or 
stroke, n (%) 
— — — — — — — — — 
Total SAEs, n (%) — — — — — — — — — 
Total deaths, n (%) 41 (4.4) 49 (5.3) 2 (2.1) 1 (1.0) 2 (3) 4 (5) 1 (1) 1 (1) 1 (1) 
Abbreviations: BES=biolimus-eluting stent; BVS=bioresorbable vascular scaffold; EES=everolimus-eluting stent; MI=myocardial infarction; SAE=serious adverse events; ScT=scaffold thrombosis. 
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7 DISCUSSION 
As a consequence of progress in vessel stent development, the introduction of fully BRS was re-
ceived with high levels of expectation not only from patients, but also from the scientific community, 
especially in terms of higher safety and clinical effectiveness. Seven years after the CE approval 
of the first BRS (Absorb®), results from eight RCTs (two international trials, and two trials located 
in Asia and four in Europe) and more the 40 single-arm studies (mostly registries from all over the 
world) are available. Current evidence from these eight RCTs (altogether including nearly 6000 
patients) now indicates a lower effectiveness in terms of patient-relevant outcomes for fully BRS 
compared with the second generation of permanent metal DES. This is apparent from the higher 
rates of target-lesion revascularisation (63/1000 vs. 47/1000), of all MI (73/1000 vs. 49/1000), of 
MACE (101/1000 vs. 74/1000), and of the combined POCE, which includes all death, all MI, and 
all revascularisation (214/1000 vs. 189/1000) after a maximum of 4 years of follow-up. For other 
endpoints, such as all-cause mortality, cardiac mortality, occurrence of angina pectoris symptoms, 
quality of life or physical functioning, no significant difference was found between patients who re-
ceived a fully BRS and those who received a permanent metal DES. However, this evidence is 
entirely based only on studies of one single product, namely Absorb® BVS. Regarding safety out-
comes, the evidence from these RCTs showed a significant higher risk of very late ScT after 1 year 
of follow-up or longer for patients treated with Absorb® BVS compared with patients treated with 
permanent metal DES (7/1000 vs. 1/1000). This rate in patients who received fully BRS is con-
sistent with the results from 20 single-arm studies with at least 2 years of follow-up, which report-
ed very late ScT in 6–7 per 1000 patients. Periprocedural MI occurred in ~2% of all patients, with 
no difference between Absorb® BVS and permanent metal DES. For all other safety outcomes, the 
evidence was low or very low with, for example, only a few single-arm studies reporting on bleeding 
as a result of antiplatelet therapy or death as a result of bleeding or stroke. In most of the studies, 
antithrombotic medication after the intervention comprised dual antiplatelet therapy for 12 months 
and aspirin indefinitely thereafter. However, all these results are exclusively based on Absorb® BVS 
data and, therefore, cannot directly be transferred to other BRS devices. 
For all of the other CE-marked BRS devices (DESolve®, Magmaris, ART Pure and Fantom®), no re-
sults from RCTs or at least nonrandomised controlled trials are currently available. Safety results 
for the CE-mark devices besides Absorb were available only from some individual single-arm short-
term studies. Therefore, the currently available evidence for these products is very low and does 
not allow reliable conclusions to be drawn with regard to their clinical effectiveness and safety.  
The risk of bias on outcome level for the included RCTs was judged to be low in most cases. Alt-
hough a blinding of the investigator performing the procedure was not possible, patients were 
masked to the treatment group for the whole study duration in most of the trials, whereas in-clinical 
events were adjudicated by an independent clinical events committee, which was unaware of treat-
ment assignment in all but one RCT. For some outcomes, such as occurrence of angina pector-
is or quality of life, risk of bias has to be judged as high, because of inadequate realisation of the 
intention-to treat (ITT) principle. For these outcomes, only some of the patients were analysed, 
which does not rule out the possibility that patients with poor outcomes might not have been con-
sidered. For all of the observational studies, a high risk of bias results from the lack of control 
groups and of a study protocol. 
In principle, fully BRS have been developed to overcome adverse events such as device throm-
bosis or restenosis that can arise from the permanent presence of metallic stents in the vessels. 
Now, 10 years after their implementation, the evidence from long-term RCTs shows exactly the 
opposite, namely more late ScT and higher rates of TLRs for patients treated with BRS devices. 
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Based on the results of some of these RCTs, in March 2017, the FDA issued a safety alert for the 
Absorb® device, investigating an increased risk for major cardiac adverse events [124]. In addi-
tion, in Europe, a Task Force of the ESC and the European Association of Percutaneous Cardio-
vascular Interventions (EAPCI) recommended that BRS should not be used preferentially to the 
current generation of permanent metal DES [125]. This led to the indefinite market withdrawal of 
the Absorb® device by the manufacturer in 2017 [126]. In February 2018, the Massachusetts Insti-
tute of Technology (MIT) analysed the microstructure of BRS to determine why these stents failed. 
With one exception (Magmaris), all of the bioresorbable stents are polymer based. The research-
es at MIT found that, on a microscopic level, these polymer stents have a very heterogeneous 
structure. Whereas the stents have a smooth crystalline structure externally, the inner layers are 
less ordered. Therefore, when the stent is inflated, these inner regions might be disrupted, leading 
to structural collapse and deformation of the stent as a result of non-uniform degradation. This 
can then block the blood flow and might lead to an increased rate of ScT or MI [127]. 
As mentioned earlier, the current evidence for fully BRS is almost exclusive based on results from 
studies investigating the no-longer-available Absorb® device. The other BRS are less well studied. 
However, given that there are considerable differences between the individual CE-marked devic-
es with regard to both the backbone (PDLLA, PLLA, tyrosine polycarbonate or magnesium), the 
drug released (everolimus, novolimus, sirolimus or no drug), the strut thickness (170 µm–125 µm) 
and the time to full mass loss (3 years for Absorb®, 1 year for all other products), the transferabil-
ity of the results from studies investigating the Absorb® device to the clinical effectiveness and 
safety of the other products is limited. Current guidelines on myocardial revascularisation state 
that any BRS should not be used outside well-controlled clinical studies [5]. Therefore, it is all the 
more important that results from long-term RCTs are also available for these other devices. Look-
ing at ClinicalTrials.gov or the WHO-ICTR database, a large number of ongoing studies are cur-
rently registered, including ten RCTs and 21 observational studies. However, there is only one 
RCT among them that examines a device other than Absorb® BVS (Magmaris) (Table A6 in Ap-
pendix 1).  
In addition, the applicability of the results from both current clinical trials and current single-arm 
studies to routine patients is limited. Most of the patients within the studies were males (60% or 
more) aged between 60 and 70 years, with, in most cases, one or a maximum of two simple le-
sions. Therefore, caution is required when transferring the results to female patients, patients with 
a wider age range, or patients with more complex lesions. Although most of the patients included 
in initial RCTs had stable angina, some recent RCTs predominantly included patients with ACS. 
Subgroup analyses comparing RCTs including more patients with stable CAD with those including 
more patients with unstable CAD showed no difference in key endpoints, such as all-cause mor-
tality, cardiac mortality, all MI, TLR or very late ScT. Therefore, the results are applicable for both 
patients with stable angina pectoris and patients with ACS. With regard to the comparative treat-
ment, only results from RCTs on BRS versus everolimus- or biolimus-eluting permanent metal 
stents were available. In routine care, other stent types and other revascularisation strategies are 
also used. The effectiveness and safety of fully BRS compared with those approaches have not 
yet been evaluated. 
This report has some limitations. First, only results published in full-text articles were included; 
therefore, some results from studies only presented at conferences might be missing. Given that 
some very recent study results have been presented at 2017 and 2018 international conferences, 
we would recommend a further update of this report when journal publications of these results are 
available. Second, in the case of results from single-arm registries, especially the different Italian 
registries, it was not always clear whether the patients evaluated in the individual publications 
came from the same or different patient populations. Thus, it was not always clear whether indi-
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vidual publications referred to the same study or reported results from different studies. Therefore, 
we only assigned publications to the same study if this was clearly evident. Otherwise, we as-
sumed that the publications reported results from separate studies. This could have led to some 
publications being be presented as individual studies when in fact they referred to the same pa-
tient population, which, therefore, was counted more than once. 
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8 CONCLUSION 
Based on the current evidence from eight RCTs, the fully bioresorbable everolimus-eluting stent 
Absorb® BVS is considered less effective than everolimus- or biolimus-eluting permanent metal 
stents. This conclusion is based on a statistically higher risk for MI and for TLR for patients treated 
with Absorb® BVS within a follow-up of up to 4 years, with no benefit for any other effectiveness 
endpoints.  
Based on the current evidence from eight RCTs, the fully bioresorbable everolimus-eluting stent 
Absorb® BVS is considered to have a worse safety profile than everolimus- or biolimus-eluting 
permanent metal stents. This conclusion is based on a statistically higher risk for very late ScT 
(after 1 year of follow-up or longer) for patients treated with Absorb® BVS. 
There is insufficient evidence to determine whether Absorb® BVS is less effective or less safe than 
other revascularisation strategies. 
There is also insufficient evidence to determine whether the other four currently CE-certificated 
fully BRS systems (DESolve®, Magmaris, Art Pure or Fantom®) are more effective than (or at least 
as effective as) permanent metal DES or other revascularisation strategies. 
There is insufficient evidence to determine whether the other four currently CE-certificated fully 
BRS systems (DESolve®, Magmaris, Art Pure or Fantom®) have better (or at least similar) safety 
profiles than permanent metal DES or other revascularisation strategies. 
There is an urgent need for RCTs or at least nonrandomised controlled trials with a higher number 
of patients and long-term follow-up to be able to determine whether the CE-certificated fully BRS 
systems (DESolve®, Magmaris, Art Pure or Fantom®) are suitable alternatives to permanent metal 
DES or other revascularisation strategies. 
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
 
DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Medline Ovid 
Date of search: 10.09.2018 
Databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Cita-
tions, Daily and Versions(R) 1946 to August 20, 2018 
# ▲ Searches Results 
1 *Heart Diseases/  48220 
2 *Myocardial Ischemia/  26561 
3 *Coronary Disease/  96306 
4 *Coronary Artery Disease/  45659 
5 *Coronary Stenosis/  8377 
6 *Coronary Occlusion/  2348 
7 *Acute Coronary Syndrome/  11181 
8 *Angina Pectoris/  19735 
9 *Angina, Stable/  794 
10 *Angina, Unstable/  5797 
11 exp Myocardial Infarction/  165258 
12 ((coronar* or heart* or cardiac*) adj4 (arteri* or artery*) adj4 (disease* or 
stenos* or occlusi* or narrow* or block* or restrict*)).ab,ot,ti.  
96234 
13 "angina*".ab,ot,ti.  52005 
14 "myocardial infarct*".ab,ot,ti.  177793 
15 CAD.ab,ot,ti.  33441 
16 CHD.ab,ot,ti.  22320 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 
16  
499417 
18 exp Stents/  69508 
19 exp Tissue Scaffolds/  17318 
20 exp Myocardial Revascularization/  87980 
21 exp Percutaneous Coronary Intervention/  47528 
22 (stent* or tube* or graft* or scaffold* or implant*).ab,ot,ti.  1156589 
23 (percutaneous adj1 coronary adj1 intervention*).ab,ot,ti.  27967 
24 (percutaneous adj1 transluminal adj1 coronary adj1 angioplasty).ab,ot,ti.  6594 
25 (pci or ptca).ab,ot,ti.  27768 
26 "angioplasty*".ab,ot,ti.  40790 
27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26  1243959 
28 exp Absorbable Implants/  7857 
29 exp Biodegradable Plastics/  372 
30 exp Biocompatible Materials/  95794 
31 (bioresorbable* or bio-resorbable* or bioabsorbable* or bio-absorbable* or 
absorbable* or biocompatible* or bio-compatible* or biodegradable* or bio-
degradable* or temporar*).ab,ot,ti.  
126007 
32 28 or 29 or 30 or 31  209014 
33 (Absorb or DESolve or Magmaris or Dreams or Fantom or "Art Pure" or 
ArtPure or ART18Z or Xlimus).ab,ot,ti.  
13381 
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34 (prospect* and (studi* or study* or trial*)).ti,ab,ot.  559244 
35 exp prospective study/  481866 
36 34 or 35  739741 
37 (randomised controlled trial or controlled clinical trial).pt. or randomi?ed.ti,ab. 
or placebo.ti,ab. or drug therapy.fs. or randomly.ti,ab. or trial.ti,ab. or 
groups.ti,ab.  
4345301 
38 exp animals/ not humans.sh.  4495487 
39 37 not 38  3761288 
40 exp clinical trial/  807207 
41 exp Clinical Trials as Topic/  317484 
42 clinical trial.pt.  512330 
43 40 or 41 or 42  1045822 
44 27 and 32  63338 
45 17 and 44  3172 
46 39 and 45  1109 
47 43 and 45  661 
48 36 and 45  538 
49 46 or 47 or 48  1370 
50 17 and 33  359 
51 49 or 50  1526 
52 limit 51 to yr="2008 -Current"  1109 
53 limit 52 to (English or French or German or Spanish)  1085 
 
EMBASE 
Date of search: 10.09.2018 
Databases: Ovid Embase 1974 to 2018 September 7 
# ▲ Searches Results 
1 *Heart Diseases/  10646 
2 *Myocardial Ischemia/  20822 
3 *Coronary Disease/  17169 
4 *Coronary Artery Disease/  80571 
5 *Coronary Stenosis/  7554 
6 *Coronary Occlusion/  53 
7 *Acute Coronary Syndrome/  20370 
8 *Angina Pectoris/  22191 
9 *Angina, Stable/  1317 
10 *Angina, Unstable/  3690 
11 exp Myocardial Infarction/  339261 
12 ((coronar* or heart* or cardiac*) adj4 (arteri* or artery*) adj4 (disease* or 
stenos* or occlusi* or narrow* or block* or restrict*)).ab,ot,ti.  
143135 
13 "angina*".ab,ot,ti.  69862 
14 "myocardial infarct*".ab,ot,ti.  246061 
15 CAD.ab,ot,ti.  56807 
16 CHD.ab,ot,ti.  34166 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 
16  
616969 
18 exp Stents/  153915 
19 exp Tissue Scaffolds/  13458 
20 exp Myocardial Revascularization/  28766 
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21 exp Percutaneous Coronary Intervention/  88952 
22 (stent* or tube* or graft* or scaffold* or implant*).ab,ot,ti.  1413639 
23 (percutaneous adj1 coronary adj1 intervention*).ab,ot,ti.  48533 
24 (percutaneous adj1 transluminal adj1 coronary adj1 angioplasty).ab,ot,ti.  7516 
25 (pci or ptca).ab,ot,ti.  56859 
26 "angioplasty*".ab,ot,ti.  55988 
27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26  1543258 
28 exp Absorbable Implants/  5566 
29 exp Biodegradable Plastics/  223 
30 exp Biocompatible Materials/  46568 
31 (bioresorbable* or bio-resorbable* or bioabsorbable* or bio-absorbable* or 
absorbable* or biocompatible* or bio-compatible* or biodegradable* or bio-
degradable* or temporar*).ab,ot,ti.  
156303 
32 28 or 29 or 30 or 31  197283 
33 (Absorb or DESolve or Magmaris or Dreams or Fantom or "Art Pure" or 
ArtPure or ART18Z or Xlimus).ab,ot,ti.  
15833 
34 (prospect* and (studi* or study* or trial*)).ti,ab,ot.  829265 
35 exp prospective study/  465924 
36 34 or 35  945008 
37 ( randomised controlled trial or controlled clinical trial).pt. or ran-
domi?ed.ti,ab. or placebo.ti,ab. or drug therapy.fs. or randomly.ti,ab. or 
trial.ti,ab. or groups.ti,ab.  
6335489 
38 exp animals/ not humans.sh.  23017400 
39 37 not 38  535104 
40 exp clinical trial/  1323478 
41 exp Clinical Trials as Topic/  272254 
42 clinical trial.pt.  0 
43 40 or 41 or 42  1580427 
44 27 and 32  55838 
45 17 and 44  4022 
46 39 and 45  97 
47 43 and 45  1065 
48 36 and 45  659 
49 46 or 47 or 48  1472 
50 17 and 33  669 
51 49 or 50  1844 
52 limit 51 to yr="2008 -Current"  1630 
53 limit 52 to (English or French or German or Spanish)  1608 
54 *Heart Diseases/  10646 
55 *Myocardial Ischemia/  20822 
56 *Coronary Disease/  17169 
57 *Coronary Artery Disease/  80571 
58 *Coronary Stenosis/  7554 
59 *Coronary Occlusion/  53 
60 *Acute Coronary Syndrome/  20370 
61 *Angina Pectoris/  22191 
62 *Angina, Stable/  1317 
63 *Angina, Unstable/  3690 
64 exp Myocardial Infarction/  339261 
65 ((coronar* or heart* or cardiac*) adj4 (arteri* or artery*) adj4 (disease* or 
stenos* or occlusi* or narrow* or block* or restrict*)).ab,ot,ti.  
143135 
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66 "angina*".ab,ot,ti.  69862 
67 "myocardial infarct*".ab,ot,ti.  246061 
68 CAD.ab,ot,ti.  56807 
69 CHD.ab,ot,ti.  34166 
70 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 
67 or 68 or 69  
616969 
71 exp Stents/  153915 
72 exp Tissue Scaffolds/  13458 
73 exp Myocardial Revascularization/  28766 
74 exp Percutaneous Coronary Intervention/  88952 
75 (stent* or tube* or graft* or scaffold* or implant*).ab,ot,ti.  1413639 
76 (percutaneous adj1 coronary adj1 intervention*).ab,ot,ti.  48533 
77 (percutaneous adj1 transluminal adj1 coronary adj1 angioplasty).ab,ot,ti.  7516 
78 (pci or ptca).ab,ot,ti.  56859 
79 "angioplasty*".ab,ot,ti.  55988 
80 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79  1543258 
81 exp Absorbable Implants/  5566 
82 exp Biodegradable Plastics/  223 
83 exp Biocompatible Materials/  46568 
84 (bioresorbable* or bio-resorbable* or bioabsorbable* or bio-absorbable* or 
absorbable* or biocompatible* or bio-compatible* or biodegradable* or bio-
degradable* or temporar*).ab,ot,ti.  
156303 
85 81 or 82 or 83 or 84  197283 
86 (Absorb or DESolve or Magmaris or Dreams or Fantom or "Art Pure" or 
ArtPure or ART18Z or Xlimus).ab,ot,ti.  
15833 
87 crossover-procedure/ or double-blind procedure/ or randomised controlled 
trial/ or single-blind procedure/ or (random* or factorial* or crossover* or 
cross over* or placebo* or (doubl* adj blind*) or (singl* adj blind*) or assign* 
or allocat* or volunteer*).tw.  
2032770 
88 *clinical trial/ or *clinical study/ or *"clinical trial (topic)"/ or *comparative 
study/ or controlled clinical trial/ or *"controlled clinical trial (topic)"/ or 
*controlled study/ or *major clinical study/ or *multicentre study/ or *clinical 
article/  
553099 
89 (prospect* and (studi* or study* or trial*)).ti,ab,ot.  829265 
90 exp prospective study/  465924 
91 89 or 90  945008 
92 80 and 85  55838 
93 70 and 92  4022 
94 87 and 93  894 
95 88 and 93  255 
96 91 and 93  659 
97 94 or 95 or 96  1343 
98 70 and 86  669 
99 97 or 98  1734 
100 limit 99 to yr="2008 -Current"  1562 
101 limit 100 to (English or French or German or Spanish)  1537 
 
NLM PubMed 
Date of search: 10.09.2018 
Databases: PubMed NLM 
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Limits:  
• Language (English, German, French, Spanish) 
• Date of Publication: 01.01.2008 to current 
Search Query 
Items 
found 
#62 Search #55 OR #56 OR #36 Filters: Publication date from 2008/01/01; English; 
French; German; Spanish 
1209 
#57 Search #55 OR #56 OR #36 1845 
#56 Search #34 AND #54 1108 
#55 Search #34 AND #47 1306 
#54 Search #50 or #53 1622290 
#53 Search #51 OR #52 1044857 
#52 Search "Clinical Trial" [Publication Type] 806499 
#51 Search "Clinical Trials as Topic"[Mesh] 317223 
#50 Search #48 OR #49 739164 
#49 Search "Prospective Studies"[Mesh] 481238 
#48 Search prospect*[tiab] AND (studi*[tiab] OR study*[tiab] OR trial*[tiab]) 559260 
#47 Search #45 NOT #46 3763310 
#46 Search animals [Mesh] NOT humans [Mesh] 4493104 
#45 Search #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 4347005 
#44 Search groups [tiab] 1856579 
#43 Search trial [tiab] 518155 
#42 Search randomly [tiab] 297224 
#41 Search drug therapy [sh] 2044853 
#40 Search placebo [tiab] 196729 
#39 Search  randomised [tiab] OR randomised [tiab] 541486 
#38 Search controlled clinical trial[pt] 555872 
#37 Search  randomised controlled trial [pt] 468108 
#36 Search #17 AND #35 383 
#35 Search Absorb[tiab] or DESolve[tiab] or Magmaris[tiab] or Dreams[tiab] or Fan-
tom[tiab] or "Art Pure"[tiab] or ArtPure[tiab] or ART18Z[tiab] 
13765 
#34 Search #17 AND #33 4549 
#33 Search #27 AND #32 59321 
#32 Search #28 OR #29 OR #30 OR #31 189641 
#31 Search bioresorbable*[tiab] OR bio-resorbable*[tiab] OR bioabsorbable*[tiab] OR 
bio-absorbable*[tiab] OR absorbable*[tiab] OR biocompatible*[tiab] OR bio-
compatible*[tiab] OR biodegradable*[tiab] OR bio-degradable*[tiab] OR tempo-
rar*[tiab] 
126948 
#30 Search "Biocompatible Materials"[Mesh] 74230 
#29 Search "Biodegradable Plastics"[Mesh] 369 
#28 Search "Absorbable Implants"[Mesh] 7843 
#27 Search #18 OR #19 OR #20 OR #21 OR #22 or #23 OR #24 OR #25 OR #26 1214975 
#26 Search "angioplasty"[tiab] 41727 
#25 Search pci[tiab] OR ptca[tiab] 28223 
#24 Search percutaneous[tiab] AND transluminal[tiab] AND coronary[tiab] AND angio-
plasty[tiab] 
7405 
#23 Search percutaneous[tiab] AND coronary[tiab] AND intervention*[tiab] 32672 
#22 Search stent*[tiab] OR tube*[tiab] OR graft*[tiab] OR scaffold*[tiab] OR im-
plant*[tiab] 
1127092 
#21 Search "Percutaneous Coronary Intervention"[Mesh] 47492 
#20 Search "Myocardial Revascularization"[Mesh] 87947 
#19 Search "Tissue Scaffolds"[Mesh] 17253 
#18 Search "Stents"[Mesh] 69466 
#17 Search #1 OR #2 Or #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 Or #11 1015707 
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OR #12 OR #13 OR #14 OR #15 OR #16 
#16 Search CHD[tiab] 22706 
#15 Search CAD[tiab] 33981 
#14 Search "myocardial infarct*"[tiab] 19551 
#13 Search angina*[tiab] 53067 
#12 Search (coronar*[tiab] OR heart*[tiab] OR cardiac*[tiab]) AND (arteri*[tiab] OR 
artery*[tiab]) AND (disease*[tiab] OR stenos*[tiab] OR occlusi*[tiab] OR nar-
row*[tiab] OR block*[tiab] OR restrict*[tiab]) 
186171 
#11 Search "Myocardial Infarction"[Mesh] 165179 
#10 Search "Angina, Stable"[Majr] 794 
#9 Search "Angina, Unstable"[Majr] 7208 
#8 Search "Angina Pectoris"[Majr] 27262 
#7 Search "Acute Coronary Syndrome"[Majr] 11168 
#6 Search "Coronary Occlusion"[Majr] 2339 
#5 Search "Coronary Stenosis"[Majr] 12867 
#4 Search "Coronary Artery Disease"[Majr] 45607 
#3 Search "Coronary Disease"[Majr] 161657 
#2 Search "Myocardial Ischemia"[Majr] 330405 
#1 Search "Heart Diseases"[Majr] 890159 
 
Cochrane Library 
Date of search: 10.09.2018 
Databases: Cochrane Library - CCTR (Wiley) 
Search Query 
Items 
found 
#1 MeSH descriptor: [Heart Diseases] this term only  1850 
#2 MeSH descriptor: [Myocardial Ischemia] this term only  3201 
#3 MeSH descriptor: [Coronary Disease] this term only  6936 
#4 MeSH descriptor: [Coronary Artery Disease] this term only  5007 
#5 MeSH descriptor: [Coronary Stenosis] this term only  680 
#6 MeSH descriptor: [Coronary Occlusion] this term only  95 
#7 MeSH descriptor: [Acute Coronary Syndrome] this term only  1530 
#8 MeSH descriptor: [Angina Pectoris] this term only  3224 
#9 MeSH descriptor: [Angina, Stable] this term only  230 
#10 MeSH descriptor: [Angina, Unstable] this term only  976 
#11 MeSH descriptor: [Myocardial Infarction] explode all trees 10037 
#12 (((coronar* or heart* or cardiac*) and (arteri* or artery*) and (disease* or stenos* or occlusi* or narrow* or block* or restrict*))):ti,ab,kw 
27191 
#13 (angina*):ti,ab,kw  10812 
#14 ("myocardial infarct*"):ti,ab,kw 466 
#15 (CAD):ti,ab,kw  3623 
#16 (CHD):ti,ab,kw 2419 
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 
48461 
#18 MeSH descriptor: [Stents] explode all trees 3806 
#19 MeSH descriptor: [Tissue Scaffolds] explode all trees 68 
#20 MeSH descriptor: [Myocardial Revascularization] explode all trees 8869 
#21 MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees 4957 
#22 (stent* or tube* or graft* or scaffold* or implant*):ti,ab,kw 73791 
#23 (percutaneous and coronary and intervention*):ti,ab,kw 7798 
#24 (percutaneous and transluminal and coronary and angioplasty):ti,ab,kw 1196 
#25 (pci or ptca):ti,ab,kw 6732 
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#26 ("angioplasty*"):ti,ab,kw 7114 
#27 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 82722 
#28 MeSH descriptor: [Absorbable Implants] explode all trees 622 
#29 MeSH descriptor: [Biodegradable Plastics] explode all trees 4 
#30 MeSH descriptor: [Biocompatible Materials] explode all trees 2037 
#31 
(bioresorbable* or bio-resorbable* or bioabsorbable* or bio-absorbable* or absorba-
ble* or biocompatible* or bio-compatible* or biodegradable* or bio-degradable* or 
temporar*):ti,ab,kw 
9085 
#32 #28 or #29 or #30 or #31 9409 
#33 #27 and #32 3522 
#34 (Absorb or DESolve or Magmaris or Dreams or Fantom
 or "Art Pure" or ArtPure or 
ART18Z):ti,ab,kw 
870 
#35 #17 and #33 697 
#36 #17 and #34 142 
#37 #36 or #35 with Publication Year from 2008 to present, in Trials 577 
 
ClinicalTrials.gov 
Date of search: 27.09.2018 
Age Groups: Adult (18–64); Older Adult (65+) 
Study Type: All studies 
Search terms: 
Condition or disease: „Angina, Unstable OR Angina, Stable OR Angina Pectoris OR Coronary 
Disease OR Coronary Artery Disease OR Cardiovascular Disease OR Coronary Stenosis OR 
Coronary Occlusion OR Acute Coronary Syndrome OR Myocardial Infarction OR Myocardial 
Ischemia“ 
Other Terms: (bioresorbable OR bio-resorbable OR bioabsorbable OR bio-absorbable OR 
biodegradable OR bio-degradable) AND (stent OR scaffold) OR (Absorb OR Magmaris OR 
DESolve OR Dreams OR Fantom OR ART18Z OR "Art Pure") 
 
WHO-ICTRP 
Date of search: 27.09.2018 
Recruitment status is ALL 
ALL Phases 
Title: (bioresorbable OR bio-resorbable OR bioabsorbable OR bio-absorbable OR biodegrada-
ble OR bio-degradable) AND (stent OR scaffold) OR (Absorb OR Magmaris OR DESolve OR 
Dreams OR Fantom OR ART18Z OR "Art Pure") 
AND 
Condition: „Angina, Unstable OR Angina, Stable OR Angina Pectoris OR Coronary Disease 
OR Coronary Artery Disease OR Cardiovascular Disease OR Coronary Stenosis OR Coronary 
Occlusion OR Acute Coronary Syndrome OR Myocardial Infarction OR Myocardial Ischemia“ 
OR 
Condition: „Angina, Unstable OR Angina, Stable OR Angina Pectoris OR Coronary Disease 
OR Coronary Artery Disease OR Cardiovascular Disease OR Coronary Stenosis OR Coronary 
Occlusion OR Acute Coronary Syndrome OR Myocardial Infarction OR Myocardial Ischemia“ 
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AND  
Intervention: (bioresorbable OR bio-resorbable OR bioabsorbable OR bio-absorbable OR 
biodegradable OR bio-degradable) AND (stent OR scaffold) OR (Absorb OR Magmaris OR 
DESolve OR Dreams OR Fantom OR ART18Z OR "Art Pure") 
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DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A1: Overview of guidelines 
Name of 
society/organisation 
issuing guidance 
Date of 
issue 
Country/ies  
to which 
applicable 
Summary of 
recommendation 
Level of 
evidence (A,B,C)/ 
class of 
recommendation 
(I, IIa, IIb, III) 
European Society of 
Cardiology (ESC)  
European Association 
for Cardio-Thoracic 
Surgery (EACTS) 
2018 Europe BRS are currently not 
recommended for clinical use 
outside of clinical studies. 
C / III 
National Institute for 
Health and Care 
Excellence (NICE) 
2014 United 
Kingdom 
Current evidence on the short-
term safety and efficacy of 
bioresorbable stent 
implantation for treating 
coronary artery disease is 
adequate, but the quantity of 
evidence on the safety and 
efficacy of the procedure in the 
long term is inadequate. 
Therefore, this procedure 
should only be used with 
special arrangements for 
clinical governance, consent 
and audit or research. 
-/- 
Abbreviations: BRS=bioresorbable scaffold; EACTS=European Association for Cardio-Thoracic Surgery; ESC=European 
Society of Cardiology; NICE=National Institute for Health and Care Excellence 
Sources: [3, 5] 
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Evidence tables of individual studies included for clinical effectiveness and safety 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS  
Author, year ABSORB II 
 Chevalier 2018 [20] Serruys 2016 [23] Chevalier 2016 [27] Serruys 2015 [34] 
Study-ID NCT01425281 
Study design Single-blind, parallel two-group, multicentre RCT (2:1 ratio; superiority design) 
Country 46 sites in Europe and New Zealand 
Sponsor Abbott Vascular, Santa Clara, CA, USA 
Intervention/Product Everolimus-eluting BRS/Absorb®  
Comparator/Product Everolimus-eluting permanent metallic stent/Xience®  
Anti-platelet therapy Dual-antiplatelet therapy for a minimum of 180 days: 75 mg aspirin daily after the index procedure and throughout the length of the clinical investigation + maintenance at a 
minimum of 75 mg of clopidogrel daily or a minimum of 10 mg of prasugrel daily for a minimum of 180 days after the procedure; in case of sensitivity to clopidogrel or 
prasugrel: switch to ticlopidine according to standard hospital practice. 
Main inclusion 
criteria 
• Age 18 to <85 years; 
• Evidence of myocardial ischaemia (e.g., stable or unstable angina; silent ischemia); 
• 1 to 2 de-novo lesions each located in a different epicardial vessel (maximum ø 2.25-3.8 mm; maximum length 48 mm) 
Primary endpoint • Vasomation 
• Minimum Lumen Diameter (MLD) post nitrate minus MLD post procedure post nitrate by quantitative coronary angiography (QCA) 
Maximumfollow-up Primary outcomes: 3 years 
Clinical outcomes: 5 years 
Number of patients; 
(n) 
501 (335 vs. 166) 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 4 years: 
28 (8.4) vs. 18 (10.8) 
Mean age of 
patients (years)  
61.5 (10.0) vs. 60.9 (10.0) 
Sex (% male) 76% vs. 80% 
Previous MI; n (%) 94 (28) vs. 48 (29) 
Stable angina; n (%) 214 (64) vs. 107 (64) 
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Author, year ABSORB II 
 Chevalier 2018 [20] Serruys 2016 [23] Chevalier 2016 [27] Serruys 2015 [34] 
Unstable angina; n 
(%) 
68 (20) vs. 37 (22) 
Silent ischemia; n 
(%) 
42 (13) vs. 19 (11) 
Outcomes: Efficacy 4 year follow-up  3 year follow-up  2 year follow-up  1 year follow-up 
MACE; n (%) 42 (12.4) vs. 13 (8.0); p=0.1545 nr 25 (7.6) vs. 7 (4.30);  
RR = 1.79 (0.79 - 4.04); p=0.155 
17 (5) vs. 5 (3); Δ = 2.11% (-2.20 to 5.51); 
p=0.28 
POCE; n (%) 79 (23.6) vs. 44 (26.7); p=0.4682 68 (21) vs. 39 (24);  
RR = 0.86 (0.61 - 1.22); p=0.41 
39 (11.6) vs. 21 (12.8);  
RR = 0.90 (0.55 - 1.49); p=0.6947 
24 (7) vs. 15 (9);  
Δ = -1.84% (-7.69 to 2.98); p=0.47 
TVF; n (%) 47 (14.0) vs. 23 (14.0); p=0.997 nr 28 (8.5) vs. 11 (6.7);  
RR = 1.27 (0.65 - 2.49); p=0.4789 
18 (5) vs. 8(5);  
Δ = 0.59% (-4.26 to 4.41); p=0.78 
All-cause mortality; 
n (%) 
11 (3.2) vs. 8 (4.7); p=0.4268 8 (2) vs. 6 (4); 
RR = 0.66 (0.23 -1.87); p=0.57 
4 (1.2) vs. 1 (0.6);  
RR = 2.00 (0.23 - 17.75); p=0.699 
0 vs. 1 (0.6);  
Δ = -0.61% (3.35 to 0.65); p=0.33 
Cardiac mortality; n 
(%) 
4 (1.3) vs. 4 (2.7); p=0.2795 3 (1) vs. 3 (2);  
RR = 0.50 (0.10 - 2.43); p=0.40 
2 (0.6) vs. 0; p=0.554 0 vs. 0; Δ = 0%; p=1.0 
All myocardial 
infarction; n (%) 
29 (8.6) vs. 5 (3.3); p=0.0363 27 (8) vs. 5 (3); 
RR = 2.68 (1.05 - 6.82); p=0.0295 
18 (5.5) vs. 4 (2.4);  
RR = 2.25 (0.77 - 6.54); p=0.123 
15 (4) vs. 2 (1);  
Δ = 3.32% (-0.25 to 6.26); p=0.06 
Angina; n (%) nr free of angina: 230 (74) vs. 113 (73); 
p=0.33 
N = 313 vs. 155 
free of angina: 244 (78) vs. 119 (77); 
p=0.82 
N = 313 vs. 155 
free of angina:227 (74) vs. 113 (74); 
p=0.98 
N = 307 vs. 153 
TVR; n (%)     
All-TVR 44 (13.1) vs. 24 (14.6); p=nr 33 (10) vs. 19 (12); 
RR = 0.86 (0.51 - 1.46); p=0.58 
 8 (2) vs. 8 (5);  
Δ = -2.43% (-7.01 to 0.86); p=0.15 
ID-TVR nr  8 (2.4) vs. 7 (4.3);  
RR = 0.57 (0.21 - 1.55); p=0.265 
 
TLR; n (%)     
All-TLR 28 (8.3) vs. 9 (5.3); p=0.2545 24 (7) vs. 8 (5); 
RR = 1.49 (0.68 - 3.23); p=0.31 
 4 (1) vs. 3 (2);  
Δ = -0.61% (-4.08 to 1.60); p=0.69 
ID-TLR 22 (6.7) vs. 3 (2.0); p=0.0330  5 (1.5) vs. 3 (1.8);  
RR = 0.83 (0.20 - 3.44); p=1.0 
 
Quality of life; 
points (SD) 
nr N =313 vs. 155: 76 pts (nr) vs. 74 pts 
(nr); p=0.47 
N = 313 vs. 155 
76 pts (nr) vs. 78 pts (nr); p=0.60 
N = 313 vs. 155 
76 pts (nr) vs. 74 pts (nr); p=0.55 
N = 313 vs. 155 
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Author, year ABSORB II 
 Chevalier 2018 [20] Serruys 2016 [23] Chevalier 2016 [27] Serruys 2015 [34] 
Daily functioning; 
points (SD) 
nr 87 pts (nr) vs. 86 pts (nr); p=0.54 
N = 313 vs. 155 
87 pts (nr) vs. 86 pts (nr); p=0.53 
N = 313 vs. 155 
87 pts (nr) vs. 86 pts (nr); p=0.48 
N = 313 vs. 155 
Duration of 
procedure; min (SD) 
nr 
Outcomes: Safety 4 year follow-up  3 year follow-up  2 year follow-up  1 year follow-up 
Vascular-access-
site complication; n 
(%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
13 (4) vs. 2 (1); p=nr 
Periprocedural 
mortality; n (%) 
nr 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr nr nr 
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr nr nr 
ScT ≥1 year; n (%) 6 (1.8) vs. 0; p=0.1851 6 (1.8) vs. 0; p=0.1851 2 (0.6) vs. 0; p=0.554 na 
Other SAEs; n (%) nr nr nr nr 
Abbreviations: BRS=bioresorbable scaffold; CA=California; EES=everolimus-eluting stent; MACE=major adverse cardiac events; MI=myocardial infarction; MLD=minimum lumen diameter; na=not 
applicable; nr=not reported; POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; RR=risk ratio; SAE=serious adverse event; SD=standard deviation; TLR=target lesion 
revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation; USA=United States of America 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS (continued) 
Author, year ABSORB III 
 Kereiakes 2017 [24] Ellis 2015 [30] 
Study-ID NCT01751906 
Study design Single-blind, parallel two-group, multicentre RCT (2:1 ratio; noninferiority design) 
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Author, year ABSORB III 
 Kereiakes 2017 [24] Ellis 2015 [30] 
Country 202 sites in USA and Australia 
Sponsor Abbott Vascular, Santa Clara, CA, USA 
Intervention/Product Everolimus-eluting BRS/Absorb® 
Comparator/Product Everolimus-eluting permanent metallic stent/Xience®  
Anti-platelet therapy Loading dose of at least 300 mg aspirin within 24 hours before the procedure;  
dual antiplatelet therapy was continued for at least 1 year, and aspirin (at a dose of at least 81 mg daily) was continued indefinitely 
Main inclusion 
criteria 
• ≥18 years of age 
• Evidence of myocardial ischaemia (e.g., stable or unstable angina; postinfarct angina, silent ischemia) suitable for elective PCI; 
• 1 to 2 de-novo lesions each located in a different epicardial vessel (maximum ø 2.50-3.75 mm; maximum length ≤24 mm) 
Primary endpoint • Number of patients with TLF (cardiac death, MI in target vessel or ID-TLR) at 1 year  
Maximumfollow-up 5 years 
Number of patients; 
(n) 
2008 (1322 vs. 686) 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 3 years:  
46 (3.5) vs. 25 (3.6) 
Mean age of 
patients (years)  
63.5 (10.6) vs. 63.6 (10.3) 
Sex (% male) 70.7% vs. 70.1% 
Previous MI; n (%) 282 (21.5) vs. 150 (22.0) 
Stable angina; n (%) 757 (57.3) vs. 417 (60.8) 
Unstable angina; n 
(%) 
355 (26.9) vs. 168 (24.5) 
Silent ischemia; n 
(%) 
132 (10.2) vs. 70 (10.2) 
Outcomes: Efficacy 3 year follow-up  1 year follow-up   
 
MACE; n (%) nr 113 (8.6) vs. 47 (6.9); p=nr a 
POCE; n (%) 296 (22.7) vs. 120 (17.8); 
HR = 1.31 (1.06 - 1.62); p=0.01 
184 (14) vs. 78 (11.5); p=nr a 
TVF; n (%) 229 (17.7) vs. 86 (12.8); 
HR = 1.41 (1.10 - 1.81); p=0.006 
131 (10) vs. 53 (7.8) a 
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Author, year ABSORB III 
 Kereiakes 2017 [24] Ellis 2015 [30] 
All-cause mortality; 
n (%) 
40 (3.1) vs. 23 (3.4); 
HR = 0.90 (0.54 - 1.51); p=0.70 
15 (1.1) vs. 3 (0.4); 
RR = 2.58 (0.75 - 8.87); p=0.12 
Cardiac mortality; n 
(%) 
18 (1.4) vs. 8 (1.2); 
HR = 1.17 (0.51 - 2.69); p=0.71 
8 (0.6) vs. 1 (0.1); 
RR = 4.12 (0.52 - 32.91); p=0.29 
All myocardial 
infarction; n (%) 
132 (10.2) vs. 51 (7.6); 
HR = 1.36 (0.98 - 1.88); p=0.06 
90 (6.9) vs. 38 (5.6); 
RR = 1.22 (0.85 - 1.76); p=0.28 
Angina; n (%) nr patient reported angina: 238 (18.3) vs. 125 (18.4) 0.99 (0.82 - 1.21); p=0.93 
TVR; n (%)   
All-TVR nr 74 (5.6) vs. 31 (4.6) a 
ID-TVR 148 (11.6) vs. 51 (7.7); 
HR = 1.54 (1.12 - 2.11); p=0.008 
66 (5.0) vs. 25 (3.7); 
RR = 1.36 (0.87 - 2.14); p=0.18 
TLR; n (%)   
All-TLR nr 42 (3.2) vs. 18 (2.7) a 
ID-TLR 92 (7.2) vs. 39 (5.9); 
HR = 1.23 (0.85 - 1.79); p=0.27 
40 (3.0) vs. 17 (2.5); 
RR = 1.21 (0.69 - 2.12); p=0.50 
Quality of life; 
points (SD) 
nr 87.05 pts (13.91) vs. 86.42 pts (14.45); p=nr a 
N = 1014 vs. 514 
Daily functioning; 
points (SD) 
nr nr 
Duration of 
procedure; min (SD) 
42.2 (23.1) vs. 38.3 (20.9); p<0.001 
Outcomes: Safety 3 year follow-up  2 year follow-up  
Vascular-access-
site complication; n 
(%) 
nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr 
Periprocedural MI; n 
(%) 
41 (3.1) vs. 22 (3.2); 
RR = 0.96 (0.58 - 1.60); p=0.88 
Periprocedural 
mortality; n (%) 
nr 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr 
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 Kereiakes 2017 [24] Ellis 2015 [30] 
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr 
ScT ≥1 year; n (%) 10 (0.8) vs. 0; p=0.02 na 
Other SAEs; n (%) nr 398 (30.1) vs. 198 (28.9); p=nr a 
a Results from ClinicalTrials.gov 
Abbreviations: BVS=bioresorbable vascular scaffold; CA=California; EES=everolimus-eluting stent; HR=hazard ratio; ID-TLR=ischaemic driven target lesion revascularisation; MACE=major adverse 
cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; PCI=percutaneous coronary intervention; POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; 
RR=risk ratio; SAE=serious adverse event; SD=standard deviation; TLR=target lesion revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation; USA=United States of 
America 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS (continued) 
Author, year ABSORB Japan 
 Ali 2018 [122]; meta-analysis Onuma 2016 [26] Kimura 2015 [31] 
Study-ID NCT01844284 
Study design Single-blind, parallel two-group, multicentre RCT (2:1 ratio; noninferiority design) 
Country 38 sites in Japan 
Sponsor Abbott Vascular, Santa Clara, CA, USA 
Intervention/Product Everolimus-eluting BRS/Absorb®  
Comparator/Product Everolimus-eluting permanent metallic stent/Xience Prime or Xience Xpedition®  
Anti-platelet therapy Thienopyridine for at least 12 months and aspirin indeﬁnitely 
Main inclusion 
criteria 
• ≥20 years of age; 
• Evidence of myocardial ischaemia (e.g., stable or unstable angina, silent ischemia) suitable for elective PCI 
• 1 to 2 de-novo lesions each located in a different epicardial vessel (maximum ø 2.50-3.75 mm; maximum length ≤24 mm) 
Primary endpoint • Number of patients with TLF (cardiac death, MI in target vessel or ID-TLR) at 1 year 
Maximumfollow-up Up to 5 years 
Number of patients; 
(n) 
400 (266 vs. 134) 
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Author, year ABSORB Japan 
 Ali 2018 [122]; meta-analysis Onuma 2016 [26] Kimura 2015 [31] 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 2 years:  
8 (3.0) vs. 4 (3.0) 
Mean age of 
patients (years)  
67.1 (9.4) vs. 67.3 (9.6) 
Sex (% male) 78.9% vs. 73.9% 
Previous MI; n (%) 42 (16.0) vs. 32 (23.9) 
Stable angina; n (%) 170 (63.9) vs. 88 (65.7) 
Unstable angina; n 
(%) 
26 (9.8) vs. 22 (16.4) 
Silent ischemia; n 
(%) 
70 (26.3) vs. 24 (17.9) 
Outcomes: Efficacy 3 year follow-up  2 year follow-up  1 year follow-up  
MACE; n (%) nr nr nr 
POCE; n (%) 59 (22.9) vs. 21 (16.4); 
RR = 1.39 (0.89 - 2.19); p=nr 
52 (19.9 ) vs. 16 (12.3 ); 
RR = 1.62 (0.96 - 2.72); p=0.06 
26 (9.8) vs. 11 (8.3); 
RR = 1.19 (0.60 - 2.33); p=0.62 
TVF; n (%) nr 29 (11.1) vs. 9 (6.9); 
RR = 1.60 (0.78 - 3.29); p=0.19 
16 (6) vs. 7 (5.3); 
RR = 1.15 (0.48 - 2.72); p=0.75 
All-cause mortality; 
n (%) 
nr 4 (1.5) vs. 0; p=0.31 2 (0.8) vs. 0; p=0.55 
Cardiac mortality; n 
(%) 
1 (0.4) vs. 0; p=nr 1 (0.4) vs. 0; p=1.0 0 vs. 0; p=1.0 
All myocardial 
infarction; n (%) 
nr 14 (5.4) vs. 4 (3.1); 
RR = 1.74 (0.59 - 5.19); p=0.31 
9 (3.4) vs. 3 (2.3); 
RR = 1.51 (0.41 - 5.47); p=0.76 
Angina; n (%) nr nr nr 
TVR; n (%)    
All-TVR nr 25 (9.6) vs. 10 (7.7); 
RR = 1.25 (0.62 - 2.51); p=0.54 
13 (4.9) vs. 6 (4.5); 
RR = 1.09 (0.42 - 2.80); p=0.86 
ID-TVR nr 24 (9.2) vs. 7 (5.4); 
RR = 1.71 (0.76 - 3.86); p=0.19 
13 (4.9) vs. 5 (3.8); 
RR = 1.30 (0.48 - 3.58); p=0.60 
TLR; n (%)    
All-TLR nr 15 (5.7) vs. 7 (5.4); 
RR = 1.07 (0.45 - 2.55); p=0.88 
7 (2.6) vs. 5 (3.8); 
RR = 0.70 (0.23 - 2.17); p=0.55 
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 Ali 2018 [122]; meta-analysis Onuma 2016 [26] Kimura 2015 [31] 
ID-TLR 17 (6.8) vs. 4 (3.2); 
RR = 2.14 (0.74 - 6.23); p=nr 
14 (5.4) vs. 3 (2.3); 
RR = 2.32 (0.68 - 7.94); p=0.16 
7 (2.6) vs. 3 (2.3); 
RR = 1.17 (0.31 - 4.46); p=1.00 
Quality of life; 
points (SD) 
nr nr nr 
Daily functioning; 
points (SD) 
nr nr nr 
Duration of 
procedure; min (SD) 
49.8 (24.8) vs. 44.9 (21.7); p=0.04 
Outcomes: Safety 3 year follow-up  2 year follow-up  1 year follow-up  
Vascular-access-
site complication; n 
(%) 
nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr 
Periprocedural MI; n 
(%) 
3 (1.1) vs. 2 (1.5); 
RR = 0.75 (0.13 - 4.45); p=1.0 
Periprocedural 
mortality; n (%) 
nr 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr nr 
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr nr 
ScT ≥1 year; n (%)  4 (1.6) vs. 0; p=0.31 na 
Other SAEs; n (%) nr nr nr 
Abbreviations: BRS=bioresorbable scaffold; CA=California; EES=everolimus-eluting stent; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; 
POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; RR=risk ratio; SAE=serious adverse event; SD=standard deviation; TLF=target lesion failure; TLR=target lesion 
revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation; USA=United States of America 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS (continued) 
Author, year ABSORB China 
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 Xu 2018 [17] ClinicalTrials.gov (online) Gao 2015 [29] 
Study-ID NCT01923740 
Study design Open-label, parallel two-group, multicentre RCT (1:1 ratio; noninferiority design for primary endpoint) 
Country 24 sites in China 
Sponsor Abbott Vascular, Santa Clara, CA, USA 
Intervention/Product Everolimus-eluting BRS/Absorb® 
Comparator/Product Everolimus-eluting permanent metallic stent/Xience®  
Anti-platelet therapy Loading dose of at least 300 mg aspirin and either clopidogrel (≥300 mg) or ticagrelor (180 mg) 6 to 24 h before the procedure;  
following PCI, aspirin 100 mg daily for at least 5 years, with clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) for a minimum of 12 months. Prasugrel was not 
available for use during this study. 
Main inclusion 
criteria 
• ≥18 years of age; 
• Evidence of myocardial ischaemia (e.g., stable or unstable angina; postinfarct angina, silent ischemia) suitable for elective PCI 
• 1 to 2 de-novo lesions each located in a different epicardial vessel (maximum ø 2.50-3.75 mm; maximum length ≤24 mm) 
Primary endpoint • Angiographic in-segment late loss (LL) after 1 year 
Maximumfollow-up 5 years 
Number of patients; 
(n) 
480 (241 vs. 239 ( randomised)) 
475 (238 vs. 237 (ITT population)) 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 3 years:  
5 (3.5) vs. 4 (1.8) a 
 
Mean age of 
patients (years)  
57.2 (11.4) vs. 57.6 (9.6) 
Sex (% male) 71.8% vs. 72.6% 
Previous MI; n (%) 40 (16.8) vs. 38 (16.0) b     
Stable angina; n (%) 53 (22.3) vs. 40 (16.9) c 
Unstable angina; n 
(%) 
154 (64.7) vs. 152 (64.1) d 
Acute MI; n (%) 18 (7.6) vs. 28 (11.8) 
Outcomes: Efficacy 3 year follow-up  
N = 236 vs. 235 
2 year follow-up  
N = 226 vs. 232 
1 year follow-up  
N =238 vs. 237 
MACE; n (%) 15 (6.4) vs. 12 (5.1); 
RR = 1.24 (0.60 - 2.60); p=0.56 
10 (4.4) vs. 11 (4.7); p=nr e 9 (3.8) vs. 10 (4.2);  
Δ = -0.4% (-4.3 to 3.3); p=0.81 
POCE; n (%) 28 (11.9) vs. 28 (11.9); 
RR = 1.00 (0.61 - 1.63); p=0.99 
22 (9.7) vs. 26 (11.2); p=nr e 19 (8.0) vs. 23 (9.7);  
Δ = -1.7% (-7.0 to 3.5); p=0.51 
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 Xu 2018 [17] ClinicalTrials.gov (online) Gao 2015 [29] 
TVF; n (%) 16 (6.8) vs. 16 (6.8); 
RR = 1.00 (0.51 - 1.94); p= 0.99 
11 (4.9) vs. 15 (6.5); p=nr e 10 (4.2) vs. 14 (5.9);  
Δ = -1.7% (-5.9 to 2.4); p=0.40 
All-cause mortality; 
n (%) 
2 (0.8) vs. 6 (2.6); 
RR = 0.33 (0.07 - 1.63); p=0.18 
1 (0.4) vs. 5 (2.1); p=nr e 0 vs. 5 (2.1);  
Δ = -2.1% (-4.4 to -0.1); p=0.03 
Cardiac mortality; n 
(%) 
1 (0.4) vs. 3 (1.3);  
RR = 0.33 (0.03 - 3.17); p=0.37 
nr 0 vs. 3 (1.3);  
Δ = -1.3% (-3.7 to 0.5); p=0.50 
All myocardial 
infarction; n (%) 
8 (3.4) vs. 5 (2.1); 
RR = 1.59 (0.53 - 4.80); p=0.40 
5 (2.2) vs. 5 (2.1); p=nr e 5 (2.1) vs. 4 (1.7);  
Δ = 0.4% (-2.4 to 3.3); p=1.0 
Angina; n (%) nr nr nr 
TVR; n (%)    
All-TVR 14 (5.9) vs. 13 (5.5); 
RR = 1.07 (0.52 - 2.23); p=0.85 
11 (4.9) vs. 13 (5.6); p=nr e 9 (3.8) vs. 12 (5.1);  
Δ = -1.3% (-5.3 to 2.6); p=0.5 
ID-TVR 12 (5.1) vs. 10 (4.3); 
RR = 1.19 (0.53 - 2.71); p=0.67 
nr 7 (2.9) vs. 9 (3.8);  
Δ = -0.9% (-4.5 to 2.6); p=0.61 
TLR; n (%)    
All-TLR 11 (4.7) vs. 8 (3.4); 
RR = 1.37 (0.56 - 3.34); p=0.49 
9 (4.0) vs. 8 (3.5); p=nr e 7 (2.9) vs. 7 (3.0);  
Δ = 0.0% (-3.4 to 3.4); p=0.99 
ID-TLR 10 (4.2) vs. 6 (2.6); 
RR = 1.66 (0.61 - 4.49); p=0.31 
nr 6 (2.5) vs. 5 (2.1);  
Δ = 0.4% (-2.6 to 3.5); p=0.77 
Quality of life; 
points (SD) 
nr nr nr 
Daily functioning; 
points (SD) 
nr nr nr 
Duration of 
procedure; min (SD) 
nr 
Outcomes: Safety 3 year follow-up  2 year follow-up  1 year follow-up  
Vascular-access-
site complication; n 
(%) 
nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr 
Periprocedural MI; n 
(%) 
3 (1.3) vs. 1 (0.4); p=0.62 e 
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 Xu 2018 [17] ClinicalTrials.gov (online) Gao 2015 [29] 
Periprocedural 
mortality; n (%) 
0 vs. 0 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr nr 
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr nr 
ScT ≥1 year; n (%) 1 (0.4) vs. 0; p=1.0 1 (0.4) vs. 0; na; p=1.0 e na 
Other SAEs; n (%) 45 (18.7) vs. 46 (19.3); p=nr
 e 
N = 241 vs. 239 
nr nr 
a Summary of withdrawals and lost to follow up 
b Data from Gao 2015 [29]; Discrepant data in Xu 2018 [17]: 40 (16.8%) vs. 40 (16.9%) 
c Data from Gao 2015 [29]; Discrepant data in Xu 2018 [17]: 53 (22.3%) vs. 41 (17.3%) 
d Data from Gao 2015 [29]; Discrepant data in Xu 2018 [17]: 156 (65.5%) vs. 153 (64.6%) 
e Results from ClinicalTrials.gov 
 
Abbreviations: BRS=bioresorbable scaffold; CA=California; EES=everolimus-eluting stent; ITT=intention-to treat; LL=lumen loss; MACE=major adverse cardiac events; MI=myocardial infarction; 
MLD=minimum lumen diameter; na=not applicable; nr=not reported; PCI=percutaneous coronary intervention; POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; RR=risk 
ratio; SAE=serious adverse event; SD=standard deviation; TLR=target lesion revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation; USA=United States of America 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS (continued) 
Author, year AIDA 
 Tijssen 2018 [18] Wykrzykowska 2015 [25] 
Study-ID NCT01858077 
Study design Single-blind, parallel two-group, multicentre RCT (1:1 ratio; noninferiority design) 
Country 5 sites in the Netherlands 
Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam 
Intervention/Product Everolimus-eluting BRS/Absorb® revision 1.1  
Comparator/Product Everolimus-eluting permanent metallic stent/Xience Prime or Xience Xpedition®  
Anti-platelet therapy Dual antiplatelet therapy was administered before the procedure in accordance with the ESC guidelines; dual-antiplatelet therapy (75-100 mg aspirin daily and 75 mg 
clopidogrel or 10 mg prasugrel or 180 mg ticagrelor daily) for a minimum of 1 year after the index procedure 
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Author, year AIDA 
 Tijssen 2018 [18] Wykrzykowska 2015 [25] 
Main inclusion 
criteria 
• ≥18 years of age 
• Evidence of coronary artery disease suitable for treatment with DES in accordance with guidelines 
• 1 or more target lesions (Maximumø 2.50-4.00 mm; maximum length ≤70 mm) 
Primary endpoint • TVF (cardiac death, MI in target vessel or TVR) at 2 years 
Maximumfollow-up 5 years 
Number of patients; 
(n) 
1845 (924 vs. 921) 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 2 years:  
35 (3.8) vs. 24 (2.6) 
Mean age of 
patients (years)  
64.3 (10.6) vs. 64.0 (10.5) 
Sex (% male) 72.5% vs. 76.0% 
Previous MI; n (%) 166 (18.0) vs. 172 (18.7) 
Stable angina; n (%) 361 (39.1) vs. 370 (40.2) 
Unstable angina; n 
(%) 
70 (7.6) vs. 87 (9.4) 
STEMI; n (%) 240 (26.0) vs. 225 (24.4) 
NSTEMI; n (%) 185 (20.0) vs. 192 (20.8) 
Outcomes: Efficacy ~3 year follow-up (median 1092 days) a 2 year follow-up 1 year follow-up  30 months follow-up 
MACE; n (%) nr nr nr nr 
POCE; n (%) 184 (19.9) vs. 170 (18.5); p=nr 155 (17.0) vs. 140 (15.3); 
HR = 1.09 (0.88 - 1.34); p=0.352 
107 (11.6) vs. 97 (10.6); 
HR = 1.09 (0.88 - 1.34); p=0.481 
161 (17.8) vs. 149 (16.1); 
HR = 1.08 (0.87 - 1.35); p=0.49 
TVF; n (%) 120 (12.9) vs. 103 (11.2); p=nr 100 (11.0) vs. 90 (9.9); 
HR = 1.12 (0.94 - 1.49); p=0.436 
70 (7.6) vs. 56 (6.1); 
HR = 1.26 (0.88 - 1.78); p=0.204 
105 (11.7) vs. 94 (10.7); 
HR = 1.12 (0.85 - 1.48); p=0.43 
All-cause mortality; 
n (%) 
41 (4.4) vs. 49 (5.3); p=nr 30 (3.3) vs. 37 (4.1); 
HR = 0.81 (0.50 - 1.31); p=0.385 
19 (2.1) vs. 23 (2.5); 
HR = 0.82 (0.45 - 1.51); p=0.528 
32 (3.5) vs. 43 (4.3); 
HR = 0.74 (0.47 - 1.17); p=0.19 
Cardiac mortality; n 
(%) 
22 (2.4) vs. 24 (2.6); p=nr 17 (1.9) vs. 20 (2.2); 
HR = 0.85 (0.44 - 1.62); p=0.618 
12 (1.3) vs. 11 (1.2); 
HR = 1.09 (0.48 - 2.47); p=0.841 
18 (2.0) vs. 23 (2.7); 
HR = 0.78 (0.42 - 1.44); p=0.43 
All myocardial 
infarction; n (%) 
69 (7.5) vs. 46 (5.0); p=nr 59 (6.5) vs. 37 (4.1); 
HR = 1.61 (1.07 - 2.42); p=0.022 
40 (4.4) vs. 28 (3.1); 
HR = 1.43 (0.89 - 2.32); p=0.141 
62 (7.1) vs. 41 (4.2); 
HR = 1.52 (1.02 - 2.25); p=0.04 
Angina; n (%) nr nr nr nr 
TVR; n (%)     
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 Tijssen 2018 [18] Wykrzykowska 2015 [25] 
All-TVR 89 (9.6) vs. 72 (7.8); p=nr 74 (8.2) vs. 63 (7.0); 
HR = 1.18 (0.84 - 1.65); p=0.333 
48 (5.2) vs. 38 (4.2); 
HR = 1.27 (0.83 - 1.94); p=0.278 
76 (8.7) vs. 65 (7.5); 
HR = 1.16 (0.84 - 1.62); p=0.37 
ID-TVR nr nr nr nr 
TLR; n (%)     
All-TLR 69 (7.5) vs. 51 (5.5); p=nr 59 (6.5) vs. 44 (4.8); 
HR = 1.35 (0.91 - 1.99); p=0.133 
38 (4.2) vs. 27 (3.0); 
HR = 1.41 (0.86 - 2.31); p=0.171 
60 (7.0) vs. 45 (5.2); 
HR = 1.33 (0.90 - 1.96); p=0.15 
ID-TLR nr nr nr nr 
Quality of life; 
points (SD) 
nr nr nr nr 
Daily functioning; 
points (SD) 
nr nr nr nr 
Duration of 
procedure; min (SD) 
49 (26) vs. 44 (23); p<0.001 
Outcomes: Safety ~3 year follow-up (median 1092 days) a 2 year follow-up 1 year follow-up  30 months follow-up 
Vascular-access-
site complication; n 
(%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
9 (1.0) vs. 6 (0.7); 
HR = 1.50 (0.53 - 4.20); p=0.44 
Periprocedural 
mortality; n (%) 
nr 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr nr nr 
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr nr nr 
ScT ≥1 year; n (%) 14 (1.5) vs. 3 (0.3); p=nr b 9 (1) vs. 2 (0.2); p=nr na 10 (1.1) vs. 2 (0.2); p=nr 
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 Tijssen 2018 [18] Wykrzykowska 2015 [25] 
Other SAEs; n (%) nr nr nr nr 
a Total number of events reported before data lock on 28 February 2018, no full analysis 
b up to 5 years follow-up  
 
Abbreviations: BRS=bioresorbable scaffold; CA=California; DES=drug-eluting stent; EES=everolimus-eluting stent; HR=hazard ratio; MACE=major adverse cardiac events; MI=myocardial infarction; 
na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; sAE=Serious adverse 
event; SD=standard deviation; STEMI=ST-segment elevation myocardial infarction; TLR=target lesion revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation; USA=United 
States of America 
 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS (continued) 
Author, year TROFI II 
 Felix 2018 [123]; meta-analysis Sabate 2016 [28] 
Study-ID NCT01986803 
Study design Single-blind, parallel two-group, multicentre RCT (1:1 ratio; noninferiority design for primary endpoint) 
Country 8 sites in the Netherlands, Denmark, Spain and Switzerland 
Sponsor European Cardiovascular Research Institute 
Abbott Vascular, Santa Clara, CA, USA 
Terumo Europe N.V. 
Intervention/Product Everolimus-eluting BRS/Absorb®  
Comparator/Product Everolimus-eluting permanent metallic stent/Xience Prime®  
Anti-platelet therapy It was recommended that patients received a loading dose of aspirin and a P2Y12 inhibitor pre-procedure, followed by dual antiplatelet therapy for at least 12 months. 
Main inclusion 
criteria 
• ≥18 years of age 
• ST-segment elevation of >1mm in >2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of >1 mm in 
>2 contiguous anterior leads 
• Primary PCI within 24 hours of symptom onset 
• 1 or more acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery (Maximumø 2.50-3.80 mm)  
Primary endpoint • Optical frequency domain imaging-derived healing score at 6 months 
Maximumfollow-up Angiographic: 6 months 
Clinical: 36 months 
Number of patients; 
(n) 
191 (95 vs. 96) 
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 Felix 2018 [123]; meta-analysis Sabate 2016 [28] 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 6 months: 2 (2.1) vs. 0 
Mean age of 
patients (years)  
59.1 (10.7) vs. 58.2 (9.6) 
Sex (% male) 76.8% vs. 87.5% 
Previous MI; n (%) 2 (2.1) vs. 3 (3.1) 
Stable angina; n (%) 0 vs. 0 
Unstable angina; n 
(%) 
0 vs. 0 
STEMI; n (%) 95 (100) vs. 95 (100) 
Outcomes: Efficacy 3 year follow-up  6 months follow-up  
MACE; n (%) nr nr 
POCE; n (%) nr nr 
TVF; n (%) nr nr 
All-cause mortality; 
n (%) 
2 (2.1) vs. 1 (1.0); 
OR = 2.04 (0.18 - 22.92); p=nr 
0 vs. 0; p=1.0 
Cardiac mortality; n 
(%) 
nr 0 vs. 0; p=1.0 
All myocardial 
infarction; n (%) 
3 (3.2) vs. 4 (4.2); 
OR = 0.75 (0.16 - 3.44); p=nr 
1 (1.0) vs. 0; p=nr 
Angina; n (%) nr free of angina: 87 (91.4) vs. 88 (91.7); p=0.94 
TVR; n (%)   
All-TVR nr 5 (5.3) vs. 5 (5.2); p=1.0 
ID-TVR nr nr 
TLR; n (%)   
All-TLR 3 (3.2) vs. 1 (1.0); 
OR = 3.10 (0.32 - 30.32); p=nr 
2 (2.1) vs. 1 (1.0); p=nr 
ID-TLR nr nr 
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Author, year TROFI II 
 Felix 2018 [123]; meta-analysis Sabate 2016 [28] 
Quality of life; 
points (SD) 
nr nr 
Daily functioning; 
points (SD) 
nr nr 
Duration of 
procedure; min (SD) 
nr 
Outcomes: Safety 3 year follow-up  6 months follow-up  
Vascular-access-
site complication; n 
(%) 
nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr 
Periprocedural MI; n 
(%) 
0 vs. 0; p=1.0 
Periprocedural 
mortality; n (%) 
0 vs. 0; p=1.0 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr 
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr 
ScT ≥1 year; n (%) nr na 
Other SAEs; n (%) nr nr 
Abbreviations: BRS=bioresorbable scaffold; CA=California; EES=everolimus-eluting stent; OR=odds ratio; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not 
reported; POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; SAE=serious adverse event; SD=standard deviation; STEMI=ST-segment elevation myocardial infarction; 
TLR=target lesion revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation; USA=United States of America 
 
Table A2: Characteristics of randomised controlled studies – Absorb® BVS (continued) 
Author, year Everbio II 
Hernandez 2017 [21]  Arroyo 2017 [22] Puricel 2015 [33] 
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Author, year Everbio II 
Hernandez 2017 [21]  Arroyo 2017 [22] Puricel 2015 [33] 
Study-ID NCT01711931 - 
Study design Assessor-blind, parallel three-group, single-centre RCT (1:1:1 ratio; noninferiority design for primary endpoint) Parallel two-group, single centre RCT (1:1 ratio); 
blinding unclear 
Country 1 site in the Switzerland 1 site in Spain 
Sponsor University of Fribourg, Switzerland 
Fonds Scientifique Cardiovasculaire, Fribourg, Switzerland  
Hospital Universitario Marques de Valdecilla, 
Department of Cardiology, Interventional Cardiology 
Unit, Santander, Spain 
Intervention/Product Everolimus-eluting BRS/Absorb® (BRS) Everolimus-eluting BRS/Absorb®  
Comparator/Product 1) Everolimus-eluting permanent metallic stent/Promus Element (EES) 
2) Biolimus-eluting permanent metallic stent/Biomatrix Flex (BES) 
Everolimus-eluting permanent Platinum Chromium 
stent/Synergy®  
Anti-platelet therapy Loading dose of either a minimum 600 mg clopidogrel, 180 mg of ticagrelor, or 60 mg prasugrel before or 
immediately after the procedure.  
Lifelong ≥100 mg daily aspirin and either 75 mg daily clopidogrel, or 90 mg twice-daily ticagrelor or 10 mg 
prasugrel for a minimum of 6 months. 
nr 
Main inclusion 
criteria 
• ≥18-70 years of age 
• Evidence of coronary artery disease (unstable angina, non-ST segment MI, ST-elevated MI) suitable for 
elective PCI 
• ≥18 years and ≤70 years of age 
• Indication for percutaneous revascularisation 
(excluding STEMI or NSTEMI) and reasonable 
candidates for BRS 
• Target lesions with ø ≥2.50 mm) 
Primary endpoint • Lumen Late Loss (LLL) at 9 months • Fluoroscopy time 
• Median dose-area product 
• Contrast agent volume 
• Periprocedural troponin release 
Maximumfollow-up 5 years 12 months 
Number of patients; 
(n)  
 238 (BRS vs. EEs vs. BES: 78 vs. 80 vs. 80) 200 (100 vs. 100) 
Patients lost to 
follow-up, 
timepoint; n (%) 
at 2 years:  
BRS 1 (1) vs. EES 3 (4) vs. BES 0 
nr 
 
Mean age of 
patients (years)  
BRS 65 (11) vs. EES 65 (11) vs. BES 65 (10) 60.8 (11) vs. 61.3 (12) 
Sex (% male) BRS 78.0% vs. EES 80.0% vs. BES 80.0% 79.0% vs. 76.0% 
Previous MI; n (%) BRS 11 (14) vs. EES 14 (18) vs. BES 16 (20) 18 (18) vs. 22 (22) 
Stable angina; n (%) BRS 41 (53) vs. EES 47 (59) vs. BES 27 (34) nr 
Unstable angina; n 
(%) 
BRS 6 (8) vs. EES 5 (6) vs. BES 9 (11) 55 (55) vs. 51 (51) 
Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 91 
Author, year Everbio II 
Hernandez 2017 [21]  Arroyo 2017 [22] Puricel 2015 [33] 
STEMI; n (%) BRS 9 (12) vs. EES 6 (8) vs. BES 8 (10) nr 
Outcomes: Efficacy 2 year follow-up 9 months follow-up  1 year follow-up  
MACE; n (%) a BRS vs. EES: 16 (20.5) vs. 13 (16.3); p=0.54 
BRS vs. BES: 16 (20.5) vs. 7 (8.8); p=0.04 
BRS vs. EES & BES: 16 (20.5) vs. 20 (12.5); p=0.12 
BRS vs. EES: 9 (11.5) vs. 11 (13.8); p=0.68 
BRS vs. BES: 9 (11.5) vs. 4 (5); p=0.14 
BRS vs. EES & BES: 9 (11.5) vs. 15 (9.4); p=0.60 
nr 
POCE; n (%) BRS vs. EES: 27 (34.6) vs. 30 (37.5); p=0.74 
BRS vs. BES: 27 (34.6) vs. 21 (26.3); p=0.30 
BRS vs. EES & BES 27 (34.6) vs. 51 (31.9); p=0.67 
BRS vs. EES: 21 (26.9) vs. 26 (32.5); p=0.44 
BRS vs. BES: 21 (26.9) vs. 15 (18.8); p=0.22 
BRS vs. EES & BES: 21 (26.9) vs. 41 (25.6); p=0.83 
nr 
TVF; n (%) nr nr nr 
All-cause mortality; 
n (%) 
BRS vs. EES: 2 (3) vs. 4 (5); p=0.68 
BRS vs. BES: 2 (3) vs. 1 (1); p=0.62 
BRS vs. EES & BES: 2 (3) vs. 5 (3); p=1.00 
BRS vs. EES: 1 (1) vs. 3 (4); p=0.62 
BRS vs. BES: 1 (1) vs. 0; p=0.49 
BRS vs. EES & BES: 1 (1) vs. 3 (2); p=1.0 
nr 
Cardiac mortality; n 
(%) 
BRS vs. EES: 1 (1) vs. 1 (1); p=1.00 
BRS vs. BES: 1 (1) vs. 0; p=0.49 
BRS vs. EES & BES: 1 (1) vs. 1 (1); p=0.55 
BRS vs. EES: 1 (1) vs. 0; p=0.49 
BRS vs. BES: 1 (1) vs. 0; p=0.49 
BRS vs. EES & BES: 1 (1) vs. 0; p=0.33 
1 (1) vs. 1 (1); p=1.0 
All myocardial 
infarction; n (%) 
BRS vs. EES: 4 (5) vs. 2 (3); p=0.44 
BRS vs. BES: 4 (5) vs. 0 (0); p=0.06 
BRS vs. EES & BES: 4 (4) vs. 2 (1); p=0.09  
BRS vs. EES: 1 (1) vs.  1 (1); p=1.0 
BRS vs. BES: 1 (1) vs. 0; p=0.49 
BRS vs. EES & BES: 1 (1) vs. 1 (1); p=0.55 
9 (9) vs. 5 (5); p=nr 
Angina; n (%) nr nr nr 
TVR; n (%)    
All-TVR BRS vs. EES: 18 (23) vs. 17 (21); p=0.85 
BRS vs. BES: 18 (23) vs. 11 (14); p=0.15 
BRS vs. EES & BES: 18 (23) vs. 28 (18); p=0.38 
BRS vs. EES: 11 (14.1) vs. 14 (17.5); p=0.56 
BRS vs. BES: 11 (14.1) vs. 8 (10); p=0.43 
BRS vs. EES & BES: 11 (14.1) vs. 22 (13.8); p=0.94 
7 (7) vs. 6 (6); p=nr b 
ID-TVR nr nr nr 
TLR; n (%)    
All-TLR BRS vs. EES: 14 (18) vs. 12 (15); p=0.67 
BRS vs. BES: 14 (18) vs. 7 (9); p=0.10 
BRS vs. EES & BES: 14 (18) vs. 19 (12); p=0.23 
BRS vs. EES: 8 (10) vs. 11 (14); p=0.50 
BRS vs. BES: 8 (10) vs. 4 (5); p=0.21 
BRS vs. EES & BES: 8 (10) vs. 15 (9); p=0.83 
5 (5) vs. 3 (3); p=0.7 
ID-TLR nr nr nr 
Quality of life; 
points (SD) 
nr nr nr 
Daily functioning; 
points (SD) 
nr nr nr 
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Author, year Everbio II 
Hernandez 2017 [21]  Arroyo 2017 [22] Puricel 2015 [33] 
Duration of 
procedure; min (SD) 
nr nr 
Outcomes: Safety 2 year follow-up 9 months year follow-up 1 year follow-up  
Vascular-access-
site complication; n 
(%) 
nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr 
Periprocedural MI; n 
(%) 
nr 6 (6) vs. 3 (3); p=0.49 c 
Periprocedural 
mortality; n (%) 
nr nr 
Bleeding as a result 
of antiplatelet 
therapy; n (%) 
nr nr  
Mortality as a result 
of bleeding and/or 
stroke; n (%) 
nr nr  
ScT ≥1 year; n (%) BRS vs. EES vs. BES: 0 vs. 0 vs. 0 na na 
Other SAEs; n (%) nr nr nr 
a Device-oriented MACE (composite of cardiac death, myocardial infarction, and target-lesion revascularisation)  
b TVR = TLR + non-target lesion TVR 
c All MI = peri-procedural MI + 12 months follow up MI 
 
Abbreviations: BES=biolimus-eluting stent; BRS=bioresorbable scaffold; EES=everolimus-eluting stent; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not 
reported; POCE=patient-oriented composite endpoint; RCT=randomised controlled trial; SAE=serious adverse event; SD=standard deviation; STEMI=ST-segment elevation myocardial infarction; 
TLR=target lesion revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation 
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Table A3: Characteristics of other relevant studies – DESolve®, Fantom® 
Author, year Gunes 2017 [61] Abizaid 2016 [76] (DESolve Nx) Nef 2018 [37] (DESolve PMCF) Abizaid 2017 [52] (Fantom II) 
Study-ID - NCT02086045 NCT02013349 NCT02539966 
Study design Single center, cross sectional study Prospective, multicenter, single-arm study Prospective, multicenter, single-
arm registry 
Prospective multi-centre, single arm 
study 
Country Turkey 13 sites in Belgium, Brazil, Denmark, 
Germany, New Zealand and Poland 
10 sites in Germany and Italy 28 sites in Australia, Belgium, Brazil, 
Denmark, France, Germany, 
Netherlands, Poland 
Sponsor Elixir Medical Corporation Elixir Medical Corporation Elixir Medical Corporation REVA Medical, Inc. 
Intervention/Product Novolimus-eluting BRS/DESolve® Novolimus-eluting BRS/DESolve® Novolimus-eluting BRS/DESolve® Sirolimus-Eluting Coronary BRS/Fantom® 
Comparator/Product none none none none 
Anti-platelet therapy ASA + P2Y12 inhibitor n=63 (55.8%); ASA + 
Clopidogrel n= 50 (44.2%) 
Aspirin-native patients were treated with 
upstream clopidogrel (300 mg) followed with 
daily oral aspirin of 100 mg. Patients free 
from chronic antiplatelet therapy were treated 
with clopidogrel (600 mg) or prasugrel (60 
mg) or ticagrelor (180 mg) loading doses 
before PCI followed with daily doses of 
clopidogrel (75 mg) or prasugrel (10 mg) or 
ticagrelor (180 mg) for 12 months. All of the 
patients were anticoagulated with 
unfractionated heparin during the procedure. 
Loading dose of aspirin (≥300 mg) and 
clopidogrel (≥300 mg) if not on long-term 
use. Post-procedure: aspirin (≥75 mg) 
indeﬁnitely and clopidogrel (75 mg daily) 
for a minimum of 12 months.  
 
 
ASA: n=101 (99%); 
Clopidogrel: n=68 (66,7%); 
Ticagrelor: n=21 (20.6%) 
Prasugrel: n=12 (11.8%) 
Ticlopidine: n=1 (1.0%) 
Dual antiplatelet therapy with aspirin plus 
clopidogrel, ticagrelor, or prasugrel for 12 
months 
Main inclusion criteria • Reference vessel diameter ≥2.5 mm, 
stentable lesions 
• Stable coronary artery disease, or 
unstable angina or non-ST segment 
elevation myocardial infarction 
• >18 years of age; 
• Symptoms of stable or unstable angina 
pectoris; 
• Presence of a single, de novo coronary 
lesion (ø 2.75-3.50 mm; 
MaximumLength 14 mm); 
• Stenosis between 50% and 90% 
• >18 years of age; 
• Evidence of myocardial 
ischemia (e.g., stable or 
unstable angina, silent 
ischemia, positive functional 
study or electrocardiogram 
changes consistent with 
ischemia); 
• De novo coronary lesions (ø 
2.75-3.50; Maximumlength 24 
mm); 
• Stenosis between 50% and 
90% 
• >18 years of age; 
• Patients with coronary artery disease 
and evidence of myocardial ischemia; 
• Presence of a single, de novo 
coronary lesion (ø 2.5-3.50; 
MaximumLength 20 mm); 
• Stenosis between 50% and 100% 
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Author, year Gunes 2017 [61] Abizaid 2016 [76] (DESolve Nx) Nef 2018 [37] (DESolve PMCF) Abizaid 2017 [52] (Fantom II) 
Primary endpoint nr MACE (cardiac death, target vessel MI or 
clinically indicated TLR) at 6 months and 
annually up to 5 years 
Late lumen loss (LLL) at 6 months 
MACE (cardiac death, target 
vessel MI or clinically indicated 
TLR) at 1, 6, 12 mo, 2, 3, 4, 5 yrs 
MACE (cardiac death, MI or TLR) at 6 
months 
Late Lumen Loss (LLL) at 6 months 
Maximumfollow-up 12 months 5 years 5 years 6 months 
Number of patients; (n) 117 126 102 240 (all)  
117 (Cohort A) 
Patients lost to follow-
up, timepoint; n (%) 
0 at 12 months:  
4 (3.2) 
at 12 months:  
1 (1) 
at 6 months:  
9 (7.7) 
Mean age of patients 
(years)  
57.6 (10.6) 62 (10) 62.0 (12.9) 62.7 (9.7) 
Sex (% male) 85.5% 68% 77.5% 70.1% 
Previous MI; n (%) 20 (17.1) 56 (44) 35 (34.3) 31 (26.5) 
Stable angina; n (%) 101 (86.3) 95 (75) nr nr 
Unstable angina; n (%) 16 (13.7) 16 (13) nr nr 
STEMI; n (%) nr nr nr nr 
NSTEMI; n (%) nr nr nr nr 
ACS; n (%) nr nr nr nr 
Outcomes: Safety 12 months follow-up 24 months follow-up 12 months follow-up 6 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
1 (0.9) 0 0 1 (0.85) 
Periprocedural 
mortality; n (%) 
0 0 0 0 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr 
nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
0 nr 0 
0 
ScT ≥1 year; n (%) na 0 na na 
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Author, year Gunes 2017 [61] Abizaid 2016 [76] (DESolve Nx) Nef 2018 [37] (DESolve PMCF) Abizaid 2017 [52] (Fantom II) 
Other SAEs; n (%) MACE: 1 (0.9) MACE: 9 (7.4) MACE: 3 (3.0) MACE: 3 (2.6) 
Abbreviations: ACS=acute coronary syndrome; ASA=acetylsalicylic acid; BRS=bioresorbable scaffold; LLL=late lumen loss; MACE=major adverse cardiac events; MI=myocardial infarction; na=not 
applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; TLR=target lesion 
revascularisation 
 
Table A4: Characteristics of other relevant studies – Magmaris (DREAMS 2G), Absorb® BVS 
Author, year 
Haude 2016 [58] 
Haude 2016 [82] 
Haude 2018 [35] 
Haude 2017 [56] (Biosolve II) 
7 Haude 2018 [35] 
Haude 2017 [56] (Biosolve III) Fam 2016 [72] Maes 2018 [38] 
Study-ID NCT01960504 NCT02716220 - - 
Study design Prospective multi-centre, single arm study Prospective multi-centre, single arm study Single center, cohort study Single center, cohort study 
Country 13 sites in Belgium, Brazil, Denmark, 
Germany, Singapore, Spain, Switzerland, 
and the Netherlands 
8 sites in Europe, South America, and 
Asia 
The Netherlands Canada 
Sponsor Biotronik AG, Switzerland. Biotronik AG, Switzerland. Abbott Vascular Internal funding 
Intervention/Product Sirolimus-eluting absorbable magnesium 
scaffold system/DREAMS 2G 
Sirolimus-eluting absorbable magnesium 
scaffold system/DREAMS 2G 
Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS /Absorb® 
Comparator/Product none none none none 
Anti-platelet therapy Dual antiplatelet treatment was 
recommended for a minimum of 6 months 
after the procedure 
Dual antiplatelet treatment was 
recommended for a minimum of 6 months 
after the procedure 
Dual antiplatelet therapy for 12 
months 
nr 
Main inclusion criteria • >18 years and <80 years of age; 
• Stable or unstable angina or documented 
silent ischaemia; 
• Maximum of two de-novo coronary lesion 
in two separate coronary arteries (ø 2.2-
3.7 mm; MaximumLength 21 mm); 
• Stenosis between 50% and 99% 
• >18 years and <80 years of age; 
• Stable or unstable angina or 
documented silent ischaemia; 
• Maximum of two de-novo coronary 
lesion in two separate coronary 
arteries (ø 2.7-3.8 mm; 
MaximumLength 21 mm); 
• Stenosis between 50% and 99% 
• >18 years of age 
• STEMI 
• Patients undergoing percutaneous 
coronary intervention (PCI) 
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Author, year 
Haude 2016 [58] 
Haude 2016 [82] 
Haude 2018 [35] 
Haude 2017 [56] (Biosolve II) 
7 Haude 2018 [35] 
Haude 2017 [56] (Biosolve III) Fam 2016 [72] Maes 2018 [38] 
Primary endpoint In segment LLL at 6 months Procedure success, defined as final 
diameter stenosis of <30% by quantitative 
coronary angiography without occurrence 
of in-hospital death, Q-wave or non-Q-
wave myocardial infarction or repeat 
target lesion revascularisation 
nr Procedural success 
Maximumfollow-up 36 months 36 months 18 months 12 months 
Number of patients; (n) 123 61 151 118 
Patients lost to follow-
up, timepoint; n (%) 
at 24 months:  
3 (2.4) 
0 6 (3.9) 0 
Mean age of patients 
(years)  
65.2 (10.3) 66.3 (11.8) 56.3 (10.22) 59 (11) 
Sex (% male) 63.4% 63.9% 72.2% 83% 
Previous MI; n (%) 29 (24) 14 (23) nr 20 (17) 
Stable angina; n (%) 88 (72) nr na 43 (36) 
Unstable angina; n (%) 17 (14) nr na 46 (39) 
STEMI; n (%)   151 (100) 11 (9.3) 
NSTEMI; n (%)   na 18 (15) 
ACS; n (%) nr nr na nr 
Outcomes: Safety 24 months follow-up 12 months follow-up 18 months follow-up 12 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
0 0 nr nr 
Periprocedural 
mortality; n (%) 
0 0 nr 0 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
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Author, year 
Haude 2016 [58] 
Haude 2016 [82] 
Haude 2018 [35] 
Haude 2017 [56] (Biosolve II) 
7 Haude 2018 [35] 
Haude 2017 [56] (Biosolve III) Fam 2016 [72] Maes 2018 [38] 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
0 0 nr nr 
ScT ≥1 year; n (%) 0 na 2 (1.5) na 
Other SAEs; n (%) All-cause mortality: 4 (3.3) All-cause mortality: 2 (3.3) nr MACE: 12 (10) 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; LLL=late lumen loss; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; 
NSTEMI=non-ST-segment elevation myocardial infarction; PCI=percutaneous coronary intervention; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS 
Author, year Costopoulos 2014 [91] Panolas 2016 [69] Jamshidi 2016 [74] Grimfjard 2017 [50] (SCAAR)  
Study-ID - - - - 
Study design Single center cohort study Single center cohort study Observational single-centre single 
arm study 
Prospective multi-centre registry 
Country Italy Italy Switzerland Up to 74 sites in Sweden 
Sponsor nr nr nr nr 
Intervention/Product Everolimus-eluting BRS /Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none none 
Anti-platelet therapy Dual antiplatelet therapy (aspirin + 
clopidogrel) for 12 months (complex lesions 
aspirin + prasugrel or ticagrelor first 3 
months) 
Dual antiplatelet therapy (aspirin + 
clopidogrel or ticagrelor or prasugrel) for 
12 months 
Patients with stable CAD: aspirin 
and clopidogrel; 
Patients with ACS: ticagrelor or 
prasugrel in addition to aspirin.  
dual antiplatelet therapy was 
recommended for 12 months. 
nr 
Main inclusion criteria • Patients undergoing percutaneous 
coronary intervention 
• Stable angina • Symptomatic stable CAD or 
acute coronary syndrome; 
• Target lesion (ø 2.5->4,0 mm) 
• All patients treated with the Absorb® or 
any of the twelve most commonly 
used modern DES 
Primary endpoint Clinical efficacy Major acute cardiovascular events 
(MACE) 
Composite endpoint of TLR, ScT, 
MI, or death at 6 or 12 months 
Incidence of definite ScT 
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Author, year Costopoulos 2014 [91] Panolas 2016 [69] Jamshidi 2016 [74] Grimfjard 2017 [50] (SCAAR)  
Maximumfollow-up 6 months 12 months 12 months 24 months 
Number of patients; (n) 92 70 65 460 
Patients lost to follow-
up, timepoint; n (%) 
0 0 16 (25) 0 
Mean age of patients 
(years)  
64.2 (11.8) 64.5 (10.3) 66.0 (10.7) 59.3 (nr) 
Sex (% male) 89.1% 91.4% 86% 79.3% 
Previous MI; n (%) 26 (28.3) 17 (28.3) 27 (42) 75 (16.3) 
Stable angina; n (%) 82 (89.1) 70 (100) 47 (72) 115 (25) 
Unstable angina; n (%) nr na 6 (9) 52 (11.3) 
STEMI; n (%) nr na 1 (2) 98 (21.3) 
NSTEMI; n (%) nr na 11 (17) 182 (39.6) 
ACS; n (%) 10 (10.9) na nr nr 
Outcomes: Safety 6 months follow-up 12 months follow-up 12 months follow-up 24 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
8 (8.7) 5 (7.1) 0 nr 
Periprocedural 
mortality; n (%) 
0 0 0 nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr nr 0 nr 
ScT ≥1 year; n (%) na na na 3 (0.7) 
Other SAEs; n (%) MACE: 3 (3.3) nr All-cause mortality: 2/49 (4.1) All-cause mortality: 5 (1.0) at 12 months 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable stent; CAD=coronary artery disease; DES=drug-eluting stent; MACE=major adverse cardiac events; MI=myocardial infarction; 
na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; PCI=percutaneous coronary intervention; SAE=serious adverse event; ScT=scaffold thrombosis; 
STEMI=ST-segment elevation myocardial infarction; TLR=target lesion revascularisation 
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Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Teeuwen 2015 [104] Felix 2016 [68] (BVS Expand) Kraak 2015 [90] Remkes 2017 [47] 
Study-ID - - - - 
Study design Prospective single centre registry Investigator-initiated, prospective, single-
center, single-arm study  
Prospective single centre registry Prospective single centre registry 
Country The Netherlands The Netherlands The Netherlands The Netherlands 
Sponsor nr Abbott Vascular Abbott Vascular nr 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none none 
Anti-platelet therapy Stable angina: dual anti-platelet therapy prior 
to treatment with aspirin 100 mg and 75 mg 
clopidogrel daily 
ACS: prasugrel 5/10 mg daily or 90 mg 
ticagrelor twice daily  
DAPT was advised for at least 12 months. 
Stable angina: 300 mg aspirin and 600 
mg clopidogrel 
acute coronary syndrome: 300 mg aspirin 
and 60 mg prasugrel or 180 mg ticagrelor. 
Patients received dual antiplatelet 
therapy (DAPT) for at least 12 
months. 
Dual antiplatelet therapy for at least 12 
months 
Main inclusion criteria • All patients with stable angina, acute 
coronary syndromes, high-risk lesions like 
ST-segment elevated myocardial 
infarction (STEMI) or BMS and DES in-
stent restenosis 
• Target lesion (ø 2.5->3,5mm) 
• Patients with NSTEMI, stable or 
unstable angina or silent ischemia; 
• De-novo lesion (ø 2.0-3,8mm) 
• Patients with a wide range of 
indications, ranging from stable 
angina to acute coronary 
syndrome, and with a diverse 
range of lesion characteristics  
• All patients who underwent PCI with at 
least one E-BRS implantation 
Primary endpoint MACE  MACE (cardiac death, MI or TLR) nr TLF (cardiac death, non-fatal target 
vessel MI, clinically-indicated TLR) 
Maximumfollow-up 24 months 18 months 6 months mean 19,8 (10) months 
Number of patients; (n) 108 249 135 105 
Patients lost to follow-
up, timepoint; n (%) 
3 (2.7) 0 3 (3) 0 
Mean age of patients 
(years)  
59.4 (12.0) 61.3 (10.2) 59 (11) 60 (11) 
Sex (% male) 69.4% 73.5% 73.0% 71.4% 
Previous MI; n (%) nr 17.7 34 (25) 12 (11.4) 
Stable angina; n (%) 54 (50) 40.6 63 (47) 62 (59.1) 
Unstable angina; n (%) 10 (9.3) 16.1 13 (10) 13 (12.3) 
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Author, year Teeuwen 2015 [104] Felix 2016 [68] (BVS Expand) Kraak 2015 [90] Remkes 2017 [47] 
STEMI; n (%) 20 (18.5) 0 17 (13) 9 (8.6) 
NSTEMI; n (%) 24 (22.2) 43.0 36 (27) 21 (20.0) 
ACS; n (%) - - - - 
Outcomes: Safety 24 months follow-up 18 months follow-up 6 months follow-up 19.8 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
1 (0.9) 2 (0.8) 0 2 (1.9) 
Periprocedural 
mortality; n (%) 
0 nr 0 nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
0 0 0 nr 
ScT ≥1 year; n (%) 0 1 (0.4) na 0 
Other SAEs; n (%) MACE: 11 (10.9) 
All-cause mortality: 3 (2.7) 
MACE: 6.8 
All-cause mortality: 4 (1.8) 
Cardiac morality: 1 (0.8) All-cause mortality: 2 (1.9) 
Cardiac mortality: 0 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable stent; CAD=coronary artery disease; DES=drug-eluting stent; MACE=major adverse cardiac events; MI=myocardial infarction; 
na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; PCI=percutaneous coronary intervention; SAE=serious adverse event; ScT=scaffold thrombosis; 
STEMI=ST-segment elevation myocardial infarction; TLR=target lesion revascularisation 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Alfonso 2017 [53] (RIBS VI) 
Widimsky 2015 [83] 
Tousek 2016 [73] (Prague 19) Iwanczyk 2017 [39] Gil 2016 [79] 
Study-ID - -   
Study design Investigator-initiated, prospective, multi-
center, single-arm study  
Prospective multicenter open-label single 
arm study 
Prospective, multi-centre registry Prospective multicenter open-label single 
arm study 
Country 19 sites in Spain 2 sites in Poland 2 sites in Poland 5 sites in Poland 
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Author, year Alfonso 2017 [53] (RIBS VI) 
Widimsky 2015 [83] 
Tousek 2016 [73] (Prague 19) Iwanczyk 2017 [39] Gil 2016 [79] 
Sponsor Sociedad Española de Cardiología; 
Abott Vascular 
Charles University Research program P 
35 and UNCE 20410 
nr nr 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none none 
Anti-platelet therapy Dual antiplatelet therapy was recommended 
for 1 year 
Dual antiplatelet therapy for 12 months 
with prasugrel or ticagrelor 
Daily dose of 75 mg ASS and 75 
mg clopidogrel or prasugrel 60 mg 
p.o. Continued with 10 mg daily 
dose (n = 3; 1.8%) or ticagrelor 
180 mg loading dose and 
continued with 2 × 90 mg daily 
dose (n = 121; 73.3%). 
Duration of dual antiplatelet 
therapy was recommended for a 
minimum of 12 months.  
All patients received acetylsalicylic acid 
(75 mg/24 h) and clopidogrel (75 mg/24 
h) at least 72 h before PCI. This dual 
antiplatelet therapy was planned for one 
year 
Main inclusion criteria • Patients with angina or objective evidence 
of ischemia; 
• In-stent restenosis (>50% diameter 
stenosis on visual assessment) 
• Target lesion (ø >2.5 mm; Maximumlength 
<32 mm) 
• Consecutive patients with STEMI 
• STEMI duration <24 hours 
• Patients with ACS; 
• At least 1 coronary artery 
stenosis (ø >2.3-<3.7 mm) 
• Age ≥18 years and ≤65 years; 
• Stable coronary artery disease; 
• De novo coronary lesions 
Primary endpoint In-segment minimal lumen diameter at 6 and 
9 months 
Combination of death, myocardial 
infarction and TVR 
nr MACE (cardiac death, MI, and clinically-
driven TLR) 
Maximumfollow-up 12 months mean 730 days (± 275) 12.4 months 12 months 
Number of patients; (n) 141 114 165 139 
Patients lost to follow-
up, timepoint; n (%) 
0 1 (0.9) 14 (8.5) 0 
Mean age of patients 
(years)  
65 (10) 60 (11) 59.9 (10.6) 59.5 (5.5) 
Sex (% male) 89% 65% 75.1% 65.5% 
Previous MI; n (%) 88 (62) 4/70 a 44 (26.7) 30 (21.6) 
Stable angina; n (%) 72 (51) 0 0 139 (100) 
Unstable angina; n (%) 69 (49) 0 95 (57.6) 0 
STEMI; n (%) 0 114 (100) 26 (15.7) 0 
NSTEMI; n (%) 0 0 45 (27.3) 0 
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Author, year Alfonso 2017 [53] (RIBS VI) 
Widimsky 2015 [83] 
Tousek 2016 [73] (Prague 19) Iwanczyk 2017 [39] Gil 2016 [79] 
ACS; n (%) - 114 (100) 165 (100) 0 
Outcomes: Safety 12 months follow-up 24 months follow-up 12 months follow-up 12 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
nr 0 0 1 (0.7) 
Periprocedural 
mortality; n (%) 
0 0 0 0 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
0 1 (0.9) nr 0 
ScT ≥1 year; n (%) na 0 (after mean 730 days follow up) na na 
Other SAEs; n (%) All-cause mortality: 0 
Cardiac mortality: 0 
MACE: 20 (14.2) 
All-cause mortality: 5 (4.4) (after mean 730 
days follow up) 
All-cause mortality: 4 (2.42) MACE: 2 (1.4) 
All-cause mortality: 1 (0.7) 
a Data reported in Widimsky 2015 [83] only for 70 patients 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-
segment elevation myocardial infarction; PCI=percutaneous coronary intervention; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; TLR=target lesion revascularisation; 
TVR=target vessel revascularisation; 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Dudek 2014 [94] Rzeszutko 2016 [48] (ORPKI Registry) Briede 2018 [41] 
Wöhrle 2018 [42] 
Nef 2017 [72] (GABI-R) 
Study-ID - - - NCT02066623 
Study design Prospective multicenter single arm registry Prospective multicenter single arm 
registry 
Prospective single center single 
arm registry 
Prospective, observational, multi-centre 
study 
Country 12 sites in Poland 151 sites in Poland Latvia 92 sites in Germany and Austria 
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Author, year Dudek 2014 [94] Rzeszutko 2016 [48] (ORPKI Registry) Briede 2018 [41] 
Wöhrle 2018 [42] 
Nef 2017 [72] (GABI-R) 
Sponsor nr No funding National Research Program 
“Biomedicine for Public Health” 
(BIO-MEDICINE); 
grant from the corporation 
“Sistemu Inovacijas” 
Abbott Vascular, Santa Clara, CA, USA 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none none 
Anti-platelet therapy Dual antiplatelet therapy for 12 months 
according to the current ESC guidelines  
nr Dual antiplatelet therapy was 
prescribed at least for 12 months 
for all patients. 
Dual antiplatelet therapy was prescribed 
for at least one year in all patients 
Main inclusion criteria • Consecutive patients with ACS (STEMI, 
NSTEMI or unstable angina) 
• Patients with stable angina or ACS; 
• De novo lesion  
• Patients with stable angina or 
ACS; 
• Target lesion (ø 2.5-4.0 mm) 
• >18 years of age; 
• Absorb® BVS implant scheduled 
Primary endpoint MACE (cardiac death, MI, and clinically-
driven TLR) at 12 months 
nr MACE (death, MI, cerebral 
infarction, CABG major bleeding, 
ScT, in-scaffold restenosis, TLR, 
TVR)  
MACE (death, MI, clinically motivated 
TVR) 
MACCE (MACE + stroke) 
Stent thrombosis 
Maximumfollow-up 12 months Periprocedural 24 months 5 years 
Number of patients; (n) 100 2258 187 3231 
Patients lost to follow-
up, timepoint; n (%) 
2 (2) 0 7 (3.8) 86 (2.6) 
Mean age of patients 
(years)  
All: 62.7 (nr) a 59.97 (10.6) 56.74 (11.85) 60.9 (11.0) 
Sex (% male) 73% 70.7% 78.6% 76.8% 
Previous MI; n (%) 39 (39) 645 (28.6) 65 (34.8) 713 (22.4) 
Stable angina; n (%) 0 1169 (52) 148 (79.1) 1075 (33.3) 
Unstable angina; n (%) 46 (46) 562 (25) 11 (5.9) 379 (11.7) 
STEMI; n (%) 16 (16) 256 (11.4) 18 (9.6) 560 (17.3) 
NSTEMI; n (%) 38 (38) 260 (11.6) 6 (3.2) 724 (22.4) 
ACS; n (%) 100 (100) - - 1663 (51.5) 
Outcomes: Safety 12 months follow-up Periprocedural 24 months follow-up 6 months follow-up 
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Author, year Dudek 2014 [94] Rzeszutko 2016 [48] (ORPKI Registry) Briede 2018 [41] 
Wöhrle 2018 [42] 
Nef 2017 [72] (GABI-R) 
Vascular-access-site 
complication; n (%) 
nr 2 (0.09) nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
2 (2) 0 0 8 (0.2) 
Periprocedural 
mortality; n (%) 
0 1 (0.04) 1 (0.5) nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr 2 (1.1) nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
0 nr nr nr 
ScT ≥1 year; n (%) na na 0 na 
Other SAEs; n (%) MACE: 4 (4) nr All-cause mortality: 7 (3.9) All-cause mortality: 40 (1.2) 
MACE: 131 (4.1) 
a Mean age: 54.3 years (STEMI), 68.4 years (NSTEMI), 60.9 years (unstable angina) 
 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; CABG=coronary artery bypass graft surgery; ESC=European Society of Cardiology; MACE=major adverse cardiac events; 
MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; SAE=serious adverse event; ScT=scaffold thrombosis; STEMI=ST-segment 
elevation myocardial infarction; TLR=target lesion revascularisation; TVR=target vessel revascularisation 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Cortese 2017a [55] Cortese 2017b [63] 
Anadol 2017 [40]  
Gori 2015 [85]  
Anadol 2018 [99] (MICAT Absorb 
Substudy) 
Wiebe 2017 [203] 
Hoppmann 2016 [475] 
Wiebe 2016 [408] (ISAR-Absorb) 
Study-ID - - NCT02180178 - 
Study design Prospective single-centre registry Prospective multicentre single arm study Prospective single-centre registry Prospective multicentre single arm study 
Country Italy 6 or 7 sites in Europe Germany 2 sites in Germany 
Sponsor nr nr Johannes Gutenberg University 
Mainz 
nr 
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Author, year Cortese 2017a [55] Cortese 2017b [63] 
Anadol 2017 [40]  
Gori 2015 [85]  
Anadol 2018 [99] (MICAT Absorb 
Substudy) 
Wiebe 2017 [203] 
Hoppmann 2016 [475] 
Wiebe 2016 [408] (ISAR-Absorb) 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none none 
Anti-platelet therapy During the procedure, patients received 
anticoagulation according to standard 
hospital practice. Glycoprotein IIb/IIIa 
inhibitors were used at the physician's 
discretion. All patients received dual 
antiplatelet therapy for at least 12 months 
after intervention. 
All patients were treated according to 
international guidelines but following local 
practice. (Specifically, all patients were 
pretreated with aspirin (chronically or with 
endovenous bolus of 250–500 mg) plus 
clopidogrel or ticagrelor or prasugrel. 
During the procedure the anticoagulant of 
choice was unfractionated heparin given 
with a bolus of 70–100 IU/kg at the 
beginning of the procedure, with 
additional boluses given according to the 
activated clotting time.) 
Dual antiplatelet therapy for 12 
months (aspirin plus clopidogrel for 
stable disease; aspirin plus 
prasugrel/ticagrelor for acute 
coronary syndromes) was 
recommended. 
All patients received a loading dose of 
aspirin and an adenosine diphosphate 
receptor antagonist according to the 
clinical presentation and guidelines, 
followed by aspirin indeﬁnitely and 12 
months of the selected adenosine 
diphosphate receptor antagonist 
Main inclusion criteria • Consecutive patients with all types of 
clinical settings and coronary lesions, 
including ACS, in-stent restenosis, small 
vessels, long lesions, and calcified 
vessels 
• Consecutive patients with any clinical 
indication including stable angina or 
ACS treated with BVS for de novo 
lesions 
• Consecutive patients treated 
with one or more Abott BVS®  
• Consecutive patients with de novo 
lesions undergoing single-vessel or 
multivessel PCI with Absorb® BVS 
• Stenosis of at least 50% diameter 
stenosis 
• Angina symptoms and/or pathological 
functional testing 
Primary endpoint LLL at 1 year 
ID-TLR at 2 years 
DOCE (cardiac death, MI or TLR) MACE (death, cardiac death, MI or 
TLR) 
MACE (death, MI or TLR) 
Maximumfollow-up 24 months 7 months (± 2) 3 years 24 months 
Number of patients; (n) 122 67 657 419 
Patients lost to follow-
up, timepoint; n (%) 
nr 0 nr 0 
Mean age of patients 
(years)  
61.72 (10.38) 58 (11) 63 (12) 66.6 (10.9) 
Sex (% male) 85.2% nr 79.0% 76.6% 
Previous MI; n (%) nr 10 (15) nr 109 (26.0) 
Stable angina; n (%) 86 (70.5) 30 (44.8) 219 (33.3) 256 (61.1) 
Unstable angina; n (%) nr 10 (14.9) 78 (11.9) 48 (11.5) 
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Author, year Cortese 2017a [55] Cortese 2017b [63] 
Anadol 2017 [40]  
Gori 2015 [85]  
Anadol 2018 [99] (MICAT Absorb 
Substudy) 
Wiebe 2017 [203] 
Hoppmann 2016 [475] 
Wiebe 2016 [408] (ISAR-Absorb) 
STEMI; n (%) 13 (10) 9 (13.5) 166 (25.3) 35 (8.4) 
NSTEMI; n (%) nr 18 (26.9) 191 (29.1) 80 (19.1) 
ACS; n (%) 36 (29.5) - - - 
Outcomes: Safety 24 months follow-up 7 months follow-up 3 years follow-up 24 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
nr 6 (8.9) nr 4 (0.95) 
Periprocedural 
mortality; n (%) 
0 0 nr nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr 0 nr nr 
ScT ≥1 year; n (%) 1 na 9 (1.7) 6 (1.4) 
Other SAEs; n (%) All-cause mortality: 1 (0.8) 
MACE: 23 (18.8) 
All-cause mortality: 0 
DOCE: 3 (4.5) 
All-cause mortality: 43 (6.5) All-cause mortality: 26 (6.3) 
MACE: 91 (21.6) 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; DOCE=device-oriented composite endpoint; ID-TLR=ischaemic driven target lesion revascularisation; LLL=late lumen loss; 
MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; PCI=percutaneous coronary intervention; 
SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; TLR=target lesion revascularisation 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year 
Costa 2018 [105] 
Costa 2018 [44] 
Campos 2018 [46] 
Costa 2016 [66] 
Costa 2015 [86] 
Abizaid 2015 [92] (Absorb EXTEND) Wöhrle 2015 [88] (ASSURE) 
Tanaka 2017 [65] Kawamoto 2015 [103] 
Study-ID NCT01023789 NCT01583608 - 
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Author, year 
Costa 2018 [105] 
Costa 2018 [44] 
Campos 2018 [46] 
Costa 2016 [66] 
Costa 2015 [86] 
Abizaid 2015 [92] (Absorb EXTEND) Wöhrle 2015 [88] (ASSURE) 
Tanaka 2017 [65] Kawamoto 2015 [103] 
Study design  Prospective, single-arm, open-label clinical 
trial 
Prospective multi-centre, observational 
registry 
Uncontrolled cohort study 
Country 56 international sites outside USA 6 sites in Germany Italy 
Sponsor Abbott Vascular, Santa Clara, CA, USA Medical Care Center Prof. Mathey, Prof. 
Schofer, Ltd. 
Abbott Vascular, Germany GmbH. 
nr 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none 
Anti-platelet therapy All patients were to be pretreated with a 
loading dose of 300 mg of clopidogrel and 
300 mg of aspirin, followed by 75 mg of 
clopidogrel daily for a minimum of 6 months 
and 75 mg of aspirin daily indefinitely. 
All patients were maintained on 75 mg 
clopidogrel daily and 100 mg aspirin for a 
minimum of six months. Aspirin 100 mg 
daily was continued thereafter. 
Dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor or prasugrel) for 12 
months 
Main inclusion criteria • ≥18 years of age; 
• Up to two de novo lesions, each located in 
a separate native epicardial vessel (ø 2.0-
3.3 mm, Maximumlength = 28 mm) a 
• Stenosis: ≥50% and <100% 
• Consecutive patients aged between 18 
and 75 years with ischaemic heart 
disease  
• One or more de novo native coronary 
artery lesions (ø 2.0-3.8 mm) 
• Stenosis: ≥50% 
• Patients undergoing percutaneous coronary intervention with bifurcation 
lesions 
Primary endpoint MACE (cardiac death, MI or ID-TLR) at 7, 30, 
180 and 360 days  
MACE (cardiac death, MI or ID-TLR) at 
24 months 
Target lesion failure MACE 
Maximumfollow-up 3 years 24 months 24 months 12 months 
Number of patients; (n) 812 183 264 119 
Patients lost to follow-
up, timepoint; n (%) 
14 (1.7) 3 (1.6) 0 0 
Mean age of patients 
(years)  
61.1 (10.7) 63.5 (9.3) 63.5 (10.5) 62.5 (11.1) 
Sex (% male) 74.3% 79.80% 236 (89.4) 106 (89.1) 
Previous MI; n (%) 230 (29) 48 (27.1) 72 (27.3) 31 (26.1) 
Stable angina; n (%) 461 (56.8) 65 (35.5) 228 (86.4) 105 (88.2) 
Unstable angina; n (%) 215 (26.5) 39 (21.3) 31 (11.7) 12 (10.1) 
STEMI; n (%) nr nr STEMI or NSTEMI: 5 (1.9%) 2 (1.7) 
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Author, year 
Costa 2018 [105] 
Costa 2018 [44] 
Campos 2018 [46] 
Costa 2016 [66] 
Costa 2015 [86] 
Abizaid 2015 [92] (Absorb EXTEND) Wöhrle 2015 [88] (ASSURE) 
Tanaka 2017 [65] Kawamoto 2015 [103] 
NSTEMI; n (%) 136 (16.7%) nr nr 
ACS; n (%) - nr 36 (13.6) 14 (11.8) 
Outcomes: Safety 3 years follow-up 12 months follow-up 24 months follow-up 12 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
22 (2.7) 0 nr 15 (12.6) 
Periprocedural 
mortality; n (%) 
0 0 nr nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr 8 (4.4) nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr 1 (0.5) nr nr 
ScT ≥1 year; n (%) 10 (1.2) na 0 na 
Other SAEs; n (%) All-cause mortality: 7 (0.86) 
MACE: 74 (9.2) 
All SAE: 295 (36.3) 
Stroke/TIA: 3 (1.7) 
MACE: 9 (5.0) 
All-cause mortality: 7 (3.5) All-cause mortality: 1 (1.4) 
a Costa 2018 [105]: Inclusion criteria = reference vessel diameter (RVD) ≥2.0 mm and ≤3.8 mm 
 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; CA=California; ID-TLR=ischaemic driven target lesion revascularisation; MACE=major adverse cardiac events; 
MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; RVD= reference vessel diameter; SAE=serious adverse event; ScT=scaffold 
thrombosis; STEMI=ST-segment elevation myocardial infarction; TIA=transient ischemic attack; USA=United States of America 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Moscarella 2015 [100] Moscarella 2016 [75] Maggio 2016 [77] Regazzoli 2018 [36] 
Study-ID - - - 
Study design Uncontrolled cohort study Prospective, single center registry Prospective multicenter registry 
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Author, year Moscarella 2015 [100] Moscarella 2016 [75] Maggio 2016 [77] Regazzoli 2018 [36] 
Country Italy Italy Italy, India 
Sponsor nr nr This research did not receive any specific 
grant from funding agencies in the public, 
commercial, or not-for-profit sectors 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none 
Anti-platelet therapy Dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor or prasugrel) for at least 12 
months 
nr Dual antiplatelet therapy (aspirin + 
clopidogrel) for 12 months; complex 
lesions aspirin + ticagrelor/prasugrel for 
12 months 
Main inclusion criteria • Patients with either DES or BMS in-stent restenosis lesions • Patients undergoing 
percutaneous coronary 
intervention (PCI) 
• ≥18 years of age 
• Patients undergoing percutaneous 
coronary intervention (PCI) 
Primary endpoint Procedural success defined as the 
successful delivery and deployment of the 
BVS at the target lesion with less than 30% 
final residual stenosis and without in-hospital 
major adverse cardiac and/or 
cerebrovascular events 
DOCE (cardiac death + target vessel 
myocardial infarction + target lesion 
revascularisation) 
Major adverse cardiac events 
(MACE) 
Target-lesion failure (TLF) and definite 
and probable scaffold thrombosis (ScT) 
Maximumfollow-up 7 months 15 months 12 months 48 months 
Number of patients; (n) 83 116 112 573 
Patients lost to follow-
up, timepoint; n (%) 
0 (0) 0 (0) 12 (11.6) 0 (0) 
Mean age of patients 
(years)  
65.2 (10.0) 66.04 (10) 55.5 (12.4) 59.1 (11) 
Sex (% male) 84.3% 84.5% 89.3% 89.9% 
Previous MI; n (%) 51 (61.4) 71 (61.2) 5 (4.5) 112 (19.5) 
Stable angina; n (%) 44 (53.0) 65 (56.0) 13 (11.6) 400 (69.8) 
Unstable angina; n (%) 18 (21.7) 24 (20.7) 15 (13.4) 146 (25.5) 
STEMI; n (%) 5 (6.0) 7 (6.0) 43 (38.4) STEMI + NSTEMI: 27 (4.7) 
NSTEMI; n (%) 16 (19.3) 20 (17.2) 31 (27.7) 
ACS; n (%) 39 (47.0) 51 (44.0) 89 (79.5) 173 (30.2) 
Outcomes: Safety 7 months follow-up 15 months follow-up 12 months follow-up 48 months follow-up 
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Author, year Moscarella 2015 [100] Moscarella 2016 [75] Maggio 2016 [77] Regazzoli 2018 [36] 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
6 (7.2) nr nr nr 
Periprocedural 
mortality; n (%) 
nr nr nr nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr 1 (1) nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr nr nr nr 
ScT ≥1 year; n (%) na 1 (0.8) na 1 (0.2) 
Other SAEs; n (%) All-cause mortality: 2 (2.4) All-cause mortality: 4 (3.4) nr All-cause mortality: 15 (4.4) 
Abbreviations: ACS=acute coronary syndrome; BMS=bare metal stent; BRS=bioresorbable scaffold; DES=drug-eluting stent; DOCE=device-oriented composite endpoint; MACE=major adverse cardiac 
events; MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; PCI=percutaneous coronary intervention; SAE=serious adverse event; 
ScT=scaffold thrombosis; STEMI=ST-segment elevation myocardial infarction; TLF=target lesion failure 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Naganuma 2017 [54] Azzalini 2016 [67] Testa 2017 [57] Ielasi 2017 [51] 
Study-ID - - NCT02004730 NCT02601781 
Study design Cohort study Multicenter registry  Multicenter, prospective registry Multicenter, prospective registry 
Country Italy 5 international sites Italy Italy (22 sites) 
Sponsor no funding nr The Italian Society of 
Interventional Cardiology (SICI-
GISE) has promoted this study. 
Abbott Vascular provided an 
unrestricted grant to SICI-GISE. 
nr 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none none 
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Author, year Naganuma 2017 [54] Azzalini 2016 [67] Testa 2017 [57] Ielasi 2017 [51] 
Anti-platelet therapy Dual antiplatelet therapy (aspirin + 
clopidogrel or ticagrelor or prasugrel) for at 
least 12 months 
nr Aspirin + according to guideline; 
P2Y12 receptor antagonist was 
administered before the procedure 
or within one hour after the 
procedure 
Aspirin indefinitely + clopidogrel or 
ticagrelor or prasugrel for at least 12 
months 
Main inclusion criteria • Patients undergoing percutaneous 
coronary intervention (PCI) with non-left 
main bifurcation lesions 
• Chronic total occlusion • Patient must have indication to 
percutaneous coronary 
intervention for: multivessel 
disease (at least two significant 
stenoses in two different 
segments NOT as a bifurcation 
lesion; for patients with two 
vessel disease at least 1 lesion 
must be >24 mm and must be 
treated with the BVS; for 
patients with 3 vessel disease a 
hybrid approach is acceptable 
provided that 2 vessels are 
treated with BVS), 
• Long (>24 mm) single vessel 
disease following: Stable 
angina or evidence of 
myocardial ischemia with stress 
echocardiography/ myocardial 
SPECT/exercise test, or 
Unstable angina / non ST-
elevation myocardial infarction 
ST-elevation myocardial 
infarction with de novo culprit 
lesion. 
• Patients with STEMI (<75 years of 
age with symptom onset <12 h) 
Primary endpoint Target lesion failure Target-vessel failure The cumulative hierarchical 
incidence of major adverse cardiac 
events (MACE) defined as: cardiac 
death, non-fatal target vessel 
myocardial infarction, or clinically 
driven target lesion 
revascularisation. 
A device oriented composite end-point of 
cardiac death, any myocardial infarction 
(STEMI or NSTEMI) clearly attributable 
to the intervention culprit vessel and 
ischemic driven TLR within 30 days after 
the index procedure 
Maximumfollow-up 24 months 24 months 12 months 1 month 
Number of patients; (n) 147 153 1002 505 
Patients lost to follow-
up, timepoint; n (%) 
nr 0 46 (4.6) 0 
Mean age of patients 
(years)  
62.7 (10.6) 60.0 (9.3) 60 (10.4) 56.6 (9.4) 
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Author, year Naganuma 2017 [54] Azzalini 2016 [67] Testa 2017 [57] Ielasi 2017 [51] 
Sex (% male) 89.8% 89.5% 85.1% 81.2% 
Previous MI; n (%) nr 50 (32.7) 208 (20.8) 22 (4.4) 
Stable angina; n (%) 131 (89.1) nr 267 (26.7) 0 
Unstable angina; n (%) 14 (9.5) nr 126 (12.6) 0 
STEMI; n (%) 2 (1.4) nr 218 (21.8) 505 (100) 
NSTEMI; n (%) 0 nr 255 (25.5) 0 
ACS; n (%) 16 (10.9) 14 (9.7) 599 (59.8) 505 (100) 
Outcomes: Safety 24 months follow-up 24 months follow-up 12 months follow-up 1 month follow-up 
Vascular-access-site 
complication; n (%) 
nr 1 (0.7) nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
13 (8.8) nr 28 (2.8) 1 (0.2) 
Periprocedural 
mortality; n (%) 
nr nr 0 nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr 21 (2.1) 7 (1.4) 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr nr nr nr 
ScT ≥1 year; n (%) 0 1 (0.7) na na 
Other SAEs; n (%) nr nr All-cause mortality: 12 (1.2) 
stroke: 2 (0.2) 
All-cause mortality: 2 (0.4) 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-
segment elevation myocardial infarction; PCI=percutaneous coronary intervention; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year 
RAI registry 
Cortese 2017 [64] Tarantini 2018 [45] Tarantini 2018 [101] Moscarella 2018 [43] 
Study-ID NCT02298413 
 Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 113 
Author, year 
RAI registry 
Cortese 2017 [64] Tarantini 2018 [45] Tarantini 2018 [101] Moscarella 2018 [43] 
Study design Multicenter, prospective registry 
Country Italy 
Sponsor No funding 
Intervention/Product Everolimus-eluting BRS/Absorb®  
Comparator/Product none 
Anti-platelet therapy Aspirin indefinitely + clopidogrel or ticagrelor or prasugrel for at least 12 months 
Main inclusion criteria • Patients undergoing percutaneous coronary intervention (PCI) with stable or unstable coronary artery disease (including ST-elevation myocardial infarction) 
Primary endpoint Target lesion revascularisation (TLR) 
Definite/probable device thrombosis 
Maximumfollow-up unclear 
Number of patients; (n) 1505 1384 1384 317 
Patients lost to follow-
up, timepoint; n (%) 
0 0 13 (0.9) 0 
Mean age of patients 
(years)  
59 (10.4) 58.5 (10) 58.4 (10.2) 55.5 (10.6) 
Sex (% male) 82% 82.2% 82.2% 81% 
Previous MI; n (%) 423 (28.1) 315 (22.8) 315 (22.8) 38 (12.0) 
Stable angina; n (%) 610 (40.4) 320 (23.1) 438 (31.7) na 
Unstable angina; n (%) 210 (14) 186 (13.4) 186 (13.4) na 
STEMI; n (%) 317 (21) 328 (23.7) 337 (24.4) 317 (100) 
NSTEMI; n (%) 364 (24.2) 341 (24.6) 339 (24.5) na 
ACS; n (%) 891 (59.2) 948 (68.5) 862 (62.3) 317 (100) 
Outcomes: Safety unclear 21.6 months follow-up 12 months follow-up 12 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
nr 21 (1.5) 21 (1.5) nr 
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Author, year 
RAI registry 
Cortese 2017 [64] Tarantini 2018 [45] Tarantini 2018 [101] Moscarella 2018 [43] 
Periprocedural 
mortality; n (%) 
20 (1.3) nr nr nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr nr nr nr 
ScT ≥1 year; n (%) nr 4 (0.3) 4 (0.3) nr 
Other SAEs; n (%) All-cause mortality: 2 (0.13) All-cause mortality: 19 (1.4) All-cause mortality: 13 (1.0) All-cause mortality: 5 (1.6) 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; MI=myocardial infarction; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; PCI=percutaneous 
coronary intervention; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; TLR=target lesion revascularisation 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year 
RAI registry (continued) Robaei 2016 [81] 
Robaei 2015 [87] Cortese 2015 [84] Ielasi 2015 [89] 
Study-ID NCT02298413 - 
Study design Multicenter, prospective registry Multicenter, prospective registry 
Country Italy Australia (2 sites) 
Sponsor No funding Funding for the Absorb® BVSused in the registry 
was sourced internally. 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none 
Anti-platelet therapy Aspirin indefinitely + clopidogrel or ticagrelor or prasugrel for at least 12 months Dual antiplatelet therapy (aspirin + clopidogrel or 
ticagrelor or prasugrel) 
Main inclusion criteria • Patients undergoing percutaneous coronary intervention (PCI) with stable or unstable coronary artery 
disease (including ST-elevation myocardial infarction) 
• Patients undergoing percutaneous coronary 
intervention (PCI) 
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Author, year 
RAI registry (continued) Robaei 2016 [81] 
Robaei 2015 [87] Cortese 2015 [84] Ielasi 2015 [89] 
Primary endpoint Cumulative occurrence of POCE (a composite of 
patient-oriented MACE, including death, MI, TLR) and 
device thrombosis at 6-month follow-up 
Procedural success, defined as BVS implantation at 
the “culprit” lesion site with less than 30% final 
stenosis and TIMI 3 flow without in-hospital major 
adverse cardiovascular events (MACE: cardiac 
death, MI or need for emergent revascularisation) 
nr 
Maximumfollow-up unclear 24 months 
Number of patients; (n) 122 74 100 
Patients lost to follow-up, 
timepoint; n (%) 
0 6 (8.1)  1 (1) 
Mean age of patients (years)  54 (48-60) 54.4 (10.5) 62.1 (12.4)  
Sex (% male) 74.6% 78.4% 68% 
Previous MI; n (%) 15 (12.3) 8 (10.8) 15 (15) 
Stable angina; n (%) na na 56 (56) 
Unstable angina; n (%) na na 25 (25) 
STEMI; n (%) 122 (100) 74 (100)  4 (4) 
NSTEMI; n (%) na na 15 (15) 
ACS; n (%) 122 (100) 74 (100) (44) 
Outcomes: Safety 6 months follow-up 6 months follow-up 24 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr 
Periprocedural MI; n (%) nr nr 4 (4.0) 
Periprocedural mortality; n 
(%) 
nr nr 0 
Bleeding as a result of 
antiplatelet therapy; n (%) 
nr nr nr 
Mortality as a result of 
bleeding and/or stroke; n (%) 
nr nr nr 
ScT ≥1 year; n (%) na na 1 (1.0) 
Other SAEs; n (%) All-cause mortality: 1 (0.8) nr All-cause mortality: 3 (3.0) 
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Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-
segment elevation myocardial infarction; PCI=percutaneous coronary intervention; POCE=patient-oriented composite endpoint; SAE=serious adverse event; STEMI=ST-segment elevation myocardial 
infarction; TIMI=thrombolysis in myocardial infarction; TLR=target lesion revascularisation 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year 
CSI-Ulm-BVS 
Hellenkamp 2017 [62] Gori 2014 [95] Markovic 2017 [60] Markovic 2016 [70] 
Study-ID NCT02162056 - - 
Study design Prospective single-center study, registry  Non-randomised observational 
registry study, single center 
Non-randomised design, registry, single 
center  
Country Germany Germany Germany 
Sponsor Research grant from Abbott Wiesbaden, Germany nr Grant from the German Ministry of 
Education and Research 
Intervention/Product Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  Everolimus-eluting BRS/Absorb®  
Comparator/Product none none none 
Anti-platelet therapy Stable coronary artery disease: aspirin plus clopidogrel(for 6 months).  
ACS: Prasugrel, ticagrelor, acetylsalicylic acid plus clopidogrel (12 months); triple therapy  
nr Dual antiplatelet therapy with aspirin 100 
mg plus clopidogrel, prasugrel or 
ticagrelor for 12 months. 
Main inclusion criteria • Stable or unstable coronary artery disease including NSTEMI or STEMI 
• Patients had to be in a haemodynamically stable condition, with left ventricular ejection 
fraction of more than 30% with a life expectancy of at least 5 years 
• Aged ≥18 years, who received 
at least one everolimus-eluting 
bioresorbable vascular scaffold 
(Absorb® BVS; Abbott Vascular) 
for treatment of coronary artery 
lesion.  
• Culprit lesion in the setting of an acute 
coronary syndrome (lesions had to be 
de  
novo, in a native coronary artery with 
a reference vessel diameter 
compatible with the use of a 2.5, 3.0 
or 3.5 mm BVS) 
Primary endpoint Cardiac death, MI not clearly related to a nontarget vessel and ischemia-driven target 
lesion revascularizirtion (TLR) 
All-cause death and/or myocardial 
infarction (MACE) 
Major adverse cardiac events (MACE) 
including death, non-fatal myocardial 
infarction (with or without ST-segment 
elevation), or need for revascularisation 
(target or non-target lesion/vessel, 
including planned staged 
revascularisations)  
Maximumfollow-up 36 months unclear 6 months 
Number of patients; (n) 319 236 204 150 
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Author, year 
CSI-Ulm-BVS 
Hellenkamp 2017 [62] Gori 2014 [95] Markovic 2017 [60] Markovic 2016 [70] 
Patients lost to follow-
up, timepoint; n (%) 
20 (6.2) nr 9 (4.4) nr 
Mean age of patients 
(years)  
62.0 (10.7) 62.7 (9.9) 64.0 (10) 61.7 (12.5) 
Sex (% male) 76.8% 78.4% 66.8% 73% 
Previous MI; n (%) nr nr nr 15 (10) 
Stable angina; n (%) 180 (56.4) 132 (55.9) 49 (25.0) na 
Unstable angina; n (%) nr 46 (19.5) 24 (12.2) 24 (16) 
STEMI; n (%) nr 16 (6.8) 63 (32.1) 66 (44) 
NSTEMI; n (%) nr 42 (17.8) 60 (30.6) 60 (40) 
ACS; n (%) 139 (43.5) 104 (44.1) 147 (75.0%) 150 (100) 
Outcomes: Safety 36 months follow-up 12 months follow-up median: 834 days follow-up 1 & 6 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
nr 21 (6.8) nr nr 
Periprocedural 
mortality; n (%) 
nr nr nr nr 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
nr nr nr nr 
ScT ≥1 year; n (%) 2 (0.6) 0 nr na 
Other SAEs; n (%) nr Cardiac death: 0 All-cause mortality: 21 (10.8),  
Cardiac mortality: 17 (8.7) 
All-cause mortality at 1 month:2 (1.4) 
Stroke: 0 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; MACE=major adverse cardiac events; MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-
segment elevation myocardial infarction; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; TLR=taget lesion revascularisation 
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Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year 
Absorb Cohort B 
Serruys 2016 [78] Diletti 2013 [96] 
Diletti 2011 [98] 
Nakatani 2015 [93] Serruys 2011 [97] 
Study-ID NCT00856856 
Study design Multicenter, uncontrolled cohort study 
Country Australia, Belgium, Denmark, France, Netherlands, New Zealand, Poland, Switzerland 
Sponsor Abbott Vascular, Santa Clara, CA, USA 
Intervention/Product Everolimus-eluting BRS/Absorb® revision 1.1 
Comparator/Product none 
Anti-platelet therapy Clopidogrel 75 mg daily for a minimum of 6 months, aspirin lifelong 
Main inclusion criteria • ≥18 years, stable or unstable angina or silent ischaemia, lesions (maximum of two) in separate native coronary arteries with a visually estimated diameter of 3.0 mm, a 
length <14 mm and a diameter stenosis ≥50% and <100% 
• [major exclusion criteria: acute myocardial infarction, unstable arrhythmias, left ventricular ejection fraction <30%, restenosis, lesions located in the left main coronary 
artery] 
Primary endpoint Ischemia-driven major adverse cardiac events (ID-TLR, MI, or cardiac death) 
Maximumfollow-up 5 years 
Number of patients; (n) 101 Cohort B2: 56 
Patients lost to follow-
up, timepoint; n (%) 
At 5 years: 
1 
0 
Mean age of patients 
(years)  
62 (9) 60 (8) 
Sex (% male) 72% 71% 
Previous MI; n (%) 25 (25) 9 (16) 
Stable angina; n (%) nr nr 
Unstable angina; n (%) 15 (14.9)  
STEMI; n (%) nr  
NSTEMI; n (%) nr  
ACS; n (%) nr  
Outcomes: Safety 5 years follow-up 12 and/or 24 months follow-up 6 months follow-up 12 months follow-up 
Vascular-access-site 
complication; n (%) 
nr nr nr nr 
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Author, year 
Absorb Cohort B 
Serruys 2016 [78] Diletti 2013 [96] 
Diletti 2011 [98] 
Nakatani 2015 [93] Serruys 2011 [97] 
Procedure-related 
nephropathy; n (%) 
nr nr nr nr 
Periprocedural MI; n 
(%) 
2 nr 1 (1) 1 (1.8) 
Periprocedural 
mortality; n (%) 
60 months: 0 24 months: 0 (of 101 (B1+B2)) nr 0 
Bleeding as a result of 
antiplatelet therapy; n 
(%) 
nr nr nr nr 
Mortality as a result of 
bleeding and/or stroke; 
n (%) 
60 months: 0 24 months: 0 (of 101 (B1+B2)) nr 0 
ScT ≥1 year; n (%) 60 months: 0 24 months: 0 (of 101 (B1+B2)) na nr 
Other SAEs; n (%) at 5 years: Cardiac mortality 0;  
All-cause mortality 3 (3.0) 
All-cause mortality: 0 (24 months) nr nr 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; CA=California; ID-TLR=ischaemic driven target lesion revascularisation; MACE=major adverse cardiac events; 
MI=myocardial infarction; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction; USA=United 
States of America 
 
Table A5: Characteristics of other relevant studies – Absorb® BVS (continued) 
Author, year Khamis 2016 [102] 
Study-ID - 
Study design Prospective, single-centre, single arm, open label study 
Country Egypt 
Sponsor nr 
Intervention/Product Everolimus-eluting BRS/Absorb®  
Comparator/Product none 
Anti-platelet therapy All patients received aspirin and clopidogrel as guidelines for DES 
Main inclusion criteria • ≥18 and ≤65 years of age 
• stable coronary artery disease 
• PCI for de novo coronary lesions 
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Author, year Khamis 2016 [102] 
Primary endpoint MACE (cardiac death, MI or ID-TLR) 
Maximumfollow-up 12 months 
Number of patients; (n) 99 
Patients lost to follow-up, 
timepoint; n (%) 
0 
Mean age of patients (years)  57.75 (9.6) 
Sex (% male) 60.6% 
Previous MI; n (%) 26 (26.2) 
Stable angina; n (%) 99 (100) 
Unstable angina; n (%) 0 
STEMI; n (%) 0 
NSTEMI; n (%) 0 
ACS; n (%) 0 
Outcomes: Safety 12 months follow-up 
Vascular-access-site 
complication; n (%) 
nr 
Procedure-related nephropathy; 
n (%) 
nr 
Periprocedural MI; n (%) 0 
Periprocedural mortality; n (%) 0 
Bleeding as a result of 
antiplatelet therapy; n (%) 
nr 
Mortality as a result of bleeding 
and/or stroke; n (%) 
nr 
ScT ≥1 year; n (%) na 
Other SAEs; n (%) MACE: 2 (2) 
Abbreviations: ACS=acute coronary syndrome; BRS=bioresorbable scaffold; DES=drug-eluting stent; ID-TVR=ischaemic driven target vessel revascularisation; MACE=major adverse cardiac events; 
MI=myocardial infarction; na=not applicable; nr=not reported; NSTEMI=non-ST-segment elevation myocardial infarction; SAE=serious adverse event; STEMI=ST-segment elevation myocardial infarction 
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List of ongoing and planned studies 
 
Table A6: List of ongoing controlled clinical trials with BRS for the treatment of cardiovascular indications (CAD) 
Study 
Identifier 
Estimated 
completion 
date 
Study type Number 
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT01844284 May 2019 RCT (non-
inferiority) 
400 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE 
PRIME®/XIENCE 
Xpedition™) 
• At least 20 years of age. 
• Evidence of myocardial ischemia (e.g., 
stable or unstable angina, silent ischemia) 
suitable for elective percutaneous coronary 
intervention (PCI). 
• Acceptable candidate for coronary artery 
bypass graft (CABG) surgery. 
• Able to take dual antiplatelet therapy for up 
to 1 year following the index procedure 
and anticoagulants prior/during the index 
procedure.  
Primary: 
• Target Lesion Failure (TLF), non-
inferiority against the active control 
[Time Frame: 12 months] 
Secondary: 
• Late Loss (LL) at 13 Months (Non-
inferiority) [Time Frame: 13 months] 
• Change in average lumen diameter, 
between pre- and post-nitrate 
injection by angiography (superiority) 
[Time Frame: 3 years] 
• Change in average lumen area, from 
post-procedure to 3 years by IVUS 
(superiority) [Time Frame: 3 years] 
• Percentage of treated segments (in 
scaffold or in-stent) that show ACh 
induced vaso-dilatation by 
angiography. [Time Frame: 4 years] 
NCT03234348 March 2019 RCT (non-
inferiority) 
151 Magnesium-
based sirolimus-
eluting BRS 
(Magmaris) 
Biodegradable polymer 
sirolimus-eluting stent 
(Orsiro) 
• At least 18 years of age. 
• ST-segment elevation Myocardial 
Infarction documented in an ambulance or 
in a Cathlab, with ≥2 mm ST segment 
elevation in at least two contiguous leads, 
presenting in the Cathlab <12 hours after 
the onset of symptoms lasting ≥20 min 
requiring primary PCI. 
• Target lesion must be a de-novo lesion 
located in a native vessel. 
• Vessel size should match available M-BRS 
scaffold sizes (≥2.75 mm, and ≤3.7 mm by 
visual assessment). 
• Lesion preparation by either manual 
thrombectomy or pre-dilatation has been 
successful, with opening of the vessel and 
TIMI ≥2 and residual stenosis <20%. 
Primary: 
• In-stent/scaffold vasodilatory 
endothelium independent response 
[Time Frame: 12 months follow-up] 
Secondary: 
• Device success [Time Frame: 
Immediate after the procedure] 
• Procedure success [Time Frame: Up 
to 7 days] 
• Device-oriented Composite Endpoint 
(DOCE) [Time Frame: 1, 6 months, 
1,2,3,4,5 years] 
• Cardiac death [Time Frame: 1, 6 
months, 1,2,3,4,5 years] 
• Target vessel MI [Time Frame: 1, 6 
months, 1,2,3,4,5 years] 
• Clinically driven target lesion 
 Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 122 
Study 
Identifier 
Estimated 
completion 
date 
Study type Number 
of 
patients 
Intervention Comparator Patient population Endpoints 
revascularization [Time Frame: 1, 6 
months, 1,2,3,4,5 years] 
• Stent/scaffold thrombosis [Time 
Frame: 1, 6 months, 1,2,3,4,5 years] 
• Patient oriented endpoint (POCE) 
[Time Frame: 1, 6 months, 1,2,3,4,5 
years] 
• All-cause death [Time Frame: 1, 6 
months, 1,2,3,4,5 years] 
• Any repeat myocardial infarction 
[Time Frame: 1, 6 months, 1,2,3,4,5 
years] 
• Any revascularisation [Time Frame: 
1, 6 months, 1,2,3,4,5 years] 
• Target lesion revascularisation [Time 
Frame: 1, 6 months, 1,2,3,4,5 years] 
• Target vessel revascularisation [Time 
Frame: 1, 6 months, 1,2,3,4,5 years] 
• MLD [Time Frame: Baseline and 1 
year follow-up] 
• %DS [Time Frame: Baseline and 1 
year follow-up] 
• Acute gain [Time Frame: Baseline] 
• Late loss [Time Frame: 1 year] 
• Binary restenosis [Time Frame: 1 
year] 
• Lumen area [Time Frame: 1 year 
follow-up] 
• Mean lumen volume [Time Frame: 1 
year follow-up] 
• % strut malapposition [Time Frame: 
1 year follow-up] 
• Tissue Prolapse [Time Frame: 1 year 
follow-up] 
• Neointimal hyperplasia [Time Frame: 
1 year follow-up] 
• Healing index [Time Frame: 1 year 
follow-up] 
• Strut coverage [Time Frame: 1 year 
follow-up] 
• RUTTS [Time Frame: 1 year follow-
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up] 
NCT01923740 July 2019 RCT (non-
inferiority) 
480 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE V EECSS) 
• At least 18 years of age  
• Evidence of myocardial ischemia (e.g., 
stable angina, unstable angina, post-infarct 
angina or silent ischemia) suitable for 
elective percutaneous coronary 
intervention (PCI). Subjects with stable 
angina or silent ischemia and <70% 
diameter stenosis must have objective sign 
of ischemia as determined by one of the 
following, echocardiogram, nuclear scan, 
ambulatory ECG or stress ECG. In the 
absence of noninvasive ischemia, 
fractional flow reserve must be done and 
indicative of ischemia. 
• Acceptable candidate for coronary artery 
bypass graft (CABG) surgery. 
Primary: 
• In-segment Late Loss (LL) - Per 
Subject Analysis [Time Frame: At 1 
year] 
• In-segment Late Loss (LL) - Per 
Lesion Analysis [Time Frame: At 1 
year] 
Secondary: 
• Acute Device Success [Time Frame: 
<or = 1 day] 
• Number of Participants With Acute 
Procedural Success [Time Frame: up 
to 7 days in hospital, 3-37 days, 0-
208 days, 0-393 days, 0-758 days, 0-
1123 days, 4 years, 5 years] 
• Number of Participants Experienced 
Death (Cardiac, Vascular, Non-
cardiovascular) [Time Frame: up to 7 
days in hospital, 3-37 days, 0-208 
days, 0-393 days, 0-758 days, 0-
1123 days, 4 years, 5 years] 
• Number of Participants With 
Myocardial Infarction [Time Frame: 
up to 7 days in hospital, 3-37 days, 
0-208 days, 0-393 days, 0-758 days, 
0-1123 days, 4 years, 5 years] 
• Number of Participants With Target 
Lesion Revascularisation (TLR) 
[Time Frame: up to 7 days in 
hospital, 3-37 days, 0-208 days, 0-
393 days, 0-758 days, 0-1123 days, 
4 years, 5 years] 
• Number of Participants With Target 
Vessel Revascularisation (TVR) 
[Time Frame: up to 7 days in 
hospital, 3-37 days, 0-208 days, 0-
393 days, 0-758 days, 0-1123 days, 
4 years, 5 years] 
• Number of Participants With All 
Coronary Revascularisation (PCI and 
CABG) [Time Frame: up to 7 days in 
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hospital, 3-37days, 0-208days, 
0.393days, 0-758 days, 0-1123 days, 
4 years, 5 years] 
• Number of Participants Experienced 
Death/All MI [Time Frame: up to 7 
days in hospital, 3-37 days, 0-208 
days, 0-393 days, 0-758 days, 0-
1123 days, 4 years, 5 years] 
• Number of Participants Experienced 
Cardiac Death/All MI [Time Frame: 
up to 7 days in hospital, 3-37 days, 
0-208 days, 0-393 days, 0-758 days, 
0-1123 days, 4 years, 5 years] 
• Number of Participants Experienced 
All Death/All MI/All Revascularisation  
[Time Frame: up to 7 days in 
hospital, 3-37 days, 0-208 days, 0-
393 days, 0-758 days, 0-1123 days, 
4 years, 5 years] 
• Number of Participants Experienced 
Cardiac Death/TV-MI/ID-TLR [Target 
Lesion Failure (TLF)] [Time Frame: 
up to 7 days in hospital, 3-37 days, 
0-208 days, 0-393 days, 0-758 days, 
0-1123 days, 4 years, 5 years] 
• Number of Participants Experienced 
Cardiac Death/All MI/ID-TVR [Target 
Vessel Failure (TVF)] [Time Frame: 
up to 7 days in hospital, 3-37days, 0-
208days, 0.393days, 0-758 days, 0-
1123days, 4 years, 5 years] 
• Number of Participants Experienced 
Cardiac Death/All MI/ID-TLR (Major 
Adverse Cardiac Event [MACE]) 
[Time Frame: up to 7 days in 
hospital, 3-37 days, 0-208 days, 0-
393 days, 0-758 days, 0-1123 days, 
4 years, 5 years] 
• Number of Participants With 
Stent/Scaffold Thrombosis (Per 
Academic Research Consortium 
Definition) 
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NCT01751906 September 
2021 
RCT (non-
inferiority) 
2008 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE V, XIENCE 
PRIME, XIENCE 
Xpedition, XIENCE 
Alpine, XIENCE Pro 
and XIENCE ProX) 
• 18 years of age. 
• Evidence of myocardial ischemia. In the 
absence of noninvasive ischemia, 
fractional flow reserve must be done and 
indicative of ischemia. 
• Acceptable candidate for coronary artery 
bypass graft (CABG) surgery. 
Primary: 
• Number of Participants With Cardiac 
Death/TV-MI/ID-TLR (TLF) [Time 
Frame: 1 year] 
Secondary: 
• Acute Success- Device Success 
(Lesion Level Analysis) [Time Frame: 
On day 0 (the day of procedure)] 
• Acute Success: Procedural Success 
(Subject Level Analysis) [Time 
Frame: On day 0 (the day of 
procedure)] 
• Number of Participants With 
Powered Secondary Endpoint: 
Angina [Time Frame: 1 yea] 
• Number of Participants With 
Powered Secondary Endpoint: All 
Revascularisation [Time Frame: 1 
year] 
• Number of Participants With 
Powered Secondary Endpoint: 
Ischemia Driven Target Vessel 
Revascularisation (ID-TVR) [Time 
Frame: 1 year] 
• Number of Participants With Death 
(Cardiac, Vascular, Non-
cardiovascular) [Time Frame: up to 7 
days in hospital, 0-30 days, 0-180 
days, 0-1 year, 2 years, 3 years, 4 
years, 5 years] 
• Number of Participants With All 
Myocardial Infarction (MI) [Time 
Frame: up to 7 days in hospital, 0-30 
days, 0-180 days, 0-1 year, 2 years, 
3 years, 4 years, 5 years] 
• Number of Participants With All 
Target Lesion Revascularisation 
(TLR) [Time Frame: up to 7 days in 
hospital, 0-30 days, 0-180 days, 0-1 
year, 2 years, 3 years, 4 years, 5 
years] 
• Number of Participants With All 
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Target Vessel Revascularisation 
(TVR) Excluding Target Lesion 
Revascularisation (TLR) [Time 
Frame: up to 7 days in hospital, 0-30 
days, 0-180 days, 0-1 year, 2 years, 
3 years, 4 years, 5 years] 
• Number of Participants With All 
Revascularisation [Time Frame: up 
to 7 days in hospital, 0-30 days, 0-
180 days, 0-1 year, 2 years, 3 years, 
4 years, 5 years] 
• Number of Participants With 
Death/All MI [Time Frame: up to 7 
days in hospital, 0-30 days, 0-180 
days, 0-1 year, 2 years, 3 years, 4 
years, 5 years] 
• Number of Participants With Cardiac 
Death/All MI [Time Frame: up to 7 
days in hospital, 0-30 days, 0-180 
days, 0-1 year, 2 years, 3 years, 4 
years, 5 years] 
• Number of Participants With Cardiac 
Death/TV-MI/ID-TLR (TLF) [Time 
Frame: up to 7 days in hospital, 0-30 
days, 0-180 days, 0-1 year, 2 years, 
3 years, 4 years, 5 years] 
• Number of Participants With Cardiac 
Death/All MI/ID-TLR (Major Adverse 
Cardiac Events-MACE) [Time Frame: 
up to 7 days in hospital, 0-30 days, 
0-180 days, 0-1 year, 2 years, 3 
years, 4 years, 5 years] 
• Number of Participants With Target 
Vessel Failure (TVF) [Time Frame: 
up to 7 days in hospital, 0-30 days, 
0-180 days, 0-1 year, 2 years, 3 
years, 4 years, 5 years] 
• Number of Participants With 
Death/All MI/All Revascularisation 
[Time Frame: up to 7 days in 
hospital, 0-30 days, 0-180 days, 0-1 
year, 2 years, 3 years, 4 years, 5 
 Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 127 
Study 
Identifier 
Estimated 
completion 
date 
Study type Number 
of 
patients 
Intervention Comparator Patient population Endpoints 
years] 
• Number of Participants With 
Scaffold/Stent Thrombosis (Per ARC 
Definition) 
NCT01858077 December 
2020 
RCT (non-
inferiority) 
1845 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE 
PRIME®/XIENCE 
Xpedition™) 
• 18 Years and older  
• Subject is an acceptable candidate for 
treatment with a drug-eluting stent in 
accordance with the applicable guidelines 
on percutaneous coronary interventions 
and the Instructions for Use of the 
ABSORB® BVS strategy and XIENCE 
family. 
Primary: 
• Target Vessel Failure (TVF) [Time 
Frame: 2 years] 
Secondary: 
• Device success [Time Frame: 1 day] 
• Procedural success [Time Frame: 1 
day] 
• Target vessel failure (TVF) [Time 
Frame: 30 days, and 1, 3, 4 and 5 
years] 
• Target lesion failure [Time Frame: 30 
days, and 1, 2, 3, 4 and 5 years] 
• All revascularisations [Time Frame: 5 
year] 
• All-cause mortality [Time Frame: 30 
days, 1 year, 2, 3, 4 and 5 years] 
• Myocardial Infarction [Time Frame: 
30 days, 1, 2, 3, 4 and 5 years] 
• Target Lesion Revascularisation 
(TLR) [Time Frame: 30 days, 1 year, 
2, 3, 4 and 5 years] 
• Target Vessel Revascularisation 
(TVR) [Time Frame: 30 days, 1 year, 
2, 3, 4 and 5 years] 
• Non-Target Vessel Revascularisation 
[Time Frame: 30 days, 1 year, 2, 3, 4 
and 5 years] 
• Scaffold/Stent Thrombosis [Time 
Frame: 30 days, 1, 2, 3, 4 and 5 
years] 
• Seattle Angina Questionnaire [Time 
Frame: 1 year and 2 years] 
• Quality of Life Questionnaire [Time 
Frame: 1 year and 2 years] 
NCT02796157 May 2019 RCT 950 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE EES) 
• Age 19-85 years 
• Patients with ischemic heart disease 
requiring PCI 
Primary: 
• Incidence of composite of major 
adverse cardiovascular events [Time 
 Bioresorbable stents for cardiovascular indications 
Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 128 
Study 
Identifier 
Estimated 
completion 
date 
Study type Number 
of 
patients 
Intervention Comparator Patient population Endpoints 
• Significant coronary de novo lesion 
(stenosis >50% by quantitative 
angiographic analysis) requiring stent ≥28 
mm in length based on angiographic 
estimation 
• Reference vessel diameter of 2.5 to 3.75 
mm by operator assessment 
Frame: 1 year after PCI] 
Secondary: 
• Not reported 
NCT02173379 April 2024 RCT (non-
inferiority) 
2610 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE V, XIENCE 
PRIME, XIENCE 
Xpedition, XIENCE 
Alpine, XIENCE Pro 
and XIENCE ProX) 
• At least 18 years of age. 
• Evidence of myocardial ischemia (e.g., 
silent ischemia, stable or unstable angina, 
non-ST-segment elevation MI (NSTEMI), 
OR recent ST-segment elevation MI 
(STEMI). Patients with stable coronary 
syndromes can be enrolled any time after 
symptom onset if eligibility criteria are 
otherwise met. Patients with acute 
coronary syndrome can be enrolled under 
the following conditions: 
o Unstable angina or NSTEMI within 2 
weeks of the index procedure. 
o STEMI >72 hours ≤2 weeks prior to 
the index procedure. 
• Suitable for PCI. Subjects with stable 
angina or silent ischemia and <70% 
diameter stenosis must have objective 
signs of ischemia as determined by one of 
the following: abnormal stress 
echocardiogram, nuclear scan, 
electrocardiogram, positron emission 
tomography, magnetic resonance imaging, 
and/or fractional flow reserve. 
• Subject must be an acceptable candidate 
for coronary artery bypass graft (CABG) 
surgery. 
• Treatment of up to three de novo lesions in 
a maximum of two epicardial vessels, with 
a maximum of two lesions per epicardial 
vessel. If only a single lesion is to be 
treated, it must be a target lesion. Up to 
one non-target lesion can be treated. Non-
target lesion treatment can occur only in a 
non-target vessel. 
Primary: 
• Number of Participants With Target 
Lesion Failure (TLF) [Time Frame: 
30 days] 
Secondary: 
• Powered TLF, Tested for Non-
inferiority of Absorb® BVS to XIENCE 
[Time Frame: 1 year] 
• Number of Participants With 
Powered Angina [Time Frame: 30 
days] 
• Percentage of Target Lesion With 
Acute Success- Device Success 
(Lesion Level Analysis) [Time Frame: 
In-hospital (≤7days)] 
• Number of Participants With Acute 
Success- Procedural Success 
(Subject Level Analysis) [Time 
Frame: In-hospital (≤7days)] 
• Number of Participants Experienced 
Death (Cardiac, Vascular, Non-
cardiovascular) [Time Frame: In-
hospital (≤7 days post index 
procedure), 30 days, 90 days, 180 
days, 270 days, 1 year, 2 years, 3 
years, 4 years, 5 years, 6 years, 7 
years, 8 years, 9 years, 10 years] 
• Number of Participants With 
Myocardial Infarction (MI) [Time 
Frame: In-hospital (≤7 days post 
index procedure), 30 days, 90 days, 
180 days, 270 days, 1 year, 2 years, 
3 years, 4 years, 5 years, 6 years, 7 
years, 8 years, 9 years, 10 years] 
• Number of Participants With Target 
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• Target lesion(s) must be located in a 
native coronary artery with a visually 
estimated or quantitatively assessed %DS 
of ≥50% and <100%, with a thrombolysis 
in myocardial infarction (TIMI) flow of ≥1, 
and one of the following: stenosis ≥70%, 
an abnormal functional test (e.g., fractional 
flow reserve ≤0.80 AND/OR a positive 
stress test), or presentation with an acute 
coronary syndrome (unstable angina or 
NSTEMI within 2 weeks of index 
procedure, or STEMI >72 hours but ≤2 
weeks prior to the index procedure). 
o Target lesion(s) must be located in a 
native coronary artery with reference 
vessel diameter (RVD) by visual 
estimation of ≥2.50 mm and ≤3.75 mm. 
o Target lesion(s) must be located in a 
native coronary artery with length by 
visual estimation of ≤24 mm. 
Lesion Revascularisation (TLR) 
[Time Frame: In-hospital (≤7 days 
post index procedure), 30 days, 90 
days, 180 days, 270 days, 1 year, 2 
years, 3 years, 4 years, 5 years, 6 
years, 7 years, 8 years, 9 years, 10 
years] 
• Number of Participants With Target 
Vessel Revascularisation (TVR) 
[Time Frame: In-hospital (≤7 days 
post index procedure), 30 days, 90 
days, 180 days, 270 days, 1 year, 2 
years, 3 years, 4 years, 5 years, 6 
years, 7 years, 8 years, 9 years, 10 
years] 
• + over 100 additional secondary 
endpoints 
NCT03076476 December 
2018 
RCT 50 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE EES) 
• Age >18 years, <75 years. 
• Lesion suitability for BVS deployment: 
target vessel calibre >2.3mm and <3.8mm 
reference diameter, without significant 
tortuosity or calcification. 
• Listed for single-vessel PCI procedure. 
• Lesion length≤28mm (to accommodate 
single BVS/DES) 
• Preserved left ventricular ejection fraction 
(EF≥50%). 
Primary: 
• Change in IMR between baseline 
and post-stent/scaffold implantation. 
[Time Frame: During procedure] 
• Change in CFR between baseline 
and post-stent/scaffold implantation. 
[Time Frame: During procedure] 
Secondary: 
• Incidence of troponin elevation post-
PCI (MI4a). [Time Frame: Measured 
6 hours after stent insertion] 
• Changes in IMR between baseline, 
post-implant and subsequent 
timepoints in sub randomised group. 
[Time Frame: 3 months follow up] 
• Incidence of post-PCI angina and 
quality of life by standardised Seattle 
angina questionnaire at telephone 
follow-up. [Time Frame: Up to 12 
months] 
• Incidence of stent & scaffold 
expansion & malapposition adjudged 
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by strut-level OCT analysis. [Time 
Frame: During index procedure and 
at 3 month follow up] 
• Incidence of stent/scaffold strut 
coverage/endothelialisation adjudged 
by strut-level OCT analysis. [Time 
Frame: During index procedure and 
at 3 month follow up] 
• Nature/phenotype of underlying 
target lesion plaque by OCT 
analysis. [Time Frame: During index 
procedure and at 3 month follow up] 
• Adverse events [Time Frame: At time 
points 1, 3, 6 & 12 months post-PCI] 
• Serious adverse events [Time 
Frame: At time points 1, 3, 6 & 12 
months post-PCI] 
NCT01942070 March 2019 RCT (non-
inferiority) 
262 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Everolimus-eluting 
permanent metal stent 
(XIENCE EES) 
• 18 years or older with acute ST-elevation 
myocardial infarction or non ST-elevation 
myocardial infarction with angiographically 
confirmed thrombus 
• Planned stent implantation in de novo 
lesions in native vessels or coronary 
bypass grafts with reference vessel 
diameter ≥2.5 mm and ≤3.9 mm 
Primary: 
• Percentage Diameter Stenosis [Time 
Frame: 6-8 months] 
Secondary : 
• Device-oriented composite endpoint 
[Time Frame: 12 months] 
• Patient-oriented composite endpoint 
[Time Frame: 12 months] 
• Composite of death or MI [Time 
Frame: 12 months] 
• Stent thrombosis [Time Frame: 12 
months] 
NCT02171065 June 2020 Multicentre 
Prospective 
Natural 
History Study 
combined with 
a RCT 
902 Everolimus-
eluting BRS 
(Absorb™ BVS) 
Sham device • Troponin positive ACS (STEMI >12 h or 
NSTEMI) occurring within the prior 2 
weeks of enrollment, with symptoms 
consistent with acute ischemia lasting >10 
minutes, intended for angiography and 
Percutaneous Coronary Intervention (PCI) 
if appropriate. 
• Patient must have one-vessel, two-vessel 
or three-vessel disease in native coronary 
arteries requiring PCI. 
• Successful PCI 
Additional for RCT: 
Primary: 
• Patient level non-culprit lesion 
related Non-Culprit Major Adverse 
Cardiac Event through 2 years 
adjudicated to an originally untreated 
non-culprit lesion [Time Frame: 2 
years] 
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• The lesion has an angiographic diameter 
stenosis <70%, and is not intended for 
revascularisation based on angiographic 
criteria and Fractional Flow 
Reserve/Instantaneous wave-free ratio. 
• The lesion has a site-determined IVUS 
plaque burden in at least one frame ≥70%. 
Note: Such a lesion may or may not be 
angiographically evident; i.e., the visually 
estimated angiographic diameter stenosis 
may range between 0% - <70%. 
• The reference vessel diameter of an 
eligible lesion is ≥2.5 mm - ≤4.0 mm 
(visually estimated) capable of being 
treated with a 2.5 mm, 3.0 mm, or 3.5 mm 
diameter BVS. 
• The lesion length of an eligible lesion is 
≤50 mm (visually estimated), capable of 
being treated by no more than two BVS 
(maximum length of each BVS 28 mm), 
allowing for 2 mm BVS overlap and 2 mm 
of "normal" reference segment treatment 
at each edge. 
• The lesion must be at least 10 mm from a 
previously implanted stent/scaffold and an 
intervening 10 mm segment must not have 
plaque burden (PB) >50% 
• A bifurcation lesion may be 
enrolled only if the side branch is 
a) ≤2.5 mm in reference vessel 
diameter, AND b) has either no 
lesion requiring treatment, or 
atherosclerotic disease limited to 
within 5 mm of its origin from the 
parent vessel such that the 
operator believes that the side 
branch can be successfully treated 
with balloon angioplasty only 
(without a stent). If a stent 
subsequently becomes necessary, 
only a permanent metallic drug-
eluting stent (DES; XIENCE 
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strongly recommended) may be 
used to treat the side branch with a 
T-stent technique. 
Abbreviations: ACS=acute coronary syndrome; ARC=Academic Research Consortium; BRS=bioresorbable scaffold; BVS=bioresorbable vascular scaffold; CABG=coronary artery bypass graft surgery; 
CFR=coronary flow reserve; DOCE=device-oriented composite endpoint; ECG=electrocardiography; EES=everolimus-eluting stent; EF=ejection fraction; ID-TLR=ischaemic driven target lesion 
revascularisation; ID-TVR=ischaemic driven target vessel revascularisation; IMR=index of microvascular resistance; IVUS=intravascular ultrasound; LL=lumen loss; MACE=major adverse cardiac events; 
MI=myocardial infarction; MLD=minimum lumen diameter; NSTEMI=non-ST-segment elevation myocardial infarction; OCT=optical coherence tomography; PCI=percutaneous coronary intervention; 
RCT=randomised controlled trial; RUTTS=ratio of uncovered to total stent struts per cross-section score; STEMI=ST-segment elevation myocardial infarction; TIMI=thrombolysis in myocardial infarction; 
TLF=target lesion failure; TLR=target lesion revascularisation; TVF=target vessel failure; TVR=target vessel revascularisation 
Sources: ClinicalTrials.gov; WHO-ICTRP (http://www.who.int/ictrp/en/) 
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Table A7: Risk of bias – study level (RCTs) – Absorb® BVS 
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Absorb II Low Low Low Higha Low Low 
Absorb III Low Low Low Lowb Low Low 
Absorb China Low Low Higha Higha Low Low 
Absorb Japan Low Low Low Lowc  Low Low 
AIDA Low Low Low Higha Low Low 
Trofi II Low Low Low Higha Low Low 
Everbio II Low Low Higha Higha Low Low 
Hernandez  Uncleard Uncleare Unclearf Unclearf Low Low 
Comments:  
a Not blinded 
b Investigators doing the procedure not blinded; follow-up personnel were unaware of study-group assignments 
c blinded site personnel were assigned to conduct scheduled clinical follow-up 
d Method of randomization not described 
e Method of allocation concealment not described 
f No information about blinding 
Sources: [17-34] 
 
Table A8: Risk of bias – outcome level (RCTs) – Absorb® BVS 
Outcome 
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All-cause mortality 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Everbio II Low Low Low Low Low 
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Cardiac mortality 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Everbio II Low Low Low Low Low 
Hernandez Unclear Low Low Low Unclear 
Angina 
Absorb II Low Higha Low Low High 
Absorb III Low Highb Low Low High 
Trofi II Low Unclear Low Low Unclear 
Myocardial infarction 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Everbio II Low Low Low Low Low 
Hernandez Unclear Low Low Low Unclear 
MACE 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Everbio II Low Low Low Low Low 
TVR 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Everbio II Low Low Low Low Low 
Hernandez Unclear Low Low Low Unclear 
[name of technology] for [indication] 
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TLR 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Everbio II Low Low Low Low Low 
Hernandez Unclear Low Low Low Unclear 
Quality of Life 
Absorb II Low Higha Low Low High 
Absorb III Low Highb Low Low High 
Daily Functioning 
Absorb II Low Higha Low Low High 
Duration of Procedure 
Absorb III Highc Low Low Low High 
Absorb Japan Highc Low Low Low High 
AIDA Highc Low Low Low High 
Peri-procedural MI 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Hernandez Unclear Low Highd Low High 
Peri-procedural mortality 
Absorb China Low Low Low Low Low 
Trofi II Low Low Low Low Low 
Very late scaffold thrombosis (≥1 year) 
Absorb II Low Low Low Low Low 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Absorb Japan Low Low Low Low Low 
AIDA Low Low Low Low Low 
Everbio II Low Low Low Low Low 
[name of technology] for [indication] 
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All Serious Adverse Events 
Absorb III Low Low Low Low Low 
Absorb China Low Low Low Low Low 
Comments: 
a only patients with 3 year clinical follow-up analysed 
b only patients with 1 year clinical follow-up analysed 
c Investigators doing the procedure not blinded 
d only reported, that rates are not significant different 
Abbreviations: ITT=intention to treat 
Sources: [17-34] 
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Table A9: Risk of bias – single-arm studies – DESolve® and Fantom® (IHE 20-Criteria checklist) 
Study 
Gunes 2017 
[61] 
Abizaid 2016 [76] 
(DESolve Nx) 
Nef 2018 [37] (DESolve 
PMCF) 
Abizaid 2017 [52] 
(Fantom II) 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? yes yes yes partially 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes yes yes 
3. Were the cases collected in more than one centre? no yes yes yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study 
explicit and appropriate? yes yes yes unclear 
5. Were participants recruited consecutively? unclear unclear unclear unclear 
6. Did participants enter the study at similar point in the disease? no no no unclear 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes yes yes 
8. Were additional interventions (co-interventions) clearly reported in the study? yes yes yes yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods 
section? yes yes yes yes 
10. Were relevant outcomes appropriately measured with objective and/or 
subjective methods? yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes yes yes 
14. Was the loss to follow-up reported? yes yes yes yes 
15. Does the study provide estimates of the random variability in the data analysis 
of relevant outcomes? no no no no 
16. Are adverse events reported? partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? no yes yes yes 
Overall Risk of bias moderate moderate moderate moderate 
Abbreviations: na=not applicable 
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Table A10: Risk of bias – single-arm studies – Magmaris (Dreams 2G) (IHE 20-Criteria checklist) 
Study 
Haude 2016 [58] 
Haude 2016 [82] 
Haude 2018 [35] 
Haude 2017 [56] (Biosolve II) 
7 Haude 2018 [35] 
Haude 2017 [56] (Biosolve III) 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? yes yes 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes 
3. Were the cases collected in more than one centre? yes yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? yes yes 
5. Were participants recruited consecutively? unclear unclear 
6. Did participants enter the study at similar point in the disease? no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes 
8. Were additional interventions (co-interventions) clearly reported in the study? yes yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods section? yes yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective methods? yes yes 
11. Were outcomes measured before and after intervention? na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes 
14. Was the loss to follow-up reported? yes yes 
15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? no no 
16. Are adverse events reported? partially partially 
17. Are the conclusions of the study supported by results? yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? yes yes 
Overall Risk of bias moderate moderate 
Abbreviations: na=not applicable 
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Table A11: Risk of bias – single-arm studies – Absorb® BVS (IHE 20-Criteria checklist) 
Study 
Fam 2016 
[72] 
Maes 2018 
[38] 
Costopoulos 2014 
[91] 
Panolas 2016 
[69] 
Tanaka 2017 [65] 
Kawamoto 2015 
[103] 
Moscarella 2015 
[100] 
Moscarella 2016 
[75] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? no yes yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes yes yes yes yes 
3. Were the cases collected in more than one centre? no no yes no no yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study 
explicit and appropriate? yes yes yes yes yes yes 
5. Were participants recruited consecutively? unclear yes yes yes unclear yes 
6. Did participants enter the study at similar point in the disease? yes no no yes no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes yes yes yes yes 
8. Were additional interventions (co-interventions) clearly reported in the study? yes yes yes yes yes yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods 
section? yes yes yes yes yes yes 
10. Were relevant outcomes appropriately measured with objective and/or 
subjective methods? yes yes yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na na na 
Statistical Analysis       
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes yes yes yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes yes yes yes yes 
14. Was the loss to follow-up reported? yes no no no no no 
15. Does the study provide estimates of the random variability in the data analysis 
of relevant outcomes? yes yes yes yes yes yes 
16. Are adverse events reported? partially partially partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? yes yes no no yes no 
Overall Risk of bias moderate low low low moderate low 
Abbreviations: na=not applicable 
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Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
Maggio 2016 
[77] 
Regazzoli 2018 
[36] 
Naganuma 2017 
[54] 
Azzalini 2016 
[67] 
Testa 2017 
[57] 
Ielasi 2017 
[51] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? yes yes yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes yes yes yes yes 
3. Were the cases collected in more than one centre? no yes yes yes yes yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study 
explicit and appropriate? yes yes yes yes yes yes 
5. Were participants recruited consecutively? yes yes unclear yes unclear unclear 
6. Did participants enter the study at similar point in the disease? no no no no no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes yes yes yes yes 
8. Were additional interventions (co-interventions) clearly reported in the study? yes yes yes yes yes yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods 
section? yes yes yes yes yes yes 
10. Were relevant outcomes appropriately measured with objective and/or 
subjective methods? yes yes yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes yes yes yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes yes yes yes yes 
14. Was the loss to follow-up reported? no no no no no no 
15. Does the study provide estimates of the random variability in the data analysis 
of relevant outcomes? yes yes yes yes yes yes 
16. Are adverse events reported? partially partially partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? no yes yes no yes no 
Overall Risk of bias low low moderate low moderate moderate 
Abbreviations: na=not applicable 
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Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
RAI registry 
Moscarella 2017 
[43] 
Tarantini 2018 
[45] 
Tarantini 2018 
[101] 
Cortese 2017 
[64] 
Cortese 2015 
[84] 
Ielasi 2015 
[89] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? yes yes yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes yes yes yes yes 
3. Were the cases collected in more than one centre? yes yes yes yes yes yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the 
study explicit and appropriate? yes yes yes yes yes yes 
5. Were participants recruited consecutively? unclear unclear yes yes yes unclear 
6. Did participants enter the study at similar point in the disease? no yes no no yes yes 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes yes yes yes yes 
8. Were additional interventions (co-interventions) clearly reported in the study? yes yes yes yes yes yes 
Outcome measures       
9. Are the outcome measures clearly defined in the introduction or methods 
section? yes yes yes yes yes yes 
10. Were relevant outcomes appropriately measured with objective and/or 
subjective methods? yes yes yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes yes yes yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes no yes no yes yes 
14. Was the loss to follow-up reported? no no yes no no yes 
15. Does the study provide estimates of the random variability in the data 
analysis of relevant outcomes? yes yes yes yes yes yes 
16. Are adverse events reported? partially partially partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? no yes yes yes yes yes 
Overall Risk of bias moderate moderate low low low moderate 
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Abbreviations: na: not applicable 
Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
Robaei 2016 
[81] 
Robaei 2015 
[87] 
Markovic 2017 
[60] 
Markovic 2016 
[70] 
Hellenkamp 2017 
[62] 
Gori 2014 
[95] 
Teeuwen 2015 
[104] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or 
methods section? yes yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes yes yes yes 
3. Were the cases collected in more than one centre? yes no no no no 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit 
and appropriate? yes yes yes yes partially 
5. Were participants recruited consecutively? yes unclear yes yes unclear 
6. Did participants enter the study at similar point in the disease? no no no no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes yes yes no 
8. Were additional interventions (co-interventions) clearly reported in the study? yes no no yes yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods section? yes yes yes yes yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective 
methods? yes yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes yes yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes yes yes yes 
14. Was the loss to follow-up reported? yes yes yes yes yes 
15. Does the study provide estimates of the random variability in the data analysis of 
relevant outcomes? yes yes yes yes yes 
16. Are adverse events reported? partially partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? yes yes no no no 
Overall Risk of bias low moderate moderate low moderate 
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Abbreviations: na: not applicable 
Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
Absorb B 
Diletti 2011 
[98] 
Nakatani 2015 
[93] 
Serruys 2011 
[97] 
Diletti 2013 
[96]  
Serruys 2016 
[78] 
Jamshidi 2016 
[74] 
Grimfjard 2017 [50] 
(SCAAR) 
Widimsky 2015 [83] 
Tousek 2016 [73] 
(Prague 19) 
Iwanczyk 2017 
[39] 
Gil 2016 
[79] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the 
abstract, introduction, or methods section? 
yes yes yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the study 
described? yes yes yes partially yes yes 
3. Were the cases collected in more than one centre? yes no yes yes yes yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into 
the study explicit and appropriate? yes partially partially yes yes yes 
5. Were participants recruited consecutively? unclear unclear unclear yes unclear unclear 
6. Did participants enter the study at similar point in the disease? no no no yes no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes no yes yes yes 
8. Were additional interventions (co-interventions) clearly reported in the 
study? yes yes no yes yes yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or 
methods section? yes yes partially yes yes yes 
10. Were relevant outcomes appropriately measured with objective 
and/or subjective methods? yes yes yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes 
appropriate? 
yes yes yes yes yes yes 
Results and Conclusions 
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13. Was the length of follow-up reported? yes yes yes yes yes yes 
14. Was the loss to follow-up reported? yes yes yes yes yes yes 
15. Does the study provide estimates of the random variability in the data 
analysis of relevant outcomes? yes yes yes yes yes yes 
16. Are adverse events reported? partially partially partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study 
reported? yes no no yes partially partially 
Overall Risk of bias moderate high high low low low 
Abbreviations: na=not applicable 
 
Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
Felix 2016 [68] 
(BVS Expand) 
Kraak 2015 
[90] 
Remkes 
2017 [47] 
Alfonso 2017 
[53] (RIBS VI) 
Cortese 
2017a [55] 
Cortese 
2017b [63] 
Anadol 2017 [40]  
Gori 2015 [85]  
Anadol 2018 [99] (MI-
CAT Absorb Substudy) 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly 
in the abstract, introduction, or methods section? yes yes yes yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the 
study described? yes yes yes yes yes yes yes 
3. Were the cases collected in more than one centre? no no no yes no yes no 
4. Are the eligibility criteria (inclusion and exclusion criteria) 
for entry into the study explicit and appropriate? yes partially partially yes partially no no 
5. Were participants recruited consecutively? unclear yes yes unclear yes yes yes 
6. Did participants enter the study at similar point in the 
disease? no no no no no no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? yes yes yes yes yes yes yes 
8. Were additional interventions (co-interventions) clearly 
reported in the study? yes partially partially partially yes yes partially 
Outcome measures  
9. Are the outcome measures clearly defined in the 
introduction or methods section? yes yes yes yes yes yes yes 
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10. Were relevant outcomes appropriately measured with 
objective and/or subjective methods? yes yes yes yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant 
outcomes appropriate? yes yes yes yes yes yes yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes yes yes yes yes yes 
14. Was the loss to follow-up reported? yes yes yes yes no yes no 
15. Does the study provide estimates of the random 
variability in the data analysis of relevant outcomes? yes yes yes yes yes yes yes 
16. Are adverse events reported? partially partially partially partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for 
the study reported? yes yes partially yes partially partially yes 
Overall Risk of bias low moderate moderate low moderate moderate moderate 
Abbreviations: na=not applicable 
 
Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
Dudek 2014 
[94] 
Rzeszutko 2016 [48] (ORPKI 
Registry) 
Briede 2018 
[41] 
Wöhrle 2018 [42] 
Nef 2017 [72] (GA-
BI-R) 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or 
methods section? yes yes yes yes 
Study population 
2. Are the characteristics of the participants included in the study described? yes yes yes yes 
3. Were the cases collected in more than one centre? yes yes no yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit 
and appropriate? partially partially yes partially 
5. Were participants recruited consecutively? yes yes no yes 
6. Did participants enter the study at similar point in the disease? no no no no 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? partially no no yes 
8. Were additional interventions (co-interventions) clearly reported in the study? partially no partially yes 
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Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods section? yes no yes yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective 
methods? yes unclear yes yes 
11. Were outcomes measured before and after intervention? na na na na 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes unclear yes 
Results and Conclusions 
13. Was the length of follow-up reported? yes yes yes yes 
14. Was the loss to follow-up reported? yes yes yes yes 
15. Does the study provide estimates of the random variability in the data analysis of 
relevant outcomes? yes yes yes yes 
16. Are adverse events reported? partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? no yes yes yes 
Overall Risk of bias high high moderate low 
Abbreviations: na=not applicable 
 
Table A11: Risk of bias – single-arm studies – Absorb® BVS (continued) (IHE 20-Criteria checklist) 
Study 
Wiebe 2017 [59] 
Hoppmann 2016 [80] 
Wiebe 2016 [71] (ISAR-
Absorb) 
Costa 2018 [105] 
Costa 2018 [44] 
Campos 2018 [46] 
Costa 2016 [66] 
Costa 2015 [86] 
Abizaid 2015 [92] (Absorb 
EXTEND) 
Wöhrle 2015 [88] 
(ASSURE) 
Khamis 2016 
[102] 
Study objective  
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? yes yes yes yes 
Study population  
2. Are the characteristics of the participants included in the study described? yes yes yes partially 
3. Were the cases collected in more than one centre? yes yes yes no 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study 
explicit and appropriate? yes yes yes yes 
5. Were participants recruited consecutively? yes no yes unclear 
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6. Did participants enter the study at similar point in the disease? no no no yes 
Intervention and co-intervention  
7. Was the intervention clearly described in the study? yes yes yes yes 
8. Were additional interventions (co-interventions) clearly reported in the study? yes yes yes partially 
Outcome measures  
9. Are the outcome measures clearly defined in the introduction or methods 
section? yes yes yes yes 
10. Were relevant outcomes appropriately measured with objective and/or 
subjective methods? yes yes yes yes 
11. Were outcomes measured before and after intervention? na na na na 
Statistical Analysis  
12. Were the statistical tests used to assess the relevant outcomes appropriate? yes yes yes yes 
Results and Conclusions  
13. Was the length of follow-up reported? yes yes yes yes 
14. Was the loss to follow-up reported? yes yes yes yes 
15. Does the study provide estimates of the random variability in the data analysis 
of relevant outcomes? yes yes yes yes 
16. Are adverse events reported? partially partially partially partially 
17. Are the conclusions of the study supported by results? yes yes yes yes 
Competing interest and source of support  
18. Are both competing interest and source of support for the study reported? partially yes yes partially 
Overall Risk of bias low low low moderate 
Abbreviations: na=not applicable 
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Table A12: GRADE assessment of Absorb® BVS (critical endpoints) 
Quality assessment 
Summary of findings 
Number of 
patients 
Effect  
Quality Number  
of 
studies  
Study design Risk of 
bias 
Inconsistency Indirectness Impression Other 
considerations 
Relative 
(95% CI) 
Absolute (95% CI) 
Absorb® BVS DES 
All-cause mortality (2 to 4 years follow-up) 
7 RCTs Not serious Not serious Not serious Seriousa No 5645 RR 0.84  
(0.63 to 1.11) 
32 per 1000  
(24 to 43)  
38 per 1000 ⨁⨁⨁⨀ 
moderate 
All-cause mortality (≥3 years follow-up) 
5 RCTs Not serious Not serious Not serious Seriousa No 5001 RR 0.82  
(0.62 to 1.10) 
34 per 1000  
(26 to 46)  
41 per 1000 ⨁⨁⨁⨀ 
moderate 
Cardiac mortality (6 months to 4 years follow-up) 
8 RCTs Not serious Not serious Not serious Seriousa No 5830 RR 0.91  
(0.60 to 1.39) 
15 per 1000  
(10 to 23)  
16 per 1000 ⨁⨁⨁⨀ 
moderate 
Cardiac mortality (≥3 years follow-up) 
5 RCTs Not serious Not serious Not serious Seriousa No 5185 RR 0.89  
(0.58 to 1.38) 
16 per 1000  
(11 to 25)  
18 per 1000 ⨁⨁⨁⨀ 
moderate 
MI (1 to 4 years of follow-up) 
8 RCTs Not serious Not serious Not serious Not serious No 5845 RR 1.49  
(1.21 to 1.84) 
73 per 1000  
(60 to 91)  
49 per 1000 ⨁⨁⨁⨁ 
high 
MI (≥3 years follow-up) 
5 RCTs Not serious Not serious Not serious Not serious No 5001 RR 1.44  
(1.16 to 1.80) 
77 per 1000  
(62 to 96)  
53 per 1000 ⨁⨁⨁⨁ 
high 
Periprocedural mortality 
2 RCTs Not serious Not serious Not serious Very seriousb No 419 No events of periprocedural mortality occurred 
either in BRS groups or in DES groups in 2 RCTs 
⨁⨁⨀⨀  
low 
Periprocedural MI 
7 RCTs Not serious Not serious Not serious Seriousa No 5503 RR 1.22  
(0.82 to 1.82) 
73 per 1000  
(49 to 109)  
60 per 1000 ⨁⨁⨁⨀ 
moderate 
Mortality as a result of bleeding and/or stroke (6 to 60 months follow-up) 
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Quality assessment 
Summary of findings 
Number of 
patients 
Effect  
Quality 
Number  
f 
  
Study design Risk of 
bi  
Inconsistency Indirectness Impression Other 
id ti  
Relative 
(95% CI) 
Absolute (95% CI) 
11 Single-arm 
observational 
studies 
Very 
seriousc 
Not serious Not serious Seriousd No 1402 2 death as results of bleeding and/or stroke 
occurred in 11 single-arm observational studies 
with Absorb® in 6 to 60 months follow-up 
⨁⨀⨀⨀  
very low 
Very late ScT (after at least 1 year of follow-up) 
6 RCTs Not serious Not serious Not serious Seriousd No 5549 RR 5.09 
(1.97 to 
13.17) 
7 per 1000  
(3 to 17)  
1 per 1000 ⨁⨁⨁⨀ 
moderate 
comments: 
a Imprecision was down-graded by 1 point because of a non-significant effect estimate with wide CI 
b Imprecision was down-graded by 2 points because of low number of studies and a very low event rate 
c Risk of bias was down-graded by 2 points because of study design and study quality (observational single-arm studies with predominantly moderate to high risk of bias 
d Imprecision was down-graded by 1 point because of a very low event rate  
Abbreviations: BRS=bioresorbable scaffold; BVS=bioresorbable vascular scaffold; CI=confidence interval; DES=drug-eluting stent; MI=myocardial infarction; RCT=randomised controlled trial; RR=risk 
ratio; ScT=scaffold thrombosis; 
 
Table A13: GRADE assessment of DESolve® Scaffold System (critical endpoints) 
Quality assessment 
Summary of findings 
Number of 
patients 
Effect  
Quality 
Number  
of 
studies  
Study design Risk of 
bias 
Inconsistency Indirectness Impression Other 
considerations 
Relative 
(95% CI) 
Absolute (95% CI) 
DESolve® 
Scaffold 
System 
comparator 
All-cause mortality 
Outcome not reported 
Cardiac mortality 
Outcome not reported 
MI 
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Quality assessment 
Summary of findings 
Number of 
patients 
Effect  
Quality 
Number  
f 
  
Study design Risk of 
bi  
Inconsistency Indirectness Impression Other 
id ti  
Relative 
(95% CI) 
Absolute (95% CI) 
Outcome not reported 
Periprocedural mortality 
3 Single-arm 
observational 
studies 
Very seri-
ousa 
Not serious Not serious Seriousb No 345 No events of periprocedural mortality occurred 3 
single-arm observational studies with DESolve® 
Scaffold System 
⨁⨀⨀⨀  
very low 
Periprocedural MI 
3 Single-arm 
observational 
studies 
Very seri-
ousa 
Not serious Not serious Seriousb No 345 One periprocedural MI occurred 3 single-arm 
observational studies with DESolve® Scaffold 
System 
⨁⨀⨀⨀  
very low 
Mortality as a result of bleeding and/or stroke (12 months follow-up) 
2 Single-arm 
observational 
studies 
Very seri-
ousa 
Not serious Not serious Seriousb No 219 No death as a result of bleeding and/or stroke 
occurred in 2 single-arm observational studies 
with DESolve® Scaffold System in 12 months 
follow-up 
⨁⨀⨀⨀  
very low 
Very late ScT (after at least 1 year of follow-up) 
1 Single-arm 
observational 
study 
Very seri-
ousa 
Not serious Not serious Very seriousc No 126 No very late ScT after at least 1 year of follow-up 
occurred in 1 single-arm observational studies 
with DESolve® Scaffold System 
⨁⨀⨀⨀  
very low 
comments: 
a Risk of bias was down-graded by 2 points because of study design and study quality (observational single-arm studies with moderate risk of bias 
b Imprecision was down-graded by 1 point because of a very low event rate 
c Imprecision was down-graded by 2 points because results were only available from 1 study and because of a very low event rate 
Abbreviations: CI=confidence interval; MI=myocardial infarction; ScT=scaffold thrombosis; 
 
Table A14: GRADE assessment of RMS Magmaris (critical endpoints) 
Quality assessment 
Summary of findings 
Number of 
patients 
Effect  
Quality 
Number  Study design Risk of Inconsistency Indirectness Impression Other Relative Absolute (95% CI) 
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of 
studies  
bias considerations (95% CI) RMS 
Magmaris 
comparator 
All-cause mortality 
Outcome not reported 
Cardiac mortality 
Outcome not reported 
MI 
Outcome not reported 
Periprocedural mortality 
2 Single-arm 
observational 
studiesa 
Very seri-
ous 
Not serious Serious Seriousb No 184 No events of periprocedural mortality occurred 2 
single-arm observational studies with RMS 
Magmaris 
⨁⨀⨀⨀  
very low 
Periprocedural MI 
2 Single-arm 
observational 
studiesa 
Very seri-
ous 
Not serious Not serious Seriousb No 184 No periprocedural MI occurred 2 single-arm 
observational studies with RMS Magmaris 
⨁⨀⨀⨀  
very low 
Mortality as a result of bleeding and/or stroke (24 months follow-up) 
2 Single-arm 
observational 
studiesa 
Very 
serious 
Not serious Not serious Seriousb No 184 No death as a result of bleeding and/or stroke 
occurred in 2 single-arm observational studies 
RMS Magmaris in 24 months follow-up 
⨁⨀⨀⨀  
very low 
Very late ScT (after at least 1 year of follow-up) 
1 Single-arm 
observational 
studya 
Very 
serious 
Not serious Not serious Very seriousc No 123 No very late ScT after at least 1 year of follow-up 
occurred in 1 single-arm observational studies 
with RMS Magmaris 
⨁⨀⨀⨀  
very low 
comments: 
a Risk of bias was down-graded by 2 points because of study design and study quality (observational single-arm studies with moderate risk of bias 
b Imprecision was down-graded by 1 point because of a very low event rate 
c Imprecision was down-graded by 2 points because results were only available from 1 study and because of a very low event rate 
Abbreviations: CI=confidence interval; MI=myocardial infarction; RMS=resorbable magnesium scaffold; ScT=scaffold thrombosis; 
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Table A15: GRADE assessment of Fantom® BRS (critical endpoints) 
Quality assessment 
Summary of findings 
Number of 
patients 
Effect  
Quality Number  
of 
studies  
Study design Risk of 
bias 
Inconsistency Indirectness Impression Other 
considerations 
Relative 
(95% CI) 
Absolute (95% CI) 
Fantom® BRS comparator 
All-cause mortality 
Outcome not reported 
Cardiac mortality 
Outcome not reported 
MI 
Outcome not reported 
Periprocedural mortality 
1 Single-arm 
observational 
studya 
Very seri-
ous 
Not serious Not serious Very seriousb No 117 No events of periprocedural mortality occurred 2 
single-arm observational studies with Fantom® 
BRS 
⨁⨀⨀⨀  
very low 
Periprocedural MI 
1 Single-arm 
observational 
studya 
Very seri-
ous 
Not serious Not serious Very seriousb No 117 One periprocedural MI occurred 1 single-arm 
observational study with Fantom® BRS 
⨁⨀⨀⨀  
very low 
Mortality as a result of bleeding and/or stroke (6 months follow-up) 
1 Single-arm 
observational 
studya 
Very 
serious 
Not serious Not serious Very seriousb No 117 No death as a result of bleeding and/or stroke 
occurred in 2 single-arm observational study with 
Fantom® BRS in 6 months follow-up 
⨁⨀⨀⨀  
very low 
Very late ScT (after at least 1 year of follow-up) 
Outcome not reported 
comments: 
a Risk of bias was down-graded by 2 points because of study design and study quality (observational single-arm study with moderate risk of bias 
b Imprecision was down-graded by 2 points because results were only available from 1 study and because of a very low event rate 
Abbreviations: BRS=bioresorbable scaffold; CI=confidence interval; MI=myocardial infarction; ScT=scaffold thrombosis; 
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Applicability tables 
 
Table A16: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The patients in the included studies (RCTs and single-arm studies) were predominantly 
male with a mean age of 60 to 70 years. Hence, generalisability to females and other age 
groups is limited. In addition, the majority of the included study population had relatively 
simple lesions in contrast to patients with more complex lesions frequently encountered in 
daily practice. Both patients with stable CAD and patients with ACS were included in the 
studies in sufficiently large numbers. Subgroup-analyses from RCTs showed no different 
results between these groups. Therefore, the results are valid for both groups. 
Intervention The implantation procedure does not differ from routine use. Valid results are only available 
for the Absorb® BVS. Since the other BRS devices are essentially different from the 
Absorb® BVS in their structure (backbone material, strut thickness, eluted drug), 
generalisability to all fully BRS is limited. 
Comparators All currently available RCTs compare BRS to a DES (mostly EES). In routine practice, 
other stent types and further revascularisation strategies (CABG) will be taken into 
consideration. From the current evidence, we do not know whether the BRS is non-inferior 
to those approaches in terms of benefits and harms. 
Outcomes The primary outcomes in most of the RCTs were surrogate endpoints, which do not reflect 
the most important clinical benefits and harms. Patient-relevant outcomes such as TLF, 
TVF were MACE or cardiac death were the primary outcomes in two RCTs and in most of 
the included single-arm observational studies. In addition, they were secondary outcomes 
in all other RCTs. Long-term results with a follow-up of three or more years were available 
from 4 RCTs, in all other studies, maximum length of follow-up was about two years. For 
safety, valid results are limited to ScT and periprocedural cardiac events. All other safety 
outcomes, especially those related to the anti-thrombotic therapy, were rarely reported. 
Setting The setting in the studies has not been described precisely but most of the procedures 
seem to have been undertaken in highly specialised university units. The transferability to a 
low-volume cardiac catheterisation lab with less experienced cardiologists may be limited. 
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
Table A17: Regulatory status 
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Absorb® BVS  EU CE 
mark 
Yes …improving 
coronary luminal 
diameter in 
patients with 
ischemic heart 
disease due to 
de novo native 
coronary artery 
lesions1 
Patients who cannot tolerate, 
including allergy or hypersensitivity 
to, procedural anticoagulation or 
the post-procedural antiplatelet 
regimen. 
Patients with hypersensitivity or 
contraindication to everolimus or 
structurally-related compounds, or 
known hypersensitivity to scaffold 
components (poly (L-lactide), poly 
(D,L-lactide), platinum) or with 
contrast sensitivity.j 
January 
2011 / 
May 2015 
(Absorb 
GT1) 
Yesk 
Absorb® BVS USA FDA Yes July 2016 Yesb 
DESolve® 
Scaffold 
System 
EU CE 
mark 
Yes …treatment of 
patients with 
CADl 
- May 2014 Yes 
RMS Magmaris EU CE 
mark 
Yes …treating CADm - June 2016 Yes 
ART Pure 
Bioresorbable 
Scaffold 
EU CE 
mark 
Yes …to treat CADn - May 2015 Yes 
Fantom® BRS EU CE 
mark 
Yes …treatment of 
CADo 
- April 2017 Yes 
Abbreviations: BRS=bioresorbable scaffold; BVS=bioresorbable vascular scaffold; CE=Communauté Européenne; 
EU=European Union; RMS=resorbable magnesium scaffold; USA=United States of America; 
 
Table A18: Summary of (reimbursement) recommendations in European countries for the 
technology 
Country and 
issuing 
organisation 
Summary of 
(reimbursement) 
recommendations and 
restrictions 
Summary of reasons for 
recommendations, 
rejections and 
restrictions Source 
NICE, England This procedure should only 
be used with special 
Current evidence on the 
short-term safety and 
https://www.nice.org.uk/
guidance/ipg492 
                                                     
j https://www.vascular.abbott/us/products/coronary-intervention/absorb-bioresorbable-scaffold-dissolving-stent.html 
k Manufacturer stopped selling the first-generation Absorb® BVS on 14th September 2017 
l 
http://elixirmedical.com/index.php?mact=News,cntnt01,detail,0&cntnt01articleid=26&cntnt01origid=56&cntnt01returnid=56 
m https://www.biotronik.com/en-au/newsroom/press-releases/press-release-magmaris-ce-mark-june15-en 
n http://art-stent.com/wp-content/uploads/2015/05/ART-News-150518.pdf 
o https://globenewswire.com/news-release/2018/02/26/1387381/0/en/REVA-Announces-CE-Mark-and-First-Implant-of-the-
Fantom-Encore-Bioresorbable-Scaffold.html 
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Country and 
issuing 
organisation 
Summary of 
(reimbursement) 
recommendations and 
restrictions 
Summary of reasons for 
recommendations, 
rejections and 
restrictions Source 
arrangements for clinical 
governance, consent and 
audit or research. 
efficacy of BRS 
implantation for treating 
coronary artery disease is 
adequate, but the quantity 
of evidence on the safety 
and efficacy of the 
procedure in the long term 
is inadequate. 
LBI-HTA, Austria The inclusion in the 
catalogue of benefits is 
currently not recommended. 
The current evidence is not 
sufficient to prove that the 
BRS is more or at least 
equally effective and safer 
than current 
revascularisation 
technologies. 
http://eprints.hta.lbg.ac.a
t/1060/ 
HAS, France The performance is 
insufficient for registration of 
the Absorb® device on the 
list of products and services 
provided in Article L.165-1 
of the Social Security Code. 
The therapeutic value of the 
Absorb® stent cannot be 
established in the 
indications claimed. 
https://www.has-
sante.fr/portail/upload/do
cs/evamed/CEPP-
5281_ABSORB%20528
1_occultations%20accep
t%C3%A9es%20par%20
HG%20le%2025%2010
%202017.pdf 
Abbreviations: HAS=Haute Autorité de Santé; LBI-HTA=Ludwig Boltzmann Institute for Health Technology Assessment; 
NICE=National Institute for Health and Care Excellence 
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APPENDIX 3: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
PATIENT AND SOCIAL AND LEGAL ASPECTS 
1 Ethical  
1.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any new ethical issues? 
No 
 
1.2 Does comparing the new technology to the defined, existing comparators point to any 
differences that may be ethically relevant? 
No 
 
2 Organisational  
2.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) require organisational changes? 
No 
  
2.2 Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be organisationally relevant? 
No 
 
3 Social  
3.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any new social issues? 
No 
  
3.2 Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be socially relevant? 
No 
  
4 Legal   
4.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any legal issues? 
No 
 
4.2 Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be legally relevant? 
No 
 
 
For the purpose of transparency, a separate document with comments on the 2nd draft as-
sessment from external experts and the MAH/manufacturer(s) (fact check), as well as re-
sponses from authors, is available on the EUnetHTA website. 
 
